cyclosporine has been researched along with Psoriasis in 718 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.14) | 18.7374 |
| 1990's | 251 (34.96) | 18.2507 |
| 2000's | 201 (27.99) | 29.6817 |
| 2010's | 209 (29.11) | 24.3611 |
| 2020's | 56 (7.80) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, A; Pandey, S; Tripathi, P; Yadav, JS | 1 |
| Akiyama, M; Hashimoto, Y; Honma, M; Iinuma, S; Ishida-Yamamoto, A; Ishii, N; Komatsu, S; Nozaki, H; Shibaki, H; Takeichi, T | 1 |
| Almutlaq, H; McFeely, O; Pender, E; Storan, E; Victory, L | 1 |
| Abdel Fadeel, DA; El Batreek, MH; Helmy A, Y; Samy, NA; Tawfik, AA | 1 |
| Goodarzi, A; Kalantari, Y; Sadeghi, S; Seirafianpour, F | 1 |
| Jendoubi, F; Masson Regnault, M; Paul, C; Shourick, J; Tauber, M | 1 |
| Bahloul, E; Bougacha-Elleuch, N; Ennouri, M; Fakhfakh, F; Marrakchi, S; Sellami, K; Turki, H | 1 |
| Bhatnagar, A; Kishore, K; Kothari, R; Mitra, D; Valarmathi, T | 1 |
| Boroń, K; Dąbala, M; Kasela, T; Mistarz, M; Oskar Grabarek, B; Wieczorek, W; Wierzbik-Strońska, M; Zawidlak-Węgrzyńska, B | 1 |
| Krebs, B; Menter, AM; Valdecantos, WC; Weiss, J; Zema, CL | 1 |
| Gondaliya, P; Kalia, K; Maheshwari, R; Polaka, S; Raval, N; Tambe, V; Tekade, RK; Todke, P | 1 |
| Bhardwaj, P; Gupta, R; Pandey, S; Ramchandra Patil, P; Tripathi, P | 1 |
| Chang, YT; Chou, YJ; Pan, TY; Wu, CY | 1 |
| Barilà, D; Cattel, F; Dapavo, P; Gallo, G; Mastorino, L; Panzone, M; Quaglino, P; Ribero, S | 1 |
| Antonatos, C; Digka, D; Evangelou, E; Georgiou, S; Grafanaki, K; Kyriakoy, A; Liaropoulos, A; Moschonas, NΚ; Patsatsi, A; Roussaki-Schulze, A; Sotiriadis, D; Stavrou, EF; Vasilopoulos, Y; Zafiriou, E | 1 |
| Imafuku, S; Sato, E; Takano-Kawasaki, S; Yamaguchi, K | 1 |
| Ahn, J; Cho, YA; Choe, YB; Hong, JY; Kim, CY; Kim, SM; Lee, YW; Sung, JY; Won, S; Yu, DA | 1 |
| Carrascosa, JM | 1 |
| Alabas, OA; Bewley, A; Griffiths, CEM; Hampton, PJ; Laws, PM; Lunt, M; Mason, KJ; Owen, CM; Reynolds, NJ; Smith, CH; Warren, RB; Yiu, ZZN | 1 |
| Blanchard, I; Kodali, N; Kunamneni, S; Lebwohl, MG | 1 |
| Furue, M; Harada, K; Hashimoto, A; Hatano, Y; Higashi, Y; Ikeda, K; Imafuku, S; Ito, K; Kaneko, S; Katayama, E; Kikuchi, S; Koike, Y; Kuwashiro, M; Matsuzaka, Y; Miyagi, T; Morizane, S; Murota, H; Nakahara, T; Ohata, C; Ohyama, B; Okada, E; Okazaki, F; Ota, M; Saito, K; Sasaki, N; Sugita, K; Takahashi, K; Tsuruta, N; Yamaguchi, K; Yanase, T; Yonekura, K; Yoshida, Y | 1 |
| Jin, HZ; Wang, HM; Xu, JM | 1 |
| Buda, P; Dąbala, M; Grabarek, BO; Kasela, T; Świder, M | 1 |
| Aala, WJF; Chen, PH; Chuang, YR; Hong, YK; Hsu, CK; Jeng, YC; Lin, YC; Yang, CC | 1 |
| Aw, D; Chandran, NS; Choi, E; Cook, A; Martin, A; Phuan, C; Yang, S | 1 |
| Bulut, H; Engin, B; Gökalp, E; Kutlubay, Z; Özkoca, D; Serdaroğlu, S; Songür, A; Tanakol, A; Tüzün, Y; Vehid, HE | 1 |
| Andreadou, I; Ikonomidis, I; Kapniari, I; Katsimbri, P; Loukeri, E; Makavos, G; Papadavid, E; Parissis, J; Pavlidis, G; Rafouli-Stergiou, P; Theodoropoulos, K; Thymis, J; Triantafyllidi, H; Tsoumani, M; Varoudi, M | 1 |
| Garncarczyk, A; Grabarek, BO; Michalska-Bańkowska, A; Wcisło-Dziadecka, D | 1 |
| Gola, J; Grabarek, BO; Michalska-Bańkowska, A; Wcisło-Dziadecka, D | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Farley Prater, EA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ | 1 |
| Lim, YL; Toh, JJ; Yew, YW | 1 |
| Gupta, AR; Joshi, SV; Maulvi, FA; Pandey, SS; Patel, PS; Shah, DO; Shah, KM; Shukla, MR | 1 |
| Du, Z; Li, N; Lu, C; Wu, D; Yuan, X; Zhang, M; Zhu, W | 1 |
| Bavaharan, B; Kawali, A; Mahendradas, P; Mohan, A; Sanjay, S; Shetty, B | 1 |
| Silverberg, JI; Singh, P | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rahimi, RS; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Tapper, EB; Wong, EB; Wu, JJ | 1 |
| Akiyama, M; Ando, Y; Ohshima, Y; Takama, H; Watanabe, D; Yanagishita, T | 1 |
| Chao, YH; Chen, HH; Huang, WC; Lee, PY; Lin, CC; Tung, YT | 1 |
| Aloisi, E; Bartezaghi, M; Bongiorno, MR; Cannavò, SP; Cuccia, A; Florio, T; Germino, M; Manzoni, R; Marsili, F; Mazzotta, A; Orsenigo, R; Persechino, S; Pettinato, M; Prignano, F; Sarkar, R; Stinco, G; Tabanelli, M; Tiberio, R; Travaglini, M | 1 |
| Baker, C; Berry, W; Daniel, BS; Foley, P | 1 |
| Babuna Kobaner, G; Polat Ekinci, A | 1 |
| Chen, M; Lian, N; Liu, L; Shi, L | 1 |
| D, S; Dogra, S; Rajagopalan, M | 1 |
| Di Lernia, V; Feliciani, C; Goldust, M | 1 |
| Abramovits, W; Schlessinger, J | 1 |
| Amber, T; Tabassum, S | 1 |
| Villani, AP | 1 |
| Chavan, D; Jamale, V; Kale, M; Nikam, B; Shah, S | 1 |
| Ahn, KJ; Cho, YA; Choe, YB; Hong, JR; Hong, JY; Jeong, H; Kim, H; Kim, SM; Lee, YW; Yang, HS | 1 |
| Chat, VS; Han, G; Kearns, DG; Uppal, SK; Wu, JJ | 1 |
| Biswasroy, P; Ghosh, G; Kar, B; Pradhan, D; Rath, G | 1 |
| Aylı, M; Caliskan, E; Coban, SN; Esme, P; Ugur, B | 1 |
| Acosta Felquer, ML; Galimberti, ML; LoGiudice, L; Mazzuoccolo, L; Rosa, J; Soriano, ER | 1 |
| Croney, S | 1 |
| Jerome, D; Kim, WB; Yeung, J | 1 |
| Basri, M; Fard Masoumi, HR; Musa, SH; Salim, N; Shamsudin, N | 1 |
| Albertini, G; Banfi, G; Bellia, G; Berardesca, E; Cassano, N; Chimenti, S; Colombo, D; De Simone, C; Fiori, GG; Graziottin, A; Micali, G; Stingeni, L; Vena, GA; Zagni, E | 1 |
| Fujishige, A; Fujita, H; Igarashi, A; Imafuku, S; Morita, A; Nakagawa, H; Ohtsuki, M; Tada, Y; Tani, Y; Teshima, R; Yamaguchi, M | 1 |
| Fujita, Y; Ito, T; Izumi, K; Kosumi, H; Maya, Y; Natsuga, K; Nomura, T; Sadanobu, N; Shimizu, H; Shinkuma, S; Ujiie, H; Yanagi, T | 1 |
| Honma, M; Iinuma, S; Ishida-Yamamoto, A; Minami-Hori, M | 1 |
| Addis, A; Adenubiova, E; Busard, CI; Cazzaniga, S; Cohen, AD; Feldhamer, I; Gkalpakiotis, S; Hutten, BA; Kojanova, M; Lichem, R; Naldi, L; Quehenberger, F; Spuls, PI; Stern, RS; Wolf, P | 1 |
| Quyyumi, AA; Samman Tahhan, A; Sandesara, PB | 1 |
| Al-Khalili, A; Dutz, JP | 1 |
| Deng, W; Miao, C; Zhang, X | 1 |
| Minagawa, A; Ogawa, E; Okuyama, R; Sato, Y | 1 |
| Armstrong, AW; Enos, CW; Gottlieb, A; Langley, RG; Lebwohl, M; Merola, JF; Ryan, C; Siegel, MP; Van Voorhees, AS; Weinberg, JM; Whitlock, SM; Wu, JJ | 1 |
| Bardazzi, F; Magnano, M; Odorici, G; Patrizi, A; Tengattini, V | 1 |
| Boldorini, RL; Colombo, E; Dagna, L; Giacalone, A; Gironi, LC; Landucci, G; Savoia, P; Tiberio, R | 1 |
| Long, A; Marik, PE | 1 |
| Georgesen, C; Magro, C; Wang, X; Wildman, H | 1 |
| Inkeles, MS; No, D; Wu, JJ | 1 |
| Berti, E; Damiani, G; Fiore, M; Leone, S; Maraolo, AE | 1 |
| Baraldo, M; Buligan, C; Cimarosti, R; Pinzani, C; Stinco, G | 1 |
| Alkan, A; Incel Uysal, P; Sahin, B; Yalcin, B; Yuksel, S | 1 |
| Akiyama, M; Fujita, Y; Goto, K; Ishijima, K; Ishikawa, Y; Iwata, H; Miyazawa, H; Nishio, S; Oi, R; Shimizu, H; Shinmei, Y; Takeichi, T | 1 |
| Iizuka, H; Sato, K; Takagi, A; Takahashi, H | 1 |
| Brzezińska-Wcisło, L; Grabarek, B; Mazurek, U; Michalska-Bańkowska, A; Michalski, P; Wcisło-Dziadecka, D | 1 |
| Börjesson, C; Guinard, E; Konstantinou, MP; Livideanu, CB; Mazereeuw-Hautier, J; Meyer, N; Paul, C; Tauber, M | 1 |
| Bigi, L; Conti, A; Lasagni, C; Pellacani, G | 1 |
| Fernandez, AP; Hu, JZ; Husni, ME; Mazloom, SE; Warren, CB; Ya, J; Yan, D | 1 |
| Ashcroft, DM; Griffiths, CEM; Jabbar-Lopez, ZK; Kleyn, CE; Mason, KJ; McElhone, K; Owen, CM; Reynolds, NJ; Smith, CH; Warren, RB; Williams, S; Wilson, N; Yiu, ZZN | 1 |
| Amy de la Breteque, M; Avenel-Audran, M; Bastien, M; Beauchet, A; Bégon, E; Beneton, N; Boyé, T; Fougerousse, AC; Girard, C; Khemis, A; Maccari, F; Mahé, E; Pallure, V; Parier, J; Perrot, JL; Reguiai, Z; Tournier, A | 1 |
| Baran, R; Chiheb, S; Daniel, CR; Di Chiacchio, N; Gregoriou, S; Grover, C; Haneke, E; Iorizzo, M; Pasch, M; Piraccini, BM; Rich, P; Richert, B; Rigopoulos, D; Rompoti, N; Rubin, AI; Singal, A; Starace, M; Tosti, A; Triantafyllopoulou, I; Zaiac, M | 1 |
| Chicharro, P; Daudén, E; Herrero-Moyano, M; Lara, S; Muñoz-Aceituno, E; Pedraz, J; Reolid, A | 1 |
| Ahn, KJ; Choe, YB; Hong, JR; Lee, YW | 1 |
| Carrascosa, JM; Daudén, E; Guisado, C; Puig, L; Sulleiro, S | 1 |
| Bulbake, U; Doppalapudi, S; Khan, W; Walunj, M | 1 |
| Gola, J; Grabarek, B; Michalska-Bańkowska, A; Wcisło-Dziadecka, D | 1 |
| Fukai, K; Imanishi, A; Kawamura, N; Kono, M; Maekawa, N; Nishida, M; Shiratori, T; Takeichi, T | 1 |
| Gautam, RK; Gupta, A; Sardana, K | 1 |
| Borro, M; Ferone, D; Murdaca, G; Negrini, S | 1 |
| Hirai, Y; Kaji, T; Kawakami, Y; Miyake, T; Morita, A; Morizane, S; Sugiura, K; Takahashi, M; Yamasaki, O | 1 |
| Arnone, M; Bernardo, WM; Carvalho, AVE; Takahashí, MDF | 1 |
| Campoli, M; Cinotti, E; Fimiani, M; Pellegrino, M; Rubegni, P; Tognetti, L | 1 |
| Arnone, M; Azulay-Abulafia, L; Bernardo, WM; Bortoletto, MCC; Bressan, AL; Carvalho, AVE; Felix, PAO; Fieri, LC; Jaime, TJ; Magalhaes, RF; Neffá, JM; Nunes, DH; Oliveira, MFSP; Ramos, AMC; Romiti, R; Souza, CDS; Takahashi, MDF; Terena, AC | 1 |
| Bongiorno, MR; Caruso, P; Curiale, S; Gurreri, R; Pistone, G; Tilotta, G | 1 |
| Bogaards, NA; de Vries, AC; Hooft, L; Lebwohl, M; Pasch, M; Spuls, PI; Velema, M | 1 |
| Chandrashekar, L; Mohanan, S; Ramassamy, S; Thappa, DM | 1 |
| Asano, Y; Kadono, T; Kamata, M; Kanda, N; Kawashima, T; Mitsui, H; Sato, S; Shibata, S; Sugaya, M; Tada, Y; Tatsuta, A; Watanabe, S | 1 |
| Gupta, R; Koo, J; Levin, E; Liao, W; Wu, JJ | 1 |
| Mrowietz, U | 3 |
| Aydin, F; Canturk, T; Senturk, N; Turanli, AY; Yuksel, EP | 1 |
| Bellia, G; Cassano, N; Colombo, MD; Vena, GA | 1 |
| Laquer, V; Nguyen, T; Ta, T; Tan, B | 1 |
| Heinecke, GM; Lebwohl, MG; Levitt, JO; Luber, AJ | 1 |
| Haufe, E; Nast, A; Rosumeck, S; Schmitt, J; Sporbeck, B; Thomaschewski, G | 1 |
| Bagel, J; Blauvelt, A; Hsu, S; Hugh, J; Lebwohl, M; Nijhawan, RI; Van Voorhees, AS; Weinberg, JM | 1 |
| Burden, AD; Burfield, L | 1 |
| Furukawa, F; Ito, T; Iwatsuki, K; Matsue, H; Shimada, S; Takigawa, M; Tokura, Y | 1 |
| Brault, Y; Gallo, G; Germain, JM; Mallbris, L; Marino, V; Micali, G; Wilsmann-Theis, D | 1 |
| Alsina-Gibert, M; Belinchón, I; Carazo, C; Carrascosa, JM; Carretero, G; Dauden, E; De la Cueva-Dobao, P; Ferrán, M; Ferrandiz, C; García-Doval, I; Gómez-García, FJ; Herrera-Ceballos, E; Jiménez-Puya, R; López-Estebaranz, JL; Rivera, R; Sánchez-Carazo, JL; Torrado, R; Vanaclocha Sebastián, F | 1 |
| Ali, FR; Green, R; Judge, MR; McMullen, E; Motta, L | 1 |
| Fassos, I; Karra, A; Mamuris, Z; Ntoumou, E; Patsatsi, A; Roussaki-Schulze, A; Sarafidou, T; Sarri, C; Sotiriadis, D; Stamatis, C; Tsalta, A; Vasilopoulos, Y; Zafiriou, E | 1 |
| Chiarolanza, I; Di Lernia, V; Ficarelli, E; Lallas, A; Possemato, N; Salvarani, C | 1 |
| Strober, BE | 1 |
| Aractingi, S; Aubin, F; Barnetche, T; Beylot-Barry, M; Cantagrel, A; Joly, P; Jullien, D; Le Maitre, M; Misery, L; Ortonne, JP; Paul, C; Richard, MA; Rouzaud, M; Sevrain, M; Villani, AP | 1 |
| Habeshian, KA; Levitt, JO | 1 |
| Davis, SA; Feldman, SR; Fleischer, AB; Shaw, MK | 1 |
| Akçali, C; Guven, EH; Guvenc, U; Inaloz, HS; Kirtak, N; Ozgoztasi, O | 1 |
| Foroncewicz, B; Krawczyk, M; Lerut, J; Majewski, S; Mucha, K; Pączek, L | 1 |
| Errichetti, E; Patrone, P; Pegolo, E; Stinco, G | 1 |
| Weiss, JM | 1 |
| Altomare, G; Ayala, F; Bardazzi, F; Bellia, G; Chimenti, S; Colombo, D; Flori, ML; Girolomoni, G; Micali, G; Parodi, A; Peris, K; Vena, GA | 2 |
| Darrieux, L; Luce, K; Ortonne, N; Safa, G; Tisseau, L | 1 |
| Ilyas, SU; Orpin, S | 1 |
| Brod, BA; Callis Duffin, K; Gelfand, JM; Kalb, RE; Krueger, GG; Linn, KA; Robertson, AD; Schleicher, SM; Shin, DB; Shinohara, RT; Sperber, BR; Stierstorfer, MB; Takeshita, J; Troxel, AB; Van Voorhees, AS; Wang, S; Weisman, JD | 1 |
| Ahlehoff, O; Bryld, LE; Gislason, G; Gniadecki, R; Hansen, PR; Iversen, L; Kristensen, SL; Lasthein, S; Lindhardsen, J; Skov, L; Torp-Pedersen, C | 1 |
| Kirby, B; Ryan, C | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Foulkes, AC; Warren, RB | 1 |
| Abeni, D; Giannantoni, P; Paradisi, A; Tabolli, S | 1 |
| Akiyama, M; Okuyama, R; Sugiura, K; Uchiyama, R | 1 |
| Ara, M; Gracia, T; Pastushenko, E | 1 |
| López-González, R; Martín-Martínez, MA; Pérez-Vicente, S; Silva-Fernández, L | 1 |
| Al-Ismail, D; Anderson, E; Batul Syed, S; Burden-Teh, E; Carmichael, A; Caruana, D; Darne, S; Dolman, S; Glover, M; Helbling, I; Hughes, B; Hughes, J; Jones, V; Jury, C; Kalavala, M; Katugampola, R; Lam, ML; McPherson, T; Moore, A; Murphy, R; Natarajan, S; Richards, L; Taibjee, SM; Taylor, A; Webster, S | 1 |
| Frambach, Y; Gerdes, S; Jacobi, A; Mössner, R; Philipp, S; Weyergraf, AJ; Wilsmann-Theis, D | 1 |
| Foley, C; Leonard, N; Wynne, B | 1 |
| Bernardez Guerra, C; Feltes, F; Macías del Toro, E; Ramírez Bellver, JL | 1 |
| Hashimoto, T; Imanishi, A; Imanishi, H; Koga, H; Sowa-Osako, J; Tateishi, C; Tsuruta, D | 1 |
| Kim, CH; Kim, JY; Lee, AY | 1 |
| Bitterman, H; Cohen, AD; Cohen, Y; Dreiher, J; Feldhamer, I; Greenberg-Dotan, S; Hammerman, A; Harman-Boehm, I; Moser, H; Shalom, G; Zisman, D | 1 |
| Chow, C; Ellis, CN; Luger, TA; Morgenstern, H; Simpson, MJ | 1 |
| Chow, C; Chubb, H; Ellis, CN; Luger, TA; Simpson, MJ | 1 |
| Aimetti, M; Ercoli, E; Manavella, V; Romano, F | 1 |
| Matsunaga, K; Takahashi, M; Takeuchi, M | 1 |
| Bangsgaard, N; Rørbye, C; Skov, L | 1 |
| Cassano, N; Garcovich, C; Garcovich, S; Vena, GA | 1 |
| Armstrong, AW; Blauvelt, A; Krueger, GG | 1 |
| Au, SC; Garber, C; Gottlieb, A; Plotnikova, N; Sorensen, EP | 1 |
| Creighton-Smith, M; Dumont, N; Garber, C; Gottlieb, AB; Sorensen, EP | 1 |
| Klufas, DM; Strober, BE; Wald, JM | 1 |
| Hashimoto, T; Iizuka, H; Ikawa, S; Ishida-Yamamoto, A; Ishii, N; Sato, K; Takagi, A; Takahashi, H | 1 |
| Augustin, M; Mrowietz, U; Radtke, MA; Reich, K; Rustenbach, SJ; Spehr, C; Thaci, D | 1 |
| Doi, T; Fujisawa, T; Mizutani, Y; Ogura, S; Seishima, M; Suzuki, S; Yoshida, S | 1 |
| Arenberger, P; Bachelez, H; Barker, J; Dauden, E; de Jong, EM; Feist, E; Gisondi, P; Jacobs, A; Jobling, R; Kemény, L; Maccarone, M; Mrowietz, U; Nast, A; Ormerod, AD; Papp, KA; Paul, C; Reich, K; Rosumeck, S; Saiag, P; Smith, C; Spuls, PI; Talme, T; Thio, HB; van de Kerkhof, P; Werner, RN; Yawalkar, N | 1 |
| Chang, CH; Lai, MS; Lee, MS; Lin, RY | 1 |
| Armstrong, AW; Karunaratne, M; Papp, KA; Reich, K; Valdecantos, W | 1 |
| Belloni Fortina, A; Boccaletti, V; Calzavara Pinton, PG; Cambiaghi, S; Corazza, M; Di Lernia, V; Ficarelli, E; Gisondi, P; Guarneri, C; Lasagni, C; Neri, I; Panzone, M; Stingeni, L | 1 |
| Bae, SH; Kim, SJ; Lee, JB; Lee, SC; Won, YH; Yun, SJ | 1 |
| Abasq, C; Aubin, F; Barbarot, S; Begon, E; Boralevi, F; Bourrat, E; Bursztejn, AC; Charbit, L; Chiaverini, C; Droitcourt, C; Hadj-Rabia, S; Lasek, A; Mahé, E; Mallet, S; Maruani, A; Mazereeuw-Hautier, J; Phan, A; Plantin, P; Souillet, AL | 1 |
| Bulbul Baskan, E; Saricaoglu, H; Tunali, S; Yazici, S | 1 |
| Fallah Arani, S; Neumann, HA; Thio, HB | 1 |
| Aldredge, L; Armstrong, AW; Yamauchi, PS | 1 |
| Belloni Fortina, A; Bonamonte, D; Calzavara Pinton, P; Cambiaghi, S; Corazza, M; DI Lernia, V; DI Nuzzo, S; Gisondi, P; Guarneri, C; Lasagni, C; Neri, I; Offidani, A; Panzone, M; Stingeni, L | 1 |
| Carpentieri, A; De Marco, IM; Loconsole, F; Loiacono, A; Pacello, L; Picconi, O | 1 |
| Balestri, R; Bardazzi, F; Magnano, M; Patrizi, A; Tengattini, V | 1 |
| Hata, M; Iwata, H; Seishima, M; Takahashi, T | 1 |
| Soleymani, T; Vassantachart, JM; Wu, JJ | 1 |
| Alfageme Roldán, F; Bermejo Hernando, A; Calvo González, JL; Marqués Sánchez, P | 1 |
| Amarji, B; Dogra, S; Katare, OP; Kumar, R; Kumar, S; Mahajan, R; Singh, B; Vinay, K | 1 |
| Anliker, M; Boehncke, WH; Borradori, L; Conrad, C; French, LE; Gilliet, M; Häusermann, P; Itin, P; Kolios, AG; Laffitte, E; Mainetti, C; Navarini, AA; Yawalkar, N | 1 |
| Markham, T; O'Gorman, SM; Storan, ER | 1 |
| Matos, RS; Torres, T | 1 |
| Alsina, M; Belinchón, I; Carrascosa, JM; Carretero, G; Dauden, E; Dávila-Seijo, P; De la Cueva-Dobao, P; Descalzo, MA; Ferrán, M; Ferrandiz, C; García-Doval, I; Gómez-García, FJ; Herrera-Ceballos, E; Jiménez-Puya, R; Llamas, M; López-Estebaranz, JL; Rivera, R; Sánchez-Carazo, JL; Torrado, R; Vanaclocha, F | 1 |
| Dogra, S; Handa, S; Mahajan, R; Narang, T | 1 |
| Camarero-Mulas, C; Daudén, E; Martinez-Mera, C; Sanz-Sánchez, T | 1 |
| Alpsoy, E; Bulbul-Baskan, E; Ergun, T; Onsun, N; Salman, A; Saricam, MH; Sarioz, A; Seckin Gencosmanoglu, D | 1 |
| Cline, A; Feldman, SR; Smith, J | 1 |
| Kim, JE; Ko, JY; Koh, WS; Oh, EH; Ro, YS; Shin, JM | 1 |
| Naldi, L | 2 |
| Choi, CW; Kim, BR; Seo, E; Youn, SW | 1 |
| Cassel, KP; Eckersley, D; Moscati, RM; Singh, PA | 1 |
| Arenberger, P; Cetkovska, P; Dolezal, T; Fialova, J; Gkalpakiotis, S; Jircikova, J; Kojanova, M | 1 |
| Barker, JN; Capon, F; Choon, SE; Lau, BW; Lim, DZ | 1 |
| Gottlieb, AB; Korman, N; Krueger, GG; Sterry, W; Van De Kerkhof, P | 1 |
| Cordoro, KM | 1 |
| Buell, C; Koo, J | 1 |
| Naidoo, P; Rambiritch, V | 1 |
| Ohtsuka, T | 1 |
| Altieri, E; Baricordi, O; Borghi, A; Fogli, E; Melchiorri, L; Rizzo, R; Stignani, M; Virgili, A | 1 |
| Cassano, N; Vena, GA | 1 |
| Gürer, MA; Ilter, N; Ozden, MG; Solaktekin, N; Suer, OE | 1 |
| Del Giglio, M; Di Francesco, V; Girolomoni, G; Gisondi, P; Zamboni, M | 1 |
| Kamino, H; Lane, TK; Meehan, S; Pomeranz, MK; Walters, RF | 1 |
| Bruni, F; Calvieri, S; Carboni, V; Carlomagno, V; D'Epiro, S; Giancristoforo, S; Maiani, E; Mattozzi, C; Richetta, A | 1 |
| Anis, AH; Bansback, N; Feldman, SR; Sizto, S; Willian, MK | 1 |
| Fodor, J; Gergely, P; Juhász, T; Matta, C; Molnár, Z; Nagy, G; Szíjgyártó, Z; Veress, G; Zákány, R | 1 |
| Clark, LN; Lebwohl, M; Patel, RV; Weinberg, JM | 1 |
| Abe, M; Hasegawa, M; Ishikawa, O; Syuto, T; Yokoyama, Y | 1 |
| Hagiwara, M; Iyatomi, H; Kimoto, M; Miyake, A; Ogawa, K; Oka, H; Tanaka, M | 1 |
| Harada, K; Kawamura, T; Nakagomi, D; Shibagaki, N; Shimada, S; Yagasaki, A | 1 |
| Gohar, A | 1 |
| Adişen, E; Gülekon, A; Gürer, MA; Tekin, O | 1 |
| Beissert, S; Frieling, U; Frosch, PJ; Haase, I; Loske, KD; Luger, TA; Pauser, S; Sticherling, M | 1 |
| Dubertret, L | 1 |
| Barker, J; Bos, JD; Burmester, GR; Chimenti, S; Dubertret, L; Eberlein, B; Erdmann, R; Ferguson, J; Girolomoni, G; Gisondi, P; Giunta, A; Griffiths, C; Hönigsmann, H; Hussain, M; Jobling, R; Karvonen, SL; Kemeny, L; Kopp, I; Leonardi, C; Maccarone, M; Menter, A; Mrowietz, U; Naldi, L; Nast, A; Nijsten, T; Ormerod, AD; Ortonne, JP; Orzechowski, HD; Pathirana, D; Rantanen, T; Reich, K; Reytan, N; Richards, H; Rzany, B; Saiag, P; Smith, C; Spuls, PI; Thio, HB; van de Kerkhof, P | 1 |
| Adişen, E; Gürer, MA | 1 |
| Salgo, R; Thaçi, D | 1 |
| Elewski, BE; Gottlieb, AB; Lebwohl, M; Rosmarin, DM | 1 |
| Alomar, A; Barco, D; Puig, L | 1 |
| Bergler-Czop, B; Brzezińska-Wcisło, L; Lis-Święty, A | 1 |
| Hashimoto, Y; Igawa, S; Iizuka, H; Kajino, M; Mizumoto, T; Nakamura, S; Nishi, K; Takahashi, H | 1 |
| Alomar, A; Barco, D; Puig, L; Vilarrasa, E | 1 |
| Bao, Y; Guérin, A; Gupta, SR; Latremouille-Viau, D; Mulani, PM; Saurat, JH; Wu, EQ; Yu, AP | 1 |
| Cooper, AJ; Dolianitis, C; Foley, PA; Hack, SP; Quirk, C; Sullivan, JR; Thirunavukkarasu, K | 1 |
| Lacarrubba, F; Massimino, D; Micali, G; Musumeci, ML; Nasca, MR | 1 |
| Furukawa, F; Hashimoto, T; Kaminaka, C; Kanazawa, N | 1 |
| Boulinguez, S | 2 |
| Jensen, P; Skov, L; Zachariae, C | 1 |
| Albertini, G; Di Lernia, V | 1 |
| Caldarola, G; Carbone, A; De Simone, C; Pellicano, R | 1 |
| Forner, MJ; Jordá, E; López, V; Martín, JM; Molina, I; Santonja, N | 1 |
| Abdellaoui, A; Al-Daraji, WI; Dempsey, E; Prescott, R; Tugrul, S; Zelger, B | 1 |
| Di Lernia, V; Ricci, C | 1 |
| Barker, JN; Bashir, SJ; Chew, AL; Johnston, A; Smith, CH | 1 |
| Di Lernia, V; Guareschi, E | 1 |
| Nagano, Y; Nakajima, H; Nakajima, K; Sano, S; Takahashi, M; Takahashi, Y; Tarutani, M; Yamamoto, M | 1 |
| Becker, EM; Gattu, S; Koo, JY | 1 |
| Feldman, SR; Rajpara, AN | 1 |
| Brocard, A; Dréno, B; Knol, AC; Peuvrel, L; Quéreux, G; Renaut, JJ | 1 |
| Di Lernia, V | 1 |
| Bodur, S; Gümüşel, M; Mevlitoğlu, I; Özdemir, M | 1 |
| O'Rielly, DD; Rahman, P | 1 |
| Martin, L | 1 |
| Alsina-Gibert, M; Sánchez-Regaña, M; Sola-Ortigosa, J; Umbert-Millet, P; Vidal-Fernández, M | 1 |
| Hibino, M; Muro, Y; Shimoyama, Y; Sugiura, K; Tomita, Y | 1 |
| Beschmann, H; Boehncke, S; Boehncke, WH; Diehl, S; Fichtlscherer, S; Garbaraviciene, J; Hardt, K; Salgo, R; Thaçi, D | 1 |
| Lotti, T; Pescitelli, L; Prignano, F; Ricceri, F; Ruffo, G | 1 |
| Amaya, M; Natsume, S; Okubo, Y; Tsuboi, R; Usui, K | 1 |
| Abe, M; Ishikawa, O; Syuto, T; Yokoyama, Y | 1 |
| Ortonne, JP; Paul, C | 1 |
| Aractingi, S; Aubin, F; Bachelez, H; Cribier, B; Gallini, A; Joly, P; Jullien, D; Le Maître, M; Maza, A; Misery, L; Montaudié, H; Ortonne, JP; Paul, C; Richard, MA; Sbidian, E | 2 |
| Battistella, M; Le Maître, M | 1 |
| Bebo, BF; Frankel, A; Gottlieb, A; Hsu, S; Korman, NJ; Lebwohl, M; Van Voorhees, AS | 1 |
| Jarvis, JN; Kim, NN; Lio, PA; Morgan, GA; Pachman, LM | 1 |
| Alifrangis, L; Andersen, S; Dam, TN; Rosada, C; Stenderup, K | 1 |
| Botti, E; Chimenti, S; Costanzo, A; Spallone, G; Talamonti, M; Teoli, M | 1 |
| Furuhashi, T; Kaneko, N; Morita, A; Saito, C; Shintani, Y | 1 |
| Rallis, E; Verros, CD | 1 |
| Augustin, M; Glaeske, G; Radtke, M; Reich, K; Schäfer, I | 1 |
| Christofidou, E; Koumantaki-Mathioudaki, E; Rallis, E; Rigopoulos, D; Stavropoulos, P | 1 |
| Battistella, M; Boulinguez, S | 1 |
| Cassano, N; Galluccio, A; Pezza, M; Vena, GA; Vestita, M | 1 |
| Asahina, A; Asano, Y; Kikuchi, K; Kimura, T; Saeki, H; Sato, S; Sugaya, M; Tada, Y; Tamaki, K; Yamamoto, M | 1 |
| Aksoy, Y; Karaduman, A; Pinar, A; Yıldırım, FE | 1 |
| Cerri, A; Colombo, L; Crespi, E; Gualandri, L; Mapelli, ET; Marconi, M; Menni, S | 1 |
| Chu, DH; Rosenbach, M; Van Voorhees, AS | 1 |
| Hagedorn, PH; Labuda, T; Moller, K; Norsgaard, H; Olsen, GM; Svensson, L | 1 |
| Aggelakou-Vaitis, S; Dousdampanis, P; Gellner, K; Triga, K | 1 |
| Bachelez, H; Paul, C | 1 |
| Garat, H; Paul, C | 1 |
| Beylot-Barry, M; Le Maître, M | 1 |
| Hollenberg, MD; Imai, Y; Ishikawa, C; Nakagawa, N; Sakaguchi, Y; Takei-Taniguchi, R; Tsuda, T; Yamanishi, K | 1 |
| El-Eishi, NH; Hegazy, RA; Kadry, D; Rashed, L | 1 |
| Honma, M; Iizuka, H; Ishida-Yamamoto, A; Takahashi, H; Tsuji, H | 1 |
| Gökbel, H; Mevlitoğlu, I; Okudan, N; Ozdemir, M; Yüksel, M | 1 |
| Abdel Halim, DM; Abdel Hay, RM; El-Darouti, MA; Hegazy, RA | 1 |
| Boehncke, WH | 1 |
| Arcese, A; Camplone, G; Carlesimo, M; Di Russo, PP; Gamba, A; La Pietra, M; Mari, E; Orsini, D | 1 |
| Calvieri, S; Cantisani, C; D'Epiro, S; Giancristoforo, S; Macaluso, L; Mattozzi, C; Morrone, S; Richetta, AG; Salvi, M | 1 |
| Chinoy, H; Foulkes, AC; Griffiths, CE; Warren, RB | 1 |
| Abuchar, A; Dehesa, L; Kerdel, FA; Nuno-Gonzalez, A; Vitiello, M | 1 |
| Dainichi, T; Fukuda, S; Hamada, T; Hashimoto, T; Ishii, N; Karashima, T; Kawakami, T; Koga, H; Nakama, T; Natsuaki, Y; Ohyama, B; Ono, F; Sogame, R; Tsuruta, D; Yasumoto, S | 1 |
| Abuabara, K; Bebo, BF; Callis Duffin, K; Gelfand, JM; Krueger, GG; Shin, DB; Troxel, AB; Van Voorhees, AS; Wan, J | 1 |
| Frambach, Y; Gerdes, S; Mössner, R; Philipp, S; Rotterdam, S; Weyergraf, A; Wilsmann-Theis, D | 1 |
| Smith, BL; Vine, K; Votava, HJ | 1 |
| Bertoldi, AM; Borghi, A; Corazza, M; Giari, S; Mantovani, L; Virgili, A | 1 |
| Brégégère, FM; Frušić-Zlotkin, M; Larush, L; Magdassi, S; Milner, Y; Neuman, R; Soroka, Y; Tivony, R; Verkhovsky, L | 1 |
| Avitan-Hersh, E; Bergman, R; Erisson, S; Solt, I | 1 |
| Fernandes, IC; Selores, M; Torres, T | 1 |
| Akasaka, E; Haruki, Y; Ikoma, N; Kato, M; Kojima, T; Mabuchi, T; Manabe, Y; Ozawa, A; Yahagi, E; Yamada-Hiruma, A; Yamaoka, H | 1 |
| Alves, R; Pinto-Almeida, T; Rosmaninho, A; Sanches, M; Selores, M | 1 |
| Abeldaño, A; Andrada, R; Mazzuoccolo, LD; Neglia, V; Pellerano, G | 1 |
| Benes, P; Benz, RE; Färber, L; Langendorf, Y; Schopf, RE | 1 |
| Feldman, SR; Housman, TS; Mellen, BG; Rodewald, EJ | 1 |
| Bell, HK; Parslew, RA | 1 |
| Oh-i, T; Okuda, T | 1 |
| Burg, G; Forster, A; Heinzerling, L; Kamarashev, J; Lor, P; Nestle, FO | 1 |
| Gordon, KB; McClure, SL; Valentine, J | 1 |
| Duncan, JI; Horroccks, A; Ormerod, AD; Thomson, AW | 1 |
| Bräutigam, M; Christophers, E; Kaufmann, R; Paul, C; Thaçi, D; Weidinger, G | 1 |
| van de Kerkhof, P | 1 |
| Zackheim, HS | 2 |
| Christophers, E; Dubertret, L; Guillaume, JC; Ho, VC; Lamarque, V; McGeown, C; Paul, CF; Schmidtmann, B | 1 |
| Borgia, F; Cannavò, SP; Guarneri, B; Guarneri, F; Vaccaro, M | 1 |
| Agnew, KL; Bunker, CB | 1 |
| Bos, JD; de Rie, MA; Heydendael, VM; Piskin, G; Teunissen, MB | 1 |
| Hanada, J; Hori, Y; Horikoshi, T; Jimbow, K; Kitahara, H; Morimoto, Y; Nakagawa, H; Nakayama, J; Ohkido, M; Ohtsuki, M; Ozawa, A; Sugai, J; Tamaki, K; Urabe, K | 1 |
| Bhalla, M; Thami, GP | 1 |
| Altieri, E; Corazza, M; Montanari, A; Virgili, A; Zampino, MR | 1 |
| Berth-Jones, J; Ilchyshyn, A; Perrett, CM | 1 |
| Kaur, I; Kumar, B; Sandhu, K; Saraswat, A | 1 |
| Ghoreschi, K; Mrowietz, U; Röcken, M | 1 |
| Crickx, B; Descamps, V; Fraitag, S; Grossin, M; Mahé, E | 1 |
| Kormeili, T; Lowe, NJ; Patnaik, R; Rizk, D; Yamauchi, PS | 1 |
| Lebwohl, M | 1 |
| Fujisawa, Y; Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Makimoto, A; Masuo, S; Murashige, N; Sakiyama, M; Takaue, Y; Tanosaki, R | 1 |
| Bos, JD; Bossuyt, PM; de Borgie, CA; de Rie, MA; Goldschmidt, WF; Heydendael, VM; Opmeer, BC; Reitsma, JB; Spuls, PI | 1 |
| Werner, AH | 1 |
| Lebwohl, M; Maryles, S; Rozenblit, M | 1 |
| Bermejo, M; Gallego, N; Ortuño, J; Pascual, J; Quereda, C; Sabater, J; Soria, C | 1 |
| Hasselager, E; Kragballe, K; Nørby, PL; Rømer, J; Steiniche, T; Thorn Clausen, J | 1 |
| Gürer, MA; Oztas, P | 1 |
| Hoshi, S; Kaneko, F; Kawakami, Y; Kishimoto, K; Nakamura, K; Nishibu, A; Oyama, N; Yamazaki, K | 1 |
| Dorta, S; Escoda, M; Fagundo, E; García-Bustínduy, M; García-Montelongo, R; Guimerá, FJ; Noda-Cabrera, A; Sáez, M; Sánchez-González, R | 1 |
| Bigby, M | 1 |
| Beani, JC | 1 |
| Finlay, AY; Lewis, JJ; Salek, MS; Sumner, MI | 1 |
| Feldman, SR; Garton, R | 1 |
| Christofidou, E; Doulaveri, G; Giannadaki, M; Kontochristopoulos, GJ; Zakopoulou, N | 1 |
| Balasubramaniam, P; Berth-Jones, J; Stevenson, O | 1 |
| Ho, VC | 1 |
| Dubertret, L; Ellis, CN; Finlay, AY; Finzi, AF; Griffiths, CE; Ho, VC; Johnston, A; Katsambas, A; Lison, AE; Naeyaert, JM; Nakagawa, H; Paul, C; Vanaclocha, F | 1 |
| de Rie, MA; Heydendael, VM; Rentenaar, RJ; ten Berge, IJ; van Diepen, FN | 1 |
| Dumont, FJ | 1 |
| Bos, JD; Bossuyt, PM; De Borgie, CA; De Rie, MA; Heydendael, VM; Opmeer, BC; Spuls, PI | 1 |
| Cooper, AJ; Lee, MR | 1 |
| Kaur, I; Kumar, B; Sandhu, K | 1 |
| Lebwohl, MG; Stebbins, WG | 1 |
| Coroas, AS; de Almeida, MD; de Oliveira, JG; Magina, S; Pestana, M; Santos, J | 1 |
| Nishioka, K; Yamamoto, T | 1 |
| Short, MW; Vaughan, TK | 1 |
| de Rie, MA; Spuls, PI; Tuut, MK; van Everdingen, JJ | 1 |
| Iizuka, H; Takahashi, H | 1 |
| Feldman, SR; Margolis, DJ; Nijsten, T; Rolstad, T | 1 |
| Naldi, L; Rzany, B | 3 |
| Adle-Biassette, H; Gaulard, P; Lelièvre, JD; Molinier-Frenkel, V; Papo, T; Sacre, K | 1 |
| Arbiser, J; Babichev, YO; Chang, W; Chen, S; Cruz, M; Dagnino, L; Dumont, DJ; Haninec, A; Jones, J; Jones, N; Jothy, S; Kerbel, RS; Klement, G; Master, Z; Sturk, C; Tran, J; Van Slyke, P; Voskas, D; Ward, N | 1 |
| Feldman, SR; Margolis, DJ; Nijsten, T; Rolstad, T; Stern, RS | 1 |
| Jang, HS; Jo, JH; Kim, MB; Ko, HC; Kwon, KS; Kwon, YW; Oh, CK | 1 |
| Griffiths, CE; Naldi, L | 1 |
| Coroas, A; Magina, S; Oliveira, JG; Pestana, M; Resende, C; Santos, J; Serrão, P; Soares-Da-Silva, P | 1 |
| Menter, A | 2 |
| Evans, C; Feldman, SR; Russell, MW | 1 |
| Cather, JC; Menter, A | 1 |
| Papp, KA | 1 |
| Kincaid, L | 1 |
| Bewley, SJ; Eady, RA; Edmonds, EV; Morris, SD; Short, K | 1 |
| Clausen, JT; Funding, AT; Iversen, L; Kragballe, K; Noerby, PL; Otkjaer, K; Steiniche, T | 1 |
| Massana, J; Ojeda, R; Oliete, R; Sánchez Regaña, M; Umbert, P | 1 |
| V'lckova-Laskoska, MT | 1 |
| Nishioka, K; Yamamoto, T; Yokozeki, H | 1 |
| Berth-Jones, J | 2 |
| Aspeslet, L; Bissonnette, R; Foster, RT; Huizinga, R; Lauzon, G; Maksymowych, WP; Mayo, P; Papp, K; Poulin, Y; Yatscoff, RW | 1 |
| Kress, DW | 1 |
| Lowe, NJ; Yamauchi, PS | 1 |
| Gordon, KB; Ruderman, EM | 1 |
| Abe, M; Hasegawa, M; Ishikawa, O; Sogabe, Y; Syuto, T; Yokoyama, Y | 1 |
| Kawase, A; Koike, M; Mizoguchi, M; Mizukami, T; Murakami, N; Obara, W; Shibuya, Y; Soma, Y; Watabe, H | 1 |
| Asahina, A; Kishimoto, E; Komine, M; Mitsui, H; Saeki, H; Tada, Y; Takekoshi, T; Tamaki, K | 1 |
| Aydin, F; Canturk, T; Senturk, N; Turanli, AY | 1 |
| Menon, K; Siu, K; Strober, BE | 1 |
| Dijkmans, BA; Finlay, AY; Griffiths, CE; Ho, VC; Johnston, A; Katsambas, A; Luger, TA; Mrowietz, U; Thestrup-Pedersen, K | 1 |
| Griffiths, CE; Voorhees, JJ | 1 |
| Fernandes, JC; Pereira, TM; Sousa-Basto, A; Vieira, AP | 1 |
| Daudén, E; Delgado-Jiménez, Y; García-Díez, A; García-Río, I; Pedraz, J | 1 |
| Wohlrab, J | 1 |
| El-Dars, L; Holt, PJ; Khan, S | 1 |
| Hashimoto, S; Kaneko, F; Nakamura, K; Oyama, N; Saeki, H; Tamaki, K; Tsunemi, Y | 1 |
| Dissemond, J; Grabbe, S | 1 |
| Kapoor, JR; Kapoor, R | 1 |
| Papp, KA; Rosoph, L; Toth, D | 1 |
| Balkrishnan, R; Camacho, F; Crane, MM; Feldman, SR; Fleischer, AB; Higgins, KB; Pearce, DJ; Stealey, KH | 1 |
| Antunes, H; Basto, AS; Fernandes, JC; Pereira, TM; Vieira, AP | 1 |
| Fabbri, P; Terranova, M; Torchia, D | 1 |
| Carneiro, S; Cássia, F; Cuzzi, T; Lago, E; Magalhães, G; Pessanha, F; Ramos-e-Silva, M | 1 |
| Altomare, A; Altomare, GF; Colombo, MD; Franchi, C; Frigerio, E; Garutti, C | 1 |
| Aşan, E; Erkin, G; Gürer, CK; Kölemen, F; Korkusuz, P; Sahin, S; Uğur, Y | 1 |
| Ceović, R; Husar, K; Kostović, K; Lipozencić, J; Murat-Susić, S; Pasić, A; Skerlev, M | 1 |
| Lautieri, S; Patrone, P; Stinco, G; Valent, F | 1 |
| Gyulai, R; Kemény, L | 1 |
| Gniadecki, R; Larsen, R; Ryder, LP; Svejgaard, A | 1 |
| Abe, M; Ishibuchi, H; Ishikawa, O; Sogabe, Y; Syuto, T; Yokoyama, Y | 1 |
| Girard, C; Guilhou, JJ | 1 |
| Furue, M; Imafuku, S; Tashiro, A | 1 |
| Jiaravuthisan, MM; Muhn, CY; Murphy, F; Sasseville, D; Vender, RB | 1 |
| Bos, JD; Bossuyt, PM; de Rie, MA; deBorgie, CA; Heydendael, VM; Opmeer, BC; Spuls, PI | 1 |
| Furukawa, F; Hashizume, H; Hata, M; Higashishiba, T; Ito, T; Kageyama, H; Machida, H; Matsushita, K; Shirahama, S; Takigawa, M; Tanaka, M; Tsushima, T; Yagi, H | 1 |
| Ozawa, A; Umezawa, Y | 2 |
| Arai, K; Hirano, T; Oka, K; Okubo, Y; Tsuboi, R; Uchiyama, T | 1 |
| Mabuchi, T; Ozawa, A; Umezawa, Y | 1 |
| Gottlieb, AB; Lozano, AM; Magliocco, MA; Schuler, KW; Van Saders, C | 1 |
| Pérez-Cejudo, JA; Piqué-Duran, E | 1 |
| Chen, HD; He, CD; Li, B; Xiao, T | 1 |
| Kerdel, FA; Ricotti, C | 1 |
| Rebora, A | 1 |
| Yoon, HS; Youn, JI | 1 |
| De Jong, EM; Langewouters, AM; Van De Kerkhof, PC; Van Erp, PE | 1 |
| Dolianitis, C; Street, AC; Tuxen, AJ; Yong, MK | 1 |
| Avgoustinaki, N; Chaidemenos, GC; Karakatsanis, G; Katsambas, A; Mourellou, O; Papakonstantinou, M | 1 |
| Franssen, EJ; Prins, AM; Vos, K | 1 |
| Koo, J; Maskatia, ZK | 1 |
| Stiefelhagen, P | 1 |
| De Panfilis, G; Di Nuzzo, S; Zanni, M | 1 |
| Bergbrant, IM; Flytström, I; Stenberg, B; Svensson, A | 1 |
| Bowman, EP; Cardinale, I; Fuentes-Duculan, J; Haider, AS; Kikuchi, T; Krueger, JG; Lowes, MA; Zaba, LC | 1 |
| Cardinale, I; Haider, AS; Khatcherian, A; Krueger, JG; Lowes, MA; Novitskaya, I; Suárez-Fariñas, M; Wittkowski, KM; Zaba, LC | 1 |
| Elston, CM; O'Toole, EA; Webber, NK | 1 |
| Sadighha, A; Zahed, GM | 1 |
| Hanaoka, K; Herzenberg, LA; Jiang, WY; Kubo, K; Kundu-Raychaudhuri, S; Masunaga, T; Raychaudhuri, SP; Tamura, K | 1 |
| Alegre de Miguel, V; Martínez Casimiro, L; Sánchez Carazo, JL | 1 |
| Díaz-Pérez, JL; González Hermosa, MR; Martínez de Lagrán, Z | 1 |
| Beutner, KR; Bhushan, R; Elmets, CA; Feldman, SR; Gordon, KB; Gottlieb, A; Koo, JY; Korman, NJ; Lebwohl, M; Leonardi, CL; Menter, A; Van Voorhees, AS | 1 |
| Bissonnette, R; Huizinga, RB; Lynde, CW; Maksymowych, WP; Papp, K; Rosoph, L; Searles, G; Shear, NH; Wasel, N | 1 |
| Ahdout, J; Chiu, M; Mandel, H | 1 |
| Bagot, M; Claudepierre, P | 1 |
| Benner, R; Hegmans, JP; Prens, EP; t Hooft-Benne, K; van Joost, T; Ysselmuiden, OE | 1 |
| Arnold, WP; Gerritsen, MJ; Rulo, HF; Van de Kerkhof, PC | 1 |
| Battat, L; Gilleaudeau, P; Gottlieb, AB; Heftler, N; Hodak, E; Krueger, JG; Nabeya, R; Vallat, VP; Wolfe, J | 1 |
| Lewis, HM | 1 |
| Burger, PM; Goos, M; Nussbaum, G; Ockenfels, HM; Schultewolter, T | 1 |
| Gilleaudeau, P; Gottlieb, AB; Gottlieb, SL; Heftler, NS; Johnson, R; Krueger, JG; Vallat, VP; Wolfe, J | 1 |
| Katayama, I; Kimura, K; Nishioka, K; Yamamoto, T | 1 |
| Honeyman, JF; Sánchez, L; Valdés, P | 1 |
| Katayama, I; Nishioka, K; Watanabe, K; Yamamoto, T | 1 |
| Forslund, T; Fyhrquist, F; Hannonen, P; Reitamo, S | 1 |
| Ellis, CN; Fradin, MS; Hamilton, TA; Voorhees, JJ | 1 |
| Koo, J | 4 |
| Baraldo, M; Croattino, L; Furlanut, M; Galla, F; Marzocchi, V; Poz, D | 1 |
| Camp, RD; Friedmann, PS; Heule, F; Ho, V; Reitamo, S | 1 |
| Ballardie, FW; Chalmers, RJ; Edwards, BD; Morris, DJ; O'Driscoll, JB | 1 |
| Bachmann, H; Christophers, E; Färber, L; Henneicke-von Zepelin, HH; Mrowietz, U; Welzel, D | 1 |
| Gajardo, J; Villaseca, J | 1 |
| de Moragas, JM; Puig, J; Puig, L | 1 |
| Abu-Elmagd, K; Carroll, PB; McCauley, J; Starzl, TE; Thomson, AW; Van Thiel, DH; Woo, J | 1 |
| Andrew, SM; Ballardie, FW; Chalmers, RJ; Edwards, BD; Freemont, AJ; O'Driscoll, JB | 1 |
| Ballardie, FW; Chalmers, RJ; Davies, M; Edwards, BD; Mawer, EB; Testa, HJ | 1 |
| Ballardie, FW; Bhatnagar, D; Chalmers, RJ; Durrington, PN; Edwards, BD; Gokal, R; Mackness, MI | 1 |
| Gilleaudeau, P; McClelland, PB | 1 |
| Galpin, S; Weber, J | 1 |
| Friedmann, PS; Levell, NJ; Munro, CS; Shuster, S | 1 |
| Johnson, KJ; Messana, JM; Mihatsch, MJ | 1 |
| Steen Olsen, T; Zachariae, H | 1 |
| Panizzon, R | 1 |
| Kaneko, F; Maruyama, K; Nihei, Y; Ono, I; Zhang, JZ | 1 |
| Bostad, L; Helland, S; Iversen, BM; Morken, T; Myking, A; Ofstad, J; Svarstad, E | 1 |
| Berson, M; Callens, A; Lorette, G; Machet, L; Pourcelot, L; Vaillant, L | 1 |
| Färber, L; Mahrle, G; Schulze, HJ; Steigleder, GK; Weidinger, G | 1 |
| Alkemade, HA; Arnold, WP; de Jongh, GJ; Schalkwijk, J; van de Kerkhof, PC | 1 |
| Ellis, CN; Fradin, MS; Groisser, DS; Hamilton, TA; Johnson, KJ; Leichtman, AB; Messana, JM; Mihatsch, MJ; Voorhees, JJ; Young, EW | 1 |
| Belgodere, X; Castanet, J; Lacour, JP; Ortonne, JP; Van Eslande, L | 1 |
| De Haro, T; Fletcher, A; Hutchinson, P; Jones, L; Payne, FB | 1 |
| Fernandez Lucas, M; Gonzalo, A; Orte, L; Ortuño, J; Quereda, C; Sabater, J; Soria, C | 1 |
| Bosman, B | 1 |
| Bagot, M; Binderup, L; Charue, D; Dubertret, L; Grossman, R; Pamphile, R; Revuz, J | 1 |
| Lauharanta, J | 1 |
| Amblard, P; Belaich, S; Claudy, A; de Belilovsky, C; de la Brassinne, M; Grossman, RM; Guilhou, JJ; Souteyrand, P; Thivolet, J; Thomas, P | 1 |
| Ballardie, FW; Chalmers, RJ; Davies, M; Edwards, BD; Hayes, ME; Mawer, EB; Shaw, AJ | 1 |
| de Dobbeleer, G; Noel, JC | 1 |
| Baker, BS; Fry, L; Powles, AV | 1 |
| Emmerson, RW; Wakelin, SH | 1 |
| Dobozy, A; Kemény, L; Michel, G; Ruzicka, T | 1 |
| Amerio, P; Andreassi, M; Gravante, M; Masci, S | 1 |
| Bjerke, JR; Degré, M; Gallati, H; Jablonska, S; Majewski, S; Matre, R; Tigalonova, M | 1 |
| Bardazzi, F; Peluso, AM; Tosti, A; Varotti, C | 1 |
| Catamo, F; Garcovich, A; Gatti, M; Olivetti, G; Pompili, A | 1 |
| Califano, L; Cannavò, SP; Di Mauro, D; Guarneri, B; Magaudda, L; Mondello, MR; Pergolizzi, S; Santoro, G; Vaccaro, M | 1 |
| Ballardie, FW; Chalmers, RJ; Edwards, BD; Lawson, RS; Mitchell, DM; O'Driscoll, JB; Smith, RJ; Testa, HJ | 1 |
| Gajardo, J | 1 |
| Dobozy, A; Farkas, B; Kemény, L; Kenderessy, AS; Michel, G; Olasz, E; Ruzicka, T | 1 |
| Duncan, JI; Ormerod, AD; Thomson, AW; Wakeel, RA; Winfield, AJ | 1 |
| Finzi, AF; Mozzanica, N; Pigatto, PD | 1 |
| Feldmann, R; Masgrau-Peya, E; Mesheit, J; Salomon, D; Saurat, JH | 1 |
| Robertson, RP; Seaquist, ER; Teuscher, AU | 1 |
| Abeywickrama, KH; Abi-Rached, J; Dubertret, L; Grossman, R; Laburte, C | 1 |
| Sticherling, M | 1 |
| Cattran, D; Katz, A; Murphy, GF; Pei, Y; Schachter, R; Scholey, JW | 1 |
| Cecchi, R; Giomi, A; Seghieri, G | 1 |
| Brechtel, B; Czarnetzki, BM; Toppe, E; Wellenreuther, U | 1 |
| Erkko, P; Harjula, K; Lauerma, AI; Montonen, O; Reitamo, S; Remitz, A | 1 |
| Baughman, RD | 1 |
| Bhardwaj, R; Buchegger, F; Goerdt, S; Grunert, F; Hagemeier, HH; Sorg, C; von Kleist, S | 1 |
| Burke, MD; Omar, G; Ormerod, AD; Shah, IA; Whiting, PH | 1 |
| Baadsgaard, O; Jemec, GB | 1 |
| Cooper, KD; Elder, JT; Ellis, CN; Hammerberg, C; Kojima, T; Nair, RP; Voorhees, JJ | 1 |
| Cromie, MA; Elder, JT; Fisher, GJ; Kojima, T; Voorhees, JJ | 1 |
| Ballardie, FW; Chalmers, RJ; Edwards, BD; Lawson, RS; O'Driscoll, J; Testa, HJ | 1 |
| Arnold, WP; Gerritsen, MJ; van de Kerkhof, PC | 2 |
| Gallego, N; Orofino, L; Ortuno, J; Pascual, J; Quereda, C; Sabater, J; Soria, C | 1 |
| Finzi, AF; Giannotti, B; Ippolito, F; Panconesi, E; Rebora, A | 1 |
| Burmer, GC; Krieger, JN; Kumasaka, B; Piepkorn, M | 1 |
| Kragballe, K | 1 |
| Green, C; Hawk, JL | 1 |
| Harrison, PE; Menter, A; Morris, LF; Phillips, CM; Sander, HM | 1 |
| Cooper, KD; Winslow, CM; Wong, RL | 1 |
| Baker, BS; Cook, T; Fry, L; Hulme, B; Lewis, HM; Powles, AV; Thomas, E; Valdimarsson, H | 1 |
| Brown, AL; Goodship, TH; Levell, N; Marks, J; Munro, C; Thomas, TH; Wilkinson, R | 1 |
| Goos, M; Mertins, K; Nussbaum, G; Ockenfels, HM; Schultewolter, T; Wagner, SN | 1 |
| Nevin, RJ; Schulz, EJ | 1 |
| Amend, WJ; Ellis, CN; Krueger, GG; Lebwohl, M; Menter, MA; Morison, WL; Prystowsky, JH; Roenigk, HH; See, JA; Shupack, JL; Silverman, AK; Weinstein, GD; Yocum, DE; Zanolli, MD | 1 |
| Abi-Rached, J; Blanchet, F; Chevret, S; Dubertret, L; Grossman, RM | 1 |
| Zachariae, H | 1 |
| Higuchi, S; Hori, Y; Ieiri, I; Murakami, H; Nakayama, J | 1 |
| Christophers, E | 1 |
| de Jong, EM; Gerritsen, MJ; Steijlen, PM; van de Kerkhof, PC; van der Vleuten, CJ | 1 |
| Bisighini, G; Di Lernia, V | 1 |
| Lotti, T; Mancini, A; Teofoli, P | 1 |
| Berth-Jones, J; Bourke, JF; Graham-Brown, RA; Holder, J | 1 |
| Goos, M; Jakobs, KH; Nussbaum, G; Ockenfels, HM; Oeljeklaus, P; Schneck, B; Wagner, SN | 1 |
| King, LE; Nanney, LB; Sundberg, JP | 1 |
| Guilhou, JJ | 2 |
| Mazer, JM | 2 |
| Dubertret, L; Grossman, RM; Maugée, E | 1 |
| Koo, J; Lee, J | 1 |
| Chang, CT; Charnick, S; Cohen, A; Elder, CA; Guzzo, C; Jin, J; Lowe, N; Moore, M; Nedelman, J; Simpson, K | 1 |
| Piérard, GE; Piérard-Franchimont, C | 1 |
| Ishii, M; Kobayashi, H; Taniguchi, S | 1 |
| Katayama, I; Nishioka, K; Yamamoto, T | 1 |
| Erkko, P; Lauerma, AI; Reitamo, S; Remitz, A | 1 |
| Finzi, AF | 1 |
| Gulliver, WP; Hannaford, VA; Murphy, GF; Primmett, DR | 1 |
| Baraldo, M; Croattino, L; Furlanut, M; Galla, F; Marzocchi, V; Pea, F | 1 |
| Bos, JD; De Rie, MA; Out, TA; Van Lier, RA; Witkamp, L; Zonneveld, IM | 1 |
| Goos, M; Haen, E; Nussbaum, G; Ockenfels, HM; Schneck, B; Wagner, SN | 1 |
| Danno, K; Kaji, A; Mochizuki, T | 1 |
| Bainbridge, C; Bourget, T; Dimov, I; Glass, E; Grabie, MT; Johnson, K; Kunkel, R; Lowe, NJ; Rosenbach, A; Simpson, K; Wieder, JM | 1 |
| Bordas, X; Curcó, N; Moreno, A; Peyrí, J; Sais, G; Serón, D; Servitje, O; Vidaller, A | 1 |
| Baumann, G; Borel, JF; Chapman, I; Donatsch, P; Fahr, A; Mueller, EA; Vigouret, JM | 1 |
| Li, VW; Li, WW | 1 |
| Gambla, C; Koo, J; Nguyen, Q | 1 |
| Berth-Jones, J; Voorhees, JJ | 1 |
| Iversen, L; Kragballe, K; Svendsen, M | 1 |
| Bjerring, P; Heickendorff, L; Zachariae, H | 1 |
| Altmeyer, P; Nüchel, C | 1 |
| Furuse, Y; Irimajiri, T; Katayama, I; Kimura, K; Koyano, T; Mamada, A; Miyazaki, K; Nishioka, K; Yamamoto, T | 1 |
| Chang, CT; Charnick, SB; Hwang, DS; Jin, J; Meligeni, J; Moore, MA; Nedelman, JR; Wong, R | 1 |
| Kuijpers, AL; van de Kerkhof, PC; van Dooren-Greebe, JV | 1 |
| Erkko, P; Granlund, H; Nuutinen, M; Reitamo, S | 1 |
| de Rooij, MJ; van de Kerkhof, PC | 1 |
| Abel, E; Bainbridge, C; Bauer, E; Birnbaum, JE; Brown, M; Drake, L; Evans, S; Freinkel, R; Guzzo, C; Hilss, S; Koo, J; Levine, N; Lowe, N; Margolis, D; McDonald, C; Mietlowski, W; Shupack, J; Stiller, M; Winslow, C; Wintroub, B | 1 |
| Skelton, HG; Smith, KJ | 1 |
| Bräutigam, M; Färber, L; Meffert, H; Weidinger, G | 1 |
| Batsios, K; Ioannides, D; Lazaridou, E; Mattheou-Vakali, G; Minas, A; Panagiotidou, D | 1 |
| Hansen, HE; Kragballe, K; Marcussen, N; Olsen, S; Zachariae, H | 2 |
| Berth-Jones, J; Boffa, MJ; Chalmers, RJ; Dowd, PM; Friedmann, PS; Graham-Brown, RA; Henderson, CA; Marks, R; Munro, CS; Norris, PG; Rogers, S; Sumner, MJ | 1 |
| Menné, T; Nielsen, NH | 1 |
| Durez, P; Farber, CM; Heenen, M; Liesnard, C; Parent, D; Tourne, L; Van Vooren, JP | 1 |
| Katz, HI | 1 |
| Campbell, JL; Zug, KA | 1 |
| Brown, PJ; Cains, GD; Georgouras, KE; Zagarella, SS | 1 |
| Armati, R; Hunt, MJ; Lee, SH; Salisbury, EL; Wills, EJ | 1 |
| Hirano, T; Hirata, M; Ichikawa, M; Koga, M; Kozaki, K; Kozaki, M; Matsuno, N; Nagao, T; Oh-i, T; Oka, K; Takeuchi, H; Umezawa, Y; Yoshida, M | 1 |
| Iizuka, M; Kawakubo, Y; Miyahara, M; Ohkido, M; Ozawa, A; Sugai, J | 1 |
| Bennett, WM | 1 |
| Arellano, F | 1 |
| Lowe, NJ | 1 |
| Shupack, JL | 1 |
| Weinstein, G | 1 |
| Gottlieb, AB | 1 |
| Kokelj, F; Plozzer, C; Torsello, P | 1 |
| Abrams, B; Bleehen, SS; Bräutigam, M; Burrows, D; Ettelt, MJ; Fry, L; Ganslandt, J; Happle, R; Haustein, UF; Jung, EG; Knop, J; Kühne, KH; Mellein, B; Mørk, NJ; Rogers, S; Schmidt, AG; Schopf, RE; Sumner, M; Taube, KM; Weidinger, G; Wurdel, C; Zachariae, H; Zahn, E | 1 |
| Cook, T; Fry, L; Hardman, CM; Hulme, B; Porter, WM; Powles, AV | 1 |
| Kirby, B; Rogers, S | 2 |
| Basarab, T; Griffiths, WA | 1 |
| Hirano, T; Hirata, M; Koga, M; Oh-i, T; Oka, K; Umezawa, Y | 1 |
| Paquet, P; Piérard, GE | 1 |
| Hayakawa, T; Hoshino, N; Minouchi, T; Shibata, N; Uehara, M; Yamaji, A | 1 |
| Ellis, C; Gottlieb, A; Koo, J; Krueger, G; Lebwohl, M; Linden, K; Shupack, J; Weinstein, G | 1 |
| Andreassi, L; Bartolommei, S; Flori, ML; Miracco, C; Pellegrino, M; Toti, P; Villanova, M | 1 |
| Kokelj, F; Plozzer, C; Torsello, P; Trevisan, G | 1 |
| Albano, JD; Campbell, SK; Cook, J; Farrer, A; Raman, GV | 1 |
| De Felipe, I; Redondo, P | 1 |
| Irimajiri, J; Kimura, K; Nishioka, K; Yamamoto, T; Yokozeki, H | 1 |
| Bräutigam, M; Hultsch, T; Lotz, J; Schopf, RE | 1 |
| Furue, M; Koga, T; Nakayama, J | 1 |
| Alli, N; Artüz, F; Güngör, E; Karakayali, G; Lenk, N | 1 |
| Grech, C; Mahendran, R | 1 |
| Erkko, P; Granlund, H; Lindelöf, B; Mobacken, H; Reitamo, S; Remitz, A; Rosen, K | 1 |
| Burgers, SA; van Vloten, WA | 1 |
| Georgouras, K; Wong, KC | 1 |
| Hardeman, MR; Ince, C; Meinardi, MM; Vreeken, J | 1 |
| Haruki, Y; Inaba, Y; Kobayashi, H; Ogawa, H; Ohkawara, A; Ohkido, M; Ohno, Y; Ozawa, A | 1 |
| Harrison, PV; Kirby, B | 1 |
| Cliff, S; Gharge, S; Marsden, RA; Pettengell, R | 1 |
| Benton, EC; De Silva, BD; Tidman, MJ | 1 |
| Bergman, R; Friedman-Birnbaum, R; Sprecher, E | 1 |
| Baker Damanhoury, Z; Raddadi, AA | 1 |
| Hornig, F; Paul, C | 1 |
| Dalaker, M; Iversen, OJ; Jacobsen, T; Lysvand, H | 1 |
| Berg, KJ; Cheng, H; Gullestad, L; Nordal, KP; Schwartz, MS; Simonsen, S | 1 |
| Roenigk, HH | 1 |
| Allen, BR; Barker, JN; Chalmers, RJ; Clark, CM; Davison, S; Emerson, R; Griffiths, CE; Kirby, B; Morris, AD; Saihan, EM; Zaki, I | 1 |
| Albrecht, G; Atakan, N; Clarke, P; Griffiths, CE; Ho, VC; León-Dorantes, G; Mørk, NJ; Ohannesson, A; Paul, C; Pfister, P; Reitamo, S; Vanaclocha, F | 1 |
| Avgerinou, G; Barkis, J; Degiannis, D; Demetriou, Z; Economidou, J; Katsambas, A; Psarra, K; Vareltzidis, A | 1 |
| Barthélemy, H; Bressieux, JM; Jan, V; Legoux, A; Reigneau, O; Steiner, HG; Vaillant, L | 1 |
| Dam, TN; Kang, S; Nickoloff, BJ; Voorhees, JJ | 1 |
| Carli, P; Giannotti, B | 1 |
| Linden, KG; Weinstein, GD | 1 |
| Gelfand, JM; Lebwohl, M; Tan, MH | 1 |
| Blanchet, F; Dubertret, L; Kaoukhov, A; Lahfa, M; Paul, C | 1 |
| Koo, J; Liao, W | 1 |
| Finch, TM; Tan, CY | 1 |
| Georgala, S; Koumantaki, E; Papadavid, E; Rallis, E | 1 |
| Arata, J; Matsuura, Y; Seno, A; Suemitsu, I | 1 |
| Harrison, PV; Owen, CM | 1 |
| Akan, T; Bukulmez, G; Ciliv, G | 1 |
| Davison, SC; Fry, L; Morris-Jones, R; Powles, AV | 1 |
| de Berker, D | 1 |
| Bieber, T; Bornhövd, EC; Schuller, E; Wollenberg, A | 1 |
| Andreassi, L; Flori, ML; Materno, M; Miracco, C; Pellegrino, M; Vatti, R | 1 |
| Gulliver, WP | 1 |
| Cainelli, F; Concia, E; Vento, S | 1 |
| Chodorowska, G; Czelej, D; Juszkiewicz-Borowiec, M; Krasowska, D; Pietrzak, A; Wojnowska, D | 1 |
| Beard, A; Berth-Jones, J; Dauden, E; Griffiths, CE; Ho, VC; Papp, KA; Paul, C; Puvanarajan, L; Vanaclocha, F | 1 |
| Feldman, S | 1 |
| Finlay, AY; Hakkaart-Van Roijen, L; Paul, C; Rutten, FF; Touw, CR; Verboom, P | 1 |
| Koga, M; Oh-i, T; Umezawa, Y | 1 |
| Hönigsmann, H | 1 |
| Hakkaart-van Roijen, L; Redekop, WK; Rutten, FF; Touw, KR; Verboom, P | 1 |
| Bryon, RJ; Chakrabarti, S; Griffiths, MJ; Handa, SK; Milligan, DW | 1 |
| Blomqvist, K; Davidsson, S; Molin, L; Mørk, C; Sigurgeirsson, B; Zachariae, H; Zachariae, R | 1 |
| Claudy, A; Griffiths, CE; Lahfa, M; Reitamo, S; Sassolas, B; Spuls, P | 1 |
| Bodary, S; Chi, Y; Tang, H; Tumas, DB; Varani, J; Zeigler, M | 1 |
| Marcil, I; Stern, RS | 1 |
| Ali, S; Lebwohl, M | 1 |
| Ameen, M; Barker, JN; Smith, HR | 1 |
| Burden, D; Leman, J | 1 |
| Braeutigam, M; Christophers, E; Drechsler, S; Faerber, L; Mahrle, G; Meffert, H; Mrowietz, U; Schulze, HJ; Weidinger, G | 1 |
| Duvic, M; Jones, D; Pielop, JA | 1 |
| Bodemer, C; de Prost, Y; Mahé, E; Pruszkowski, A; Teillac-Hamel, D | 1 |
| Green, J; Sinclair, RD | 1 |
| Chieregato, C; D'Onghia, FS; Miccolis, D; Rosina, P | 1 |
| Barbaud, A; Gillet, P; Reichert-Pénétrat, S; Schmutz, JL; Tréchot, P | 1 |
| Bandekar, RR; Ellis, CN; Fendrick, AM; Reiter, KL | 1 |
| Adamicová, K; Chromej, I; Cingel, P; Fetisovová, Z; Parobeková, K; Péc, J | 1 |
| Haring, P; Harvima, RJ; Laukkanen, A; Rinne, K | 1 |
| Dorner, AJ; Gilleaudeau, P; Kikuchi, T; Krueger, JG; Oestreicher, JL; Schwertschlag, U; Surette, J; Trepicchio, WL; Walters, IB | 1 |
| Markham, T; Rogers, S; Watson, A | 1 |
| Al-Daraji, WI; Grant, KR; Reynolds, NJ; Ryan, K; Saxton, A | 1 |
| Bowman, PH; Jones, C; Kashani-Sabet, M; Koo, J; LeBoit, PE; McCalmont, TH; Zackheim, HS; Zehnder, J | 1 |
| Bos, JD; de Rie, MA; Heydendael, VM; Opmeer, BC; Spuls, PI; Ten Berge, IJ | 1 |
| Das, UN; Koratkar, R; Madhavi, N; Padma, M; Ramesh, G; Sagar, PS; Sravankumar, G; Suryaprabha, P; Vijaykumar, K | 1 |
| Allen, BR | 1 |
| Ikari, Y; Kawaguchi, K; Mizoguchi, M; Mizushima, Y; Ohsuga, Y; Yanagawa, A | 1 |
| Demidem, A; Morel, P; Nicolas, JF; Revillard, JP; Rizova, H; Thivolet, J | 1 |
| Baadsgaard, O; Chang, EY; Cooper, KD; Ellis, CN; Fisher, G; Hammerberg, C; Voorhees, JJ | 1 |
| Petzelbauer, P; Wolff, K | 1 |
| Hammer, JH; Nielsen, HJ | 1 |
| Barazani, L; Carter, DM; Fu, SM; Gottlieb, AB; Granelli-Piperno, A; Grossman, RM; Khandke, L; Krueger, JG; Rivas, M; Sehgal, PB | 1 |
| Morel, P; Nicolas, JF; Revillard, JP; Rizova, H; Thivolet, J; Wijdenes, J | 1 |
| Davis, I; Jondreau, L; Kenny, C; Pak, GH; Shupack, JL; Stiller, MJ; Wachsman, S | 1 |
| Bachmann, H; Christophers, E; Färber, L; Mrowietz, U | 1 |
| Imanishi, K; Nagashima, M; Sagawa, Y; Shiohara, T | 1 |
| Goodman, MM; McCormick, A; McCullough, J; Weinstein, G; White, GM | 1 |
| Bjerke, JR | 1 |
| Färber, L; Höcher, J; Morsches, B; Rehder, M; Schopf, RE | 1 |
| Korstanje, MJ | 1 |
| Bianchi, L; Gatti, S; Nini, G | 1 |
| Detmar, M; Hettmannsperger, U; Kammler, HJ; Orfanos, CE; Owsianowski, M; Tenorio, S | 1 |
| Eckman, I; Gropper, C; Jondreau, L; Kenny, C; Shupack, JL; Stiller, MJ | 1 |
| Peter, RU; Ruzicka, T | 1 |
| Bulengo-Ransby, SM; Cantu-Gonzalez, G; Dubin, HV; Ellis, CN; Griffiths, CE; Voorhees, JJ | 1 |
| Brunetti, B; Delfino, M; Fabbrocini, G | 1 |
| Emmett, M; Menter, A; Silverman, AK | 1 |
| Fry, L | 1 |
| Erkko, P; Reitamo, S; Remitz, A | 1 |
| Fishman, K; Guzelian, PS; Hamilton, T; Kolars, JC; Lown, KS; Saenger, P; Turgeon, DK; Voorhees, JJ; Watkins, PB | 1 |
| Guzzo, C; Johnson, J; Lazarus, GS; Margolis, DJ | 1 |
| Bagot, M; Dubertret, L | 1 |
| Borradori, L; Dubertret, L; Gueissaz, F | 1 |
| Hansen, HE; Kragballe, K; Olsen, S; Zachariae, H | 1 |
| Feutren, G; Mihatsch, MJ | 1 |
| Fathman, CG; Myers, BD | 1 |
| Annesley, TM; Birnbaum, JE; Burns, MK; Duell, E; Eisen, D; Ellis, CN; Griffiths, CE; Hamilton, TA; Voorhees, JJ | 1 |
| Mihatsch, MJ; Wolff, K | 1 |
| Kadonaga, JN; Koo, JY; Lozada-Nur, FI; Wintroub, BV | 1 |
| Feutren, G; Mason, J | 1 |
| Hashimoto, K; Matsumura, N; Saijo, S; Tagami, H; Takematsu, H | 1 |
| Nielsen, HJ | 1 |
| Barr, RJ; Goodman, MM; Liao, SY; Ross, M | 1 |
| Christophers, E; Färber, L; Henneicke, HH; Mrowietz, U; Welzel, D | 1 |
| Demidem, A; Grammer, SF; Streilein, JW; Taylor, JR | 1 |
| Brinton, EA; Carter, DM; Delaney, RJ; Gottlieb, AB; Grossman, RM | 1 |
| Carter, DM; Gottlieb, AB; Grossman, RM; Khandke, L; Krane, J; Krueger, JG | 1 |
| Bernhard, JD; Person, JR | 1 |
| Hidano, A; Kawashima, M; Mitsuishi, T; Nogita, T; Terajima, S | 1 |
| Ellis, CN; Griffiths, CE; Groisser, DS; Voorhees, JJ | 1 |
148 review(s) available for cyclosporine and Psoriasis
| Article | Year |
|---|---|
A comprehensive review on possibilities of treating psoriasis using dermal cyclosporine.
Topics: Administration, Cutaneous; Administration, Oral; Cyclosporine; Humans; Hypertension; Immunosuppressive Agents; Psoriasis | 2022 |
A systematic review of the efficacy and safety of topical cyclosporine in dermatology.
Topics: Cyclosporine; Dermatology; Humans; Lichen Planus, Oral; Male; Psoriasis; Steroids | 2022 |
Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review.
Topics: Chronic Disease; Cyclosporine; Humans; Interleukin-17; Interleukin-23; Methotrexate; Psoriasis; Recurrence; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2022 |
Pustular psoriasis of pregnancy: Clinical and genetic characteristics in a series of eight patients and review of the literature.
Topics: Acitretin; Adult; CARD Signaling Adaptor Proteins; Cyclosporine; Female; Guanylate Cyclase; Humans; Infant; Infant, Newborn; Interleukins; Membrane Proteins; Pregnancy; Psoriasis; Retrospective Studies; Skin Diseases, Vesiculobullous; Steroids; Young Adult | 2022 |
Current management of generalized pustular psoriasis.
Topics: Acute Disease; CARD Signaling Adaptor Proteins; Chronic Disease; Cyclosporine; Female; Guanylate Cyclase; Humans; Interleukins; Membrane Proteins; Methotrexate; Psoriasis; Retinoids; Skin Diseases, Vesiculobullous | 2023 |
An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations.
Topics: Acitretin; Chronic Disease; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Psoriasis | 2023 |
Tapering and discontinuation of systemic medications in psoriasis patients with low disease activity.
Topics: Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Psoriasis; Quality of Life; Severity of Illness Index | 2020 |
Anti-CD6 mAbs for the treatment of psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Autoimmune Diseases; Cell Differentiation; Cyclosporine; Humans; Methotrexate; Psoriasis; Tumor Necrosis Factor-alpha | 2020 |
Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arthritis, Psoriatic; Cyclosporine; Humans; Methotrexate; Psoriasis | 2020 |
Cyclosporin in dermatology: A practical compendium.
Topics: Cyclosporine; Dermatology; Humans; Immunosuppressive Agents; Psoriasis; Skin Diseases | 2020 |
Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice.
Topics: Acitretin; Adult; Cyclosporine; Humans; Methotrexate; Psoriasis; United States | 2021 |
Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis.
Topics: Administration, Cutaneous; Animals; Cyclosporine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Liposomes; Methotrexate; Nanocapsules; Psoriasis; Salicylic Acid | 2021 |
Diagnosis and management of psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Biological Factors; Cholecalciferol; Chronic Disease; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Phototherapy; Psoriasis; Severity of Illness Index | 2017 |
Immunosuppression/Infections across Indications.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Candidiasis; Clinical Trials as Topic; Cyclosporine; Cytokines; Etanercept; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Infliximab; Methotrexate; Psoriasis; Surgical Wound Infection; Tuberculosis; Ustekinumab; Virus Diseases | 2018 |
Pathogenesis of psoriasis and development of treatment.
Topics: Biological Products; Cell Proliferation; Cyclosporine; Cytokines; Defensins; Dendritic Cells; Dermatologic Agents; Epidermal Cells; Epidermis; Humans; Keratinocytes; Phosphodiesterase 4 Inhibitors; Psoriasis; Retinoids; T-Lymphocytes, Helper-Inducer | 2018 |
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Topics: Acitretin; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Certolizumab Pegol; Cyclosporine; Dermatologic Agents; Etanercept; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Psoriasis; Thalidomide; Ustekinumab | 2018 |
Liver Illness and Psoriatic Patients.
Topics: Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Cyclosporine; Humans; Inflammation; Liver; Liver Diseases; Methotrexate; Psoriasis | 2018 |
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
Topics: Acitretin; Adult; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Fumarates; Humans; Methotrexate; Multicenter Studies as Topic; Observational Studies as Topic; Psoriasis; Severity of Illness Index; Treatment Outcome | 2019 |
Secukinumab (Cosentyx°) and plaque psoriasis.
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Cyclosporine; Etanercept; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Severity of Illness Index; Treatment Failure; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 2017 |
Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus.
Topics: Acitretin; Administration, Oral; Administration, Topical; Adult; Aged; Biological Products; Consensus; Cyclosporine; Dermatologic Agents; Disease Management; Expert Testimony; Female; Humans; Injections, Intralesional; Male; Methotrexate; Middle Aged; Nail Diseases; Practice Guidelines as Topic; Psoriasis; Recurrence; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme.
Topics: Acitretin; Antibodies, Monoclonal; Brazil; Clinical Decision-Making; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Methotrexate; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome | 2019 |
Interventions for nail psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Humans; Infliximab; Methotrexate; Nail Diseases; Psoriasis; Quality of Life; Randomized Controlled Trials as Topic; Ustekinumab | 2013 |
An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclosporine; Cytochrome P-450 Enzyme System; Drug Interactions; Etanercept; Humans; Immunoglobulin G; Infliximab; Male; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha; United States; Ustekinumab | 2014 |
Cyclosporine as maintenance therapy in patients with severe psoriasis.
Topics: Cyclosporine; Female; Humans; Immunosuppressive Agents; Male; Psoriasis | 2013 |
Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches.
Topics: Cyclosporine; Dose-Response Relationship, Drug; Humans; Immunosuppressive Agents; Psoriasis | 2013 |
Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Topics: Biological Factors; Cyclosporine; Dermatologic Agents; Fumarates; Humans; Methotrexate; Psoriasis; Randomized Controlled Trials as Topic; Retinoids; Risk Factors; Treatment Outcome | 2014 |
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Topics: Acitretin; Antibodies, Monoclonal, Humanized; Biological Therapy; Cardiovascular Diseases; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Mycophenolic Acid; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ustekinumab | 2014 |
Psoriasis.
Topics: Acitretin; Administration, Topical; Cardiovascular Diseases; Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Phototherapy; Psoriasis; Tumor Necrosis Factor-alpha | 2013 |
Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion.
Topics: Acitretin; Adrenal Cortex Hormones; Cyclosporine; Dermatologic Agents; Evidence-Based Medicine; Humans; Keratolytic Agents; Photochemotherapy; Practice Guidelines as Topic; Psoriasis | 2014 |
Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
Topics: Acitretin; Adipokines; Alcoholism; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Comorbidity; Cyclosporine; Dermatologic Agents; Diabetes Mellitus; Fumarates; Humans; Immunosuppressive Agents; Inflammation; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; Risk Factors; Smoking; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Pharmacogenomics and the resulting impact on psoriasis therapies.
Topics: Acitretin; Cyclosporine; Cytokines; HLA-C Antigens; Humans; Immunosuppressive Agents; Inflammation; Keratolytic Agents; Methotrexate; Pharmacogenetics; Phototherapy; Polymorphism, Genetic; Precision Medicine; Psoriasis; Research Design; Tumor Necrosis Factor-alpha | 2015 |
Etanercept combined with systemic drugs or phototherapy for treatment of psoriasis.
Topics: Acitretin; Antirheumatic Agents; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Etanercept; Humans; Methotrexate; Multicenter Studies as Topic; Prospective Studies; Psoriasis; Treatment Outcome; Ultraviolet Therapy | 2015 |
Weekend Ciclosporin Maintenance Therapy for Moderate Psoriasis.
Topics: Cohort Studies; Cyclosporine; Drug Administration Schedule; Humans; Maintenance Chemotherapy; Psoriasis; Treatment Outcome | 2015 |
Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments.
Topics: Acitretin; Administration, Cutaneous; Adrenal Cortex Hormones; Calcineurin Inhibitors; Calcitriol; Coal Tar; Contraindications; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Pregnancy; Pregnancy Complications; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ultraviolet Therapy; Ustekinumab | 2015 |
Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Topics: Adalimumab; Adolescent; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; Etanercept; Female; Humans; Infliximab; Male; Methotrexate; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Ultraviolet Therapy; Ustekinumab | 2015 |
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Cyclosporine; Disease Progression; Humans; Immunosuppressive Agents; Insurance, Health, Reimbursement; Keratolytic Agents; Medication Adherence; Methotrexate; Psoriasis; Symptom Flare Up; Thalidomide | 2016 |
Comparison of Guidelines for the Use of Cyclosporine for Psoriasis: A Critical Appraisal and Comprehensive Review.
Topics: Calcineurin Inhibitors; Canada; Contraindications; Cyclosporine; Dermatology; Drug Administration Schedule; Europe; Evidence-Based Medicine; Humans; Immunosuppression Therapy; Practice Guidelines as Topic; Psoriasis; T-Lymphocytes; United Kingdom; United States | 2016 |
Advances in Psoriasis.
Topics: Acitretin; Administration, Topical; Adrenal Cortex Hormones; Cyclosporine; Dermatologic Agents; Humans; Interleukins; Methotrexate; Phototherapy; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Vitamin D | 2017 |
Long-term safety of mycophenolate mofetil and cyclosporine: a review.
Topics: Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Infections; Long-Term Care; Mycophenolic Acid; Neoplasms; Pregnancy; Psoriasis; Safety | 2008 |
Treatments for psoriasis and the risk of malignancy.
Topics: Biological Products; Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Mycophenolic Acid; Psoriasis; PUVA Therapy; Skin Neoplasms; Ultraviolet Therapy | 2009 |
Retinoids, methotrexate and cyclosporine.
Topics: Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Psoriasis; Retinoids | 2009 |
Therapeutic options for palmoplantar pustulosis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Colchicine; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Phototherapy; Psoriasis; Randomized Controlled Trials as Topic; Retinoids; Treatment Outcome | 2010 |
Treatment of moderate-to-severe plaque psoriasis.
Topics: Abnormalities, Drug-Induced; Alefacept; Antibodies, Monoclonal; Clinical Trials as Topic; Contraindications; Cyclosporine; Etanercept; Female; Fumarates; Hematologic Diseases; Humans; Hypertension; Immunoglobulin G; Immunosuppressive Agents; Kidney Diseases; Male; Methotrexate; Photochemotherapy; Pregnancy; Pregnancy Complications; Psoriasis; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Retinoids; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2009 |
Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.
Topics: Adolescent; Adult; Animals; Child; Contraindications; Cyclosporine; Drug Interactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension; Kidney Diseases; Pregnancy; Psoriasis | 2010 |
Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Cyclosporine; Female; Humans; Infant, Newborn; Infliximab; Pregnancy; Pregnancy Complications; Psoriasis; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2010 |
Sonozaki syndrome: case report and review of literature.
Topics: Arthritis, Psoriatic; Cyclosporine; Female; Humans; Middle Aged; Perfusion Imaging; Psoriasis; Sternoclavicular Joint; Syndrome | 2012 |
Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review.
Topics: Acitretin; Acrodermatitis; Adalimumab; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Clobetasol; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Methotrexate; Mycophenolic Acid; Nails; Paronychia; Psoriasis; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor Inhibitors | 2010 |
Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence.
Topics: Cyclosporine; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Phototherapy; Psoriasis; Receptors, Tumor Necrosis Factor | 2010 |
Cutaneous vascular patterns in psoriasis.
Topics: Cell Proliferation; Cholecalciferol; Cyclosporine; Cytokines; Humans; Keratinocytes; Microvessels; Neovascularization, Pathologic; Psoriasis; Razoxane; Retinoids; Skin | 2010 |
[Prescription and surveillance of treatment by a systemic agent or biotherapy in psoriasis].
Topics: Biological Products; Contraindications; Cyclosporine; Drug Administration Routes; Drug Monitoring; Female; Folic Acid; Humans; Immunosuppressive Agents; Kidney Diseases; Latent Tuberculosis; Liver Cirrhosis; Medical History Taking; Methotrexate; Pregnancy; Pregnancy Complications; Psoriasis; Pulmonary Fibrosis; Recurrence; Tumor Necrosis Factor-alpha; Vaccination | 2010 |
Systemic combination treatment for psoriasis: a review.
Topics: Biological Products; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Methotrexate; Photochemotherapy; Photosensitizing Agents; Psoriasis; Retinoids; Treatment Outcome | 2010 |
A rare case of non-Hodgkins B-cell lymphoma in a psoriatic patient: a case report and literature review.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Female; Humans; Immunosuppressive Agents; Lymphoma, B-Cell; Methotrexate; Middle Aged; Psoriasis | 2010 |
Pharmacogenetics of psoriasis.
Topics: Acitretin; Adrenal Cortex Hormones; Antibodies, Monoclonal; Cyclosporine; Genetic Predisposition to Disease; Humans; Methotrexate; Pharmacogenetics; Precision Medicine; Psoriasis | 2011 |
[What's new in dermatological treatments?].
Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab | 2010 |
Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists.
Topics: Cyclosporine; Dermatology; Evidence-Based Practice; Humans; Methotrexate; Psoriasis; Retinoids; Treatment Outcome | 2011 |
Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.
Topics: Acute Kidney Injury; Administration, Oral; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Psoriasis; Risk Factors; Treatment Outcome | 2011 |
The use of cyclosporine in dermatology.
Topics: Chronic Disease; Cyclosporine; Dermatitis, Atopic; Dermatomyositis; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Prurigo; Psoriasis; Pyoderma Gangrenosum; Skin Diseases; Sweet Syndrome; Urticaria | 2012 |
The efficacy of 308nm laser treatment of psoriasis compared to historical controls.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Databases as Topic; Dermatologic Agents; Humans; Infliximab; Laser Therapy; Lasers; Phototherapy; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome; Ultraviolet Therapy | 2001 |
Comparative tolerability of systemic treatments for plaque-type psoriasis.
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Drug Combinations; Eye Diseases; Humans; Keratolytic Agents; Liver Cirrhosis; Lymphoproliferative Disorders; Methotrexate; Nausea; Pancytopenia; Pneumonia; Pruritus; Psoriasis; PUVA Therapy; Skin Neoplasms | 2002 |
Vitamin D and systemic therapy.
Topics: Acitretin; Administration, Oral; Administration, Topical; Calcitriol; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Ointments; Psoriasis | 2002 |
The FDA guidelines for the treatment of psoriasis using cyclosporine A: are they adequate?
Topics: Cyclosporine; Dermatologic Agents; Humans; Psoriasis; Time Factors; United States; United States Food and Drug Administration | 2002 |
A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.
Topics: Cholecalciferol; Cyclosporine; Cytokines; Fumarates; Humans; Inflammation Mediators; Interleukin-4; Methotrexate; Phototherapy; Psoriasis; Th1 Cells; Th2 Cells; Vitamin A | 2003 |
CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab.
Topics: Antibodies, Monoclonal; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Infliximab; Lymphoma, Large-Cell, Anaplastic; Male; Middle Aged; Psoriasis; Skin Neoplasms | 2003 |
Current systemic therapies for psoriasis: where are we now?
Topics: Acitretin; Antineoplastic Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Hydroxyurea; Keratolytic Agents; Methotrexate; Psoriasis; Remission Induction | 2003 |
Combining the new biologic agents with our current psoriasis armamentarium.
Topics: Alefacept; Antibodies, Monoclonal; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Infliximab; Methotrexate; Phototherapy; Psoriasis; PUVA Therapy; Recombinant Fusion Proteins | 2003 |
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.
Topics: Acitretin; Cyclosporine; Drug Therapy, Combination; Etretinate; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Recombinant Fusion Proteins; Treatment Outcome | 2003 |
[Prescription of phototherapy in psoriasis].
Topics: Acute Disease; Combined Modality Therapy; Cyclosporine; Furocoumarins; Humans; Immunosuppressive Agents; Photosensitizing Agents; Phototherapy; Psoriasis; Risk Factors; Severity of Illness Index; Skin Neoplasms | 2004 |
The use of ciclosporin in psoriasis: a clinical review.
Topics: Consensus; Cyclosporine; Guideline Adherence; Humans; Immunosuppressive Agents; Psoriasis; Quality of Life; Treatment Outcome | 2004 |
Ciclosporin in psoriasis clinical practice: an international consensus statement.
Topics: Consensus; Cyclosporine; Drug Administration Schedule; Guideline Adherence; Humans; Hypertension; Immunosuppressive Agents; Kidney Diseases; Psoriasis; Treatment Outcome | 2004 |
ISAtx-247 (Isotechnika/Roche).
Topics: Animals; Arthritis, Experimental; Calcineurin Inhibitors; Clinical Trials as Topic; Cyclosporine; Diabetes Mellitus, Type 1; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocyte Activation; Psoriasis; Structure-Activity Relationship | 2004 |
Biologics in combination with nonbiologics: efficacy and safety.
Topics: Antibodies, Monoclonal; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Methotrexate; Psoriasis | 2004 |
[The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis'].
Topics: Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Photochemotherapy; Practice Guidelines as Topic; Psoriasis; Safety; Treatment Outcome; Ultraviolet Therapy | 2004 |
[Treatment of the keratinizing skin disorder, psoriasis, by topical vitamin D3].
Topics: Administration, Topical; Cell Differentiation; Cell Division; Cholecalciferol; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; ErbB Receptors; Humans; Keratinocytes; Ointments; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-myc; Psoriasis; PUVA Therapy; Transglutaminases | 2004 |
Chronic plaque psoriasis.
Topics: Anthralin; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Ficusin; Humans; Nicotinic Acids; Psoriasis; Retinoids; Ultraviolet Therapy; Vitamin D | 2004 |
Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
Topics: Administration, Oral; Chronic Disease; Cyclosporine; Dermatologic Agents; Ficusin; Fumarates; Humans; Immunosuppressive Agents; Methotrexate; Photosensitizing Agents; Psoriasis; PUVA Therapy; Retinoids; Risk Assessment; Ultraviolet Therapy | 2005 |
Combining traditional agents and biologics for the treatment of psoriasis.
Topics: Acitretin; Adalimumab; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins | 2005 |
Potential future therapies for psoriasis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclosporine; Dermatologic Agents; Forecasting; Fumarates; Humans; Infliximab; Nicotinic Acids; Psoriasis; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Tacrolimus; Tumor Necrosis Factor Decoy Receptors; Ustekinumab | 2005 |
Chronic plaque psoriasis.
Topics: Anthralin; Anti-Inflammatory Agents; Combined Modality Therapy; Cyclosporine; Humans; Immunosuppressive Agents; Methotrexate; Psoriasis; PUVA Therapy; Retinoids; Ultraviolet Therapy; Vitamin D | 2005 |
Cyclosporin A-induced gingival hyperplasia in psoriasis: review of the literature and case reports.
Topics: Cyclosporine; Dermatologic Agents; Female; Gingival Hyperplasia; Humans; Middle Aged; Psoriasis | 2005 |
The use of ciclosporin in psoriasis.
Topics: Adult; Child; Cyclosporine; Dermatologic Agents; Female; Humans; Pregnancy; Psoriasis | 2005 |
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Arthritis, Rheumatoid; Cyclosporine; Disease Progression; Etanercept; Etretinate; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2006 |
Conventional systemic agents for psoriasis. A systematic review.
Topics: Acitretin; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hydroxyurea; Immunosuppressive Agents; Methotrexate; Practice Guidelines as Topic; Psoriasis; Thioguanine; Treatment Outcome | 2006 |
Update on the use of ciclosporin in immune-mediated dermatoses.
Topics: Arthritis, Psoriatic; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Patient Selection; Psoriasis; Quality of Life; Skin Diseases; Skin Diseases, Papulosquamous | 2006 |
Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Kidney; Psoriasis; T-Lymphocytes | 1990 |
Cyclosporin A treatment in severe childhood psoriasis.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; Female; Humans; Infant; Male; Psoriasis; Severity of Illness Index; Treatment Outcome | 2006 |
[Calcineurin inhibitors for topical therapy in psoriasis].
Topics: Administration, Topical; Calcineurin Inhibitors; Cell Division; Cyclosporine; Cytokines; Dermatologic Agents; Gene Expression Regulation; Granulocytes; Humans; Interleukin-2; Lymphocyte Activation; Mast Cells; Pilot Projects; Psoriasis; T-Lymphocytes; Tacrolimus | 2006 |
Chronic plaque psoriasis.
Topics: Adrenal Cortex Hormones; Alefacept; Anthralin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Cyclosporine; Cytokines; Dermatologic Agents; Humans; Methotrexate; Nicotinic Acids; Psoriasis; PUVA Therapy; Recombinant Fusion Proteins; Retinoids; Ultraviolet Therapy; Vitamin D | 2006 |
[Biologics in the treatment of psoriasis].
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Male; Methotrexate; Pregnancy; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Time Factors | 2006 |
Severe psoriasis treated with a new macrolide: everolimus.
Topics: Cyclosporine; Drug Synergism; Drug Therapy, Combination; Everolimus; Female; Humans; Immunosuppressive Agents; Middle Aged; Psoriasis; Sirolimus; Treatment Outcome | 2007 |
Treatment of childhood psoriasis.
Topics: Adrenal Cortex Hormones; Anthralin; Calcitriol; Child; Cyclosporine; Humans; Methotrexate; Nicotinic Acids; Phototherapy; Psoriasis; Retinoids | 2006 |
ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Topics: Animals; Calcineurin Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclosporine; Graft Rejection; Humans; Immunosuppressive Agents; Psoriasis; Rabbits; Randomized Controlled Trials as Topic; Skin Diseases | 2007 |
[The immunology of psoriasis: from basic research to the bedside].
Topics: Acitretin; Adrenal Cortex Hormones; Alefacept; Anthralin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoimmunity; Biomedical Research; Cell Differentiation; Cell Proliferation; Cyclosporine; Dermatologic Agents; Humans; Immunity, Cellular; Immunosuppressive Agents; Infliximab; Keratinocytes; Keratolytic Agents; Methotrexate; Psoriasis; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory; Ultraviolet Therapy | 2006 |
[Psoriasis].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Psoriatic; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; HIV Infections; Humans; Infant; Infant, Newborn; Keratolytic Agents; Methotrexate; Ointments; Phototherapy; Psoriasis; Skin; Time Factors; Vitamins | 2006 |
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Clinical Trials as Topic; Cyclosporine; Fluorouracil; Humans; Injections, Intralesional; Nail Diseases; Nails; Nicotinic Acids; Photochemotherapy; Phototherapy; Psoriasis | 2007 |
[Psoriatic erythroderma treated with etanercept].
Topics: Aged; Combined Modality Therapy; Cyclosporine; Dermatitis, Exfoliative; Etanercept; Female; Fever; Fluid Therapy; Humans; Immunoglobulin G; Immunosuppressive Agents; Psoriasis; Receptors, Tumor Necrosis Factor | 2007 |
[Long-term control of psoriasis is necessary].
Topics: Acitretin; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytokines; Dermatologic Agents; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Recurrence | 2008 |
Therapeutic progress. II: Treatment of psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Calcitriol; Coal Tar; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Emollients; Humans; Immunosuppressive Agents; Methotrexate; Phototherapy; Psoriasis; Retinoids; Tacrolimus; United Kingdom | 1994 |
FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.
Topics: Adult; Animals; Autoimmune Diseases; CD4-Positive T-Lymphocytes; Cholangitis; Cyclosporine; Diabetes Mellitus, Type 1; Digestive System Diseases; Disease Models, Animal; Drug Evaluation; Drug Evaluation, Preclinical; Female; Humans; Kidney Diseases; Male; Mice; Multiple Sclerosis; Nephrotic Syndrome; Psoriasis; Rats; Swine; Tacrolimus | 1993 |
Efficacy of cyclosporin A (CyA) in psoriasis: an overview of dose/response, indications, contraindications and side-effects.
Topics: Biopsy; Contraindications; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Male; Psoriasis; Recurrence | 1995 |
[The treatment of psoriasis].
Topics: Adrenal Cortex Hormones; Calcitriol; Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Psoriasis; Ultraviolet Therapy | 1993 |
Cytokine system as potential target for antipsoriatic therapy.
Topics: Anthralin; Cholecalciferol; Cyclosporine; Cytokines; Glucocorticoids; Humans; Keratinocytes; Psoriasis; Receptors, Cytokine; Retinoids; Ultraviolet Therapy | 1994 |
Cyclosporin in psoriasis: pathophysiology and experimental data.
Topics: CD4-Positive T-Lymphocytes; Cells, Cultured; Chemotaxis, Leukocyte; Cyclosporine; Humans; Langerhans Cells; Neutrophils; Psoriasis | 1993 |
[Concepts of the mechanisms of action of cyclosporin in psoriasis. A review with guidelines on therapy].
Topics: Calcineurin; Calmodulin-Binding Proteins; Cyclosporine; Humans; Langerhans Cells; Lymphocyte Activation; Mast Cells; Phosphoprotein Phosphatases; Psoriasis; Signal Transduction; T-Lymphocytes | 1993 |
[Treatment of psoriasis].
Topics: Adrenal Cortex Hormones; Anthralin; Combined Modality Therapy; Cyclosporine; Humans; Methotrexate; Psoriasis; PUVA Therapy; Retinoids; Tars; Ultraviolet Therapy; Vitamin D | 1993 |
The mechanisms of action of cyclosporin A in the treatment of psoriasis.
Topics: Antigen-Presenting Cells; Chemotaxis, Leukocyte; Cyclosporine; Cytokines; Humans; Keratinocytes; Lymphokines; Models, Biological; Psoriasis; T-Lymphocytes | 1993 |
Psoriasis: mechanisms and entry points for possible therapeutic interventions.
Topics: Clinical Trials as Topic; Cyclosporine; Humans; Immunosuppressive Agents; Photochemotherapy; Prognosis; Psoriasis; Tacrolimus | 1996 |
Cyclosporine: what clinicians need to know.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Patient Selection; Psoriasis | 1995 |
Adenocarcinoma of the mouth in a patient with psoriasis under short-term cyclosporine therapy.
Topics: Adenocarcinoma; Cyclosporine; Drug Administration Schedule; Humans; Immunosuppressive Agents; Male; Middle Aged; Mouth Neoplasms; Psoriasis | 1996 |
Individualized short-course cyclosporin therapy in psoriasis.
Topics: Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Humans; Psoriasis | 1996 |
In vivo pharmacological effects of ciclosporin and some analogues.
Topics: Amino Acid Isomerases; Asthma; Carrier Proteins; Cyclosporine; Immunosuppression Therapy; Immunosuppressive Agents; Peptidylprolyl Isomerase; Psoriasis | 1996 |
Advances in psoriasis therapy.
Topics: Absorption; Acitretin; Administration, Cutaneous; Calcitriol; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Keratolytic Agents; Ointments; Psoriasis | 1997 |
Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996.
Topics: Blood Pressure; Creatinine; Cyclosporine; Dermatologic Agents; Drug Interactions; Emulsions; Humans; Psoriasis | 1996 |
[Systemic therapy of psoriasis].
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Photochemotherapy; Phototherapy; Psoriasis | 1996 |
Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis.
Topics: Acitretin; Aged; Aged, 80 and over; Calcitriol; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Drug Combinations; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Prognosis; Psoriasis | 1997 |
Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
Topics: Acitretin; Administration, Topical; Calcitriol; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Drug Synergism; Drug Therapy, Combination; Etretinate; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Ointments; Phototherapy; Psoriasis; Risk; Safety; Treatment Outcome | 1997 |
Systemic treatment of severe psoriasis.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Methotrexate; Phototherapy; Prognosis; Psoriasis; Retinoids; Severity of Illness Index | 1997 |
Cyclosporine nephrotoxicity: implications for dermatology.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Kidney; Kidney Diseases; Psoriasis | 1997 |
Neoral in psoriasis therapy: toward a new perspective.
Topics: Cyclosporine; Dose-Response Relationship, Drug; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Psoriasis; Severity of Illness Index; Treatment Outcome | 1997 |
Initiating Neoral therapy.
Topics: Cyclosporine; Dose-Response Relationship, Drug; Emulsions; Humans; Immunosuppressive Agents; Kidney; Kidney Diseases; Psoriasis | 1997 |
Maintenance therapy with Neoral.
Topics: Algorithms; Cyclosporine; Emulsions; Humans; Immunosuppressive Agents; Long-Term Care; Psoriasis | 1997 |
Psoriasis therapy after remission: the next step.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Long-Term Care; Psoriasis; Remission Induction | 1997 |
The challenges of treating moderate to severe psoriasis.
Topics: Combined Modality Therapy; Cyclosporine; Humans; Immunosuppressive Agents; Long-Term Care; Psoriasis; PUVA Therapy; Remission Induction | 1997 |
Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.
Topics: Contraindications; Cyclosporine; Humans; Immunosuppressive Agents; Psoriasis | 1998 |
Cyclosporin and pregnancy.
Topics: Adult; Cyclosporine; Female; Humans; Immunosuppressive Agents; Male; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Psoriasis | 1999 |
Acitretin combination therapy.
Topics: Acitretin; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Ultraviolet Therapy | 1999 |
Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results.
Topics: Acitretin; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis | 1999 |
Cyclosporin A and retinoids in psoriasis.
Topics: Clinical Trials as Topic; Cyclosporine; Cytokines; Humans; Immunosuppressive Agents; Kidney; Psoriasis; Retinoids | 1999 |
Psoriasis: current perspectives with an emphasis on treatment.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Calcitriol; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Nicotinic Acids; Phototherapy; Psoriasis; PUVA Therapy; Retinoids; Severity of Illness Index; United States | 1999 |
Clinically significant therapeutic interactions for the practicing dermatologist.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Dermatology; Drug Interactions; Erythromycin; Humans; Methotrexate; Photosensitizing Agents; Practice Patterns, Physicians'; Psoriasis; PUVA Therapy | 1999 |
Update on psoriasis therapy: a perspective from the USA.
Topics: Acitretin; Calcitriol; Clobetasol; Cyclosporine; Dermatologic Agents; Humans; Photochemotherapy; Psoriasis; United States | 2000 |
Management of nail psoriasis.
Topics: Administration, Topical; Anti-Inflammatory Agents; Antifungal Agents; Cyclosporine; Dermatologic Agents; Female; Fluorouracil; Glucocorticoids; Humans; Keratosis; Male; Methotrexate; Nail Diseases; Psoriasis; Triamcinolone Acetonide | 2000 |
[Psoriasis vulgaris].
Topics: Cholecalciferol; Chromosomes, Human, Pair 6; Cyclosporine; Diagnosis, Differential; HLA-C Antigens; Humans; Immunosuppressive Agents; Prognosis; Psoriasis; PUVA Therapy; Retinoids | 2000 |
Advances in psoriasis treatment.
Topics: Acitretin; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Coal Tar; Cyclosporine; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Nicotinic Acids; Patient Education as Topic; Phototherapy; Psoriasis; PUVA Therapy; Quality of Life; Social Support; Triamcinolone | 2000 |
Phototherapy for psoriasis.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Methotrexate; Psoriasis; PUVA Therapy; Retinoids; Skin; Ultraviolet Therapy | 2001 |
Treatment of psoriasis. Part 2. Systemic therapies.
Topics: Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Methotrexate; Psoriasis; Retinoids | 2001 |
Psoriasis in children: a guide to its diagnosis and management.
Topics: Adrenal Cortex Hormones; Age of Onset; Child; Child, Preschool; Cyclosporine; Emollients; Humans; Immunosuppressive Agents; Methotrexate; Phototherapy; Practice Guidelines as Topic; Prevalence; Psoriasis; Retinoids; Vitamin D | 2001 |
Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.
Topics: Adolescent; Aged; Aged, 80 and over; Analysis of Variance; Cyclosporine; Dermatologic Agents; Female; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Psoriasis; Severity of Illness Index | 2001 |
Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels.
Topics: Adult; Creatinine; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney; Male; Middle Aged; Prospective Studies; Psoriasis | 2002 |
[Cyclosporin A in the therapy of inflammatory dermatoses].
Topics: Behcet Syndrome; Cyclosporine; Dermatitis; Dermatitis, Atopic; Humans; Lichen Planus; Photosensitivity Disorders; Psoriasis; Pyoderma Gangrenosum; Scleroderma, Localized | 1992 |
Can maintenance cyclosporine be used in psoriasis without decreasing renal function?
Topics: Cyclosporine; Glomerular Filtration Rate; Humans; Kidney; Psoriasis | 1992 |
[Psoriasis: therapeutic perspectives].
Topics: Calcitriol; Cyclosporine; Cytokines; Dermatologic Agents; Dihydroxycholecalciferols; Humans; Phototherapy; Psoriasis; PUVA Therapy | 1992 |
Cyclosporin for palmoplantar pustulosis.
Topics: Cyclosporine; Humans; Psoriasis | 1992 |
[Nail psoriasis].
Topics: Administration, Topical; Adrenal Cortex Hormones; Cyclosporine; Fluorouracil; Humans; Nail Diseases; Nails; Photochemotherapy; Psoriasis; PUVA Therapy; Retinoids | 1992 |
Consensus conference on cyclosporin A for psoriasis February 1992.
Topics: Cyclosporine; Drug Administration Schedule; Humans; Kidney; Morocco; Psoriasis | 1992 |
Histamine and histamine type-2 receptor antagonists in psoriasis. Mechanisms and speculations.
Topics: Cyclosporine; Histamine; Histamine Antagonists; Histamine H2 Antagonists; Humans; Methotrexate; Psoriasis; Ranitidine | 1991 |
[Cyclosporine and psoriasis].
Topics: Cyclosporine; Drug Administration Schedule; Humans; Psoriasis | 1991 |
A review and update of the clinical uses of cyclosporine in dermatology.
Topics: Alopecia; Cyclosporine; Dermatitis, Atopic; Dermatology; Humans; Lichen Planus; Mycosis Fungoides; Pemphigus; Psoriasis; Skin Diseases | 1991 |
109 trial(s) available for cyclosporine and Psoriasis
| Article | Year |
|---|---|
Efficacy of the topical cyclosporine cream assisted by fractional carbon dioxide laser vs topical clobetasol cream for the treatment of plaque psoriasis: Randomized comparative study.
Topics: Carbon Dioxide; Clobetasol; Cyclosporine; Emollients; Humans; Lasers, Gas; Psoriasis; Severity of Illness Index; Treatment Outcome | 2022 |
Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers; Brachial Artery; Cyclosporine; Echocardiography; Female; Heart Ventricles; Humans; Immunosuppressive Agents; Interleukin-17; Male; Methotrexate; Middle Aged; Prognosis; Psoriasis; Pulse Wave Analysis; Vascular Stiffness; Ventricular Function, Left | 2020 |
Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
Topics: Acitretin; Cyclosporine; Hospitals; Humans; Methotrexate; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2021 |
Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Therapy; Cyclosporine; Dermatologic Agents; Drug Substitution; Female; Humans; Interleukin-17; Japan; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome | 2017 |
Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
Topics: Adrenal Cortex Hormones; Aged; Cholecalciferol; Cyclosporine; Drug Administration Schedule; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome | 2014 |
Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.
Topics: Adult; Cyclosporine; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Etanercept; Europe; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Recurrence; Remission Induction; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis.
Topics: Acitretin; Adult; Biomarkers; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interleukin-2; Keratolytic Agents; Male; Middle Aged; Prognosis; Prospective Studies; Psoriasis; Severity of Illness Index; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician
Topics: Administration, Oral; Calcineurin Inhibitors; Clinical Competence; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Physicians; Psoriasis; Quality of Life; Severity of Illness Index; Time Factors | 2015 |
Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
Topics: Adult; Clinical Competence; Cyclosporine; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Physicians; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Biological Products; Cyclosporine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Severity of Illness Index; Treatment Outcome | 2016 |
Efficacy of Novel Topical Liposomal Formulation of Cyclosporine in Mild to Moderate Stable Plaque Psoriasis: A Randomized Clinical Trial.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Clobetasol; Cyclosporine; Dermatologic Agents; Double-Blind Method; Female; Gels; Humans; Liposomes; Male; Middle Aged; Nanostructures; Psoriasis; Severity of Illness Index; Skin Cream; Treatment Outcome; Young Adult | 2016 |
The objective Psoriasis Area and Severity Index: a randomized controlled pilot study comparing the effectiveness of ciclosporin and methotrexate.
Topics: Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Female; Humans; Male; Methotrexate; Pilot Projects; Psoriasis; Treatment Outcome | 2017 |
A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Topics: Adult; Alefacept; CD4 Lymphocyte Count; Cyclosporine; Dermatologic Agents; Drug Administration Routes; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunologic Factors; Immunosuppressive Agents; Infections; Lymphopenia; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Recombinant Fusion Proteins; Retinoids; Retreatment; Treatment Outcome; Ultraviolet Therapy | 2008 |
The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Humans; Inflammation; Male; Middle Aged; Psoriasis | 2008 |
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.
Topics: Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Diet, Reducing; Female; Humans; Life Style; Male; Middle Aged; Obesity; Psoriasis; Severity of Illness Index; Treatment Outcome; Weight Loss | 2008 |
A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis.
Topics: Adult; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Probability; Prospective Studies; Psoriasis; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2009 |
Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study.
Topics: Cyclosporine; Humans; Methotrexate; Nail Diseases; Psoriasis; Single-Blind Method | 2011 |
A global approach to psoriatic patients through PASI score and Skindex-29.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Diagnostic Self Evaluation; Emotions; Etanercept; Female; Folic Acid; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interpersonal Relations; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2011 |
Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
Topics: Adult; Cyclosporine; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Quality of Life; Treatment Outcome | 2011 |
Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
Topics: Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ointments; Pilot Projects; Psoriasis; Severity of Illness Index; Young Adult | 2012 |
CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy.
Topics: Adenosine Deaminase; Adult; Aged; Aged, 80 and over; Biomarkers; Cyclosporine; Dipeptidyl Peptidase 4; Etanercept; Female; Ficusin; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Photochemotherapy; Photosensitizing Agents; Prospective Studies; Psoriasis; Receptors, Tumor Necrosis Factor; Ultraviolet Therapy; Young Adult | 2011 |
Live attenuated varicella vaccine: a new effective adjuvant weapon in the battlefield against severe resistant psoriasis, a pilot randomized controlled trial.
Topics: Chickenpox Vaccine; Combined Modality Therapy; Cyclosporine; Drug Resistance; Female; Humans; Immunosuppressive Agents; Immunotherapy, Active; Male; Pilot Projects; Psoriasis; Severity of Illness Index; Vaccines, Attenuated | 2012 |
Maintenance treatment of psoriasis with cyclosporine A: comparison between continuous and weekend therapy.
Topics: Adult; Cyclosporine; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 2013 |
A highly decreased binding of cyclic adenosine monophosphate to protein kinase A in erythrocyte membranes is specific for active psoriasis.
Topics: Administration, Topical; Adolescent; Adult; Affinity Labels; Aged; Anthralin; Anti-Inflammatory Agents; Azides; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclosporine; Dermatologic Agents; Erythrocyte Membrane; Etretinate; Female; Humans; Keratolytic Agents; Male; Middle Aged; Protein Binding; Psoriasis; Retinoids; Severity of Illness Index | 2002 |
Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.
Topics: Administration, Topical; Adult; Body Surface Area; Body Weight; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Emulsions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Probability; Psoriasis; Quality of Life; Reference Values; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2002 |
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
Topics: Adult; Cyclosporine; Dermatologic Agents; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prospective Studies; Psoriasis; PUVA Therapy; Risk Factors; Skin Neoplasms | 2003 |
Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Male; Middle Aged; Nail Diseases; Prospective Studies; Psoriasis | 2003 |
Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ.
Topics: Adult; Aged; Cyclosporine; Female; Humans; Immunohistochemistry; Immunosuppressive Agents; Interferon-gamma; Interleukin-4; Lymphocyte Count; Male; Methotrexate; Middle Aged; Prospective Studies; Psoriasis; T-Lymphocytes | 2003 |
Long-term continuous versus intermittent cyclosporin: therapy for psoriasis.
Topics: Adult; Aged; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Long-Term Care; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome | 2003 |
Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India.
Topics: Adult; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Female; Humans; India; Male; Methotrexate; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome | 2003 |
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
Topics: Adult; Chronic Disease; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Psoriasis; Quality of Life; Severity of Illness Index | 2003 |
Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients.
Topics: Adult; CD4 Lymphocyte Count; Cyclosporine; Cytokines; Female; Humans; Interferon-gamma; Interleukin-4; Male; Methotrexate; Middle Aged; Psoriasis; Severity of Illness Index; Th1 Cells; Th2 Cells | 2004 |
Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
Topics: Administration, Oral; Adult; Cost of Illness; Cost-Benefit Analysis; Cyclosporine; Dermatology; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Hospital Costs; Humans; Immunosuppressive Agents; Male; Methotrexate; Netherlands; Outpatient Clinics, Hospital; Psoriasis; Severity of Illness Index; Treatment Outcome | 2004 |
Cyclosporine in severe psoriasis: an Indian experience.
Topics: Adult; Cyclosporine; Dermatologic Agents; Female; Humans; India; Male; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome | 2004 |
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.
Topics: Adolescent; Adult; Aged; Calcineurin Inhibitors; Cyclosporine; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis | 2006 |
Daily versus intermittent application of high-concentration tacalcitol ointment in combination with low-dose cyclosporin for psoriasis vulgaris.
Topics: Administration, Topical; Adult; Aged; Cyclosporine; Dihydroxycholecalciferols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ointments; Patient Satisfaction; Probability; Prospective Studies; Psoriasis; Risk Factors; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2006 |
Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
Topics: Adult; Aged; Chronic Disease; Cross-Over Studies; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Psoriasis | 2006 |
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Pilot Projects; Prospective Studies; Psoriasis; Recurrence; Retinoids; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Withholding Treatment | 2006 |
Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
Topics: Adult; Aged; Cell Differentiation; Cell Proliferation; Cyclosporine; Dendritic Cells; Dermis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Immunohistochemistry; Immunosuppressive Agents; Keratin-10; Keratin-14; Keratin-16; Keratinocytes; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome | 2007 |
Effect of PUVA, narrow-band UVB and cyclosporin on inflammatory cells of the psoriatic plaque.
Topics: Antigen-Presenting Cells; Antigens, CD; Cell Count; Cyclosporine; Dendritic Cells; Fluorescent Antibody Technique, Direct; Humans; Immunosuppressive Agents; Keratinocytes; Lymphocyte Subsets; Macrophages; Psoriasis; PUVA Therapy; Skin; Ultraviolet Therapy | 2007 |
Cutaneous vascular alterations in psoriatic patients treated with cyclosporine.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Female; Humans; Male; Microcirculation; Microscopic Angioscopy; Middle Aged; Psoriasis; Skin | 2007 |
Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris.
Topics: Aged; Cyclosporine; Dermatologic Agents; Drug Costs; Female; Humans; Male; Middle Aged; Patient Satisfaction; Psoriasis; Severity of Illness Index; Treatment Outcome | 2007 |
Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cyclosporine; Drug Administration Schedule; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multicenter Studies as Topic; Pilot Projects; Postprandial Period; Psoriasis; Severity of Illness Index; Skin; Statistics, Nonparametric; Treatment Outcome | 2007 |
Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Cyclosporine; Drug Monitoring; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Time Factors | 2007 |
Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis.
Topics: Administration, Oral; Adult; Area Under Curve; Cyclosporine; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Intestinal Absorption; Male; Middle Aged; Postprandial Period; Psoriasis; Statistics, Nonparametric; Time Factors | 2007 |
An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.
Topics: Adolescent; Adult; Aged; Alefacept; CD4 Lymphocyte Count; Chronic Disease; Combined Modality Therapy; Common Cold; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Focal Infection, Dental; Humans; Middle Aged; Pilot Projects; Psoriasis; Quality of Life; Recombinant Fusion Proteins; Retreatment; Suicide, Attempted; Treatment Outcome; Ultraviolet Rays | 2007 |
A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
Topics: Adult; Aged; Cyclosporine; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome | 2007 |
The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Topics: Acitretin; Adult; Aged; Alefacept; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Recombinant Fusion Proteins; Treatment Outcome | 2006 |
Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
Topics: Adolescent; Adult; Aged; Chronic Disease; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2007 |
Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
Topics: Adolescent; Adult; Aged; Cyclosporine; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2008 |
Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis.
Topics: Antigens, CD; Autoimmune Diseases; CD3 Complex; CD83 Antigen; Cyclosporine; Dendritic Cells; Gene Expression; Gene Expression Profiling; Humans; Immunoglobulins; Immunosuppressive Agents; Interleukin-17; Interleukin-2 Receptor alpha Subunit; Membrane Glycoproteins; Nitric Oxide Synthase Type II; Pharmacogenetics; Psoriasis; Signal Transduction; Skin; T-Lymphocytes, Helper-Inducer; Tumor Necrosis Factor-alpha | 2008 |
The search for effective and safe disease control in psoriasis.
Topics: Calcineurin Inhibitors; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Humans; Psoriasis; PUVA Therapy; Treatment Outcome | 2008 |
Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.
Topics: Adolescent; Adult; Aged; Blood Pressure; Calcineurin Inhibitors; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index | 2008 |
Low-dose cyclosporine A improves severe disabling psoriasis in Latin America. Latin American Multicenter Study.
Topics: Adolescent; Adult; Aged; Cyclosporine; Humans; Latin America; Middle Aged; Psoriasis | 1995 |
Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy.
Topics: Adult; Aged; Cyclosporine; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psoriasis; Remission Induction; Time Factors | 1995 |
Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Creatinine; Cyclosporine; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Ointments; Psoriasis; Recurrence; Safety; Salicylates; Salicylic Acid; Time Factors; Triglycerides | 1995 |
[Psoriasis and cyclosporine: an attempt at topical treatment].
Topics: Administration, Topical; Adult; Chronic Disease; Cyclosporine; Dimethyl Sulfoxide; Double-Blind Method; Female; Humans; Male; Middle Aged; Pharmaceutical Vehicles; Psoriasis | 1994 |
Remission of ordinary psoriasis following a short clearance course of cyclosporin.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Anthralin; Arthritis; Blood Pressure; Creatinine; Cyclosporine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nail Diseases; Photochemotherapy; Psoriasis; Recurrence; Remission Induction; Ultraviolet Therapy | 1995 |
Renal effects of maintenance low-dose cyclosporin A treatment in psoriasis.
Topics: Adult; Aged; Biopsy, Needle; Cyclosporine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Psoriasis; Renal Circulation; Time Factors | 1994 |
Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
Topics: Administration, Cutaneous; Adult; Anthralin; Arthritis, Psoriatic; Blood Pressure; Chronic Disease; Cyclosporine; Dose-Response Relationship, Drug; Etretinate; Female; Follow-Up Studies; Germany; Humans; Male; Middle Aged; Nail Diseases; Psoriasis; Recurrence; Severity of Illness Index; Skin; Time Factors; Treatment Outcome | 1995 |
A prospective study of renal structure and function in psoriasis patients treated with cyclosporin.
Topics: Adult; Aged; Creatinine; Cyclosporine; Female; Fibrosis; Glomerular Filtration Rate; Humans; Iothalamic Acid; Kidney; Male; Middle Aged; Prospective Studies; Psoriasis; Time Factors | 1994 |
Low-dose cyclosporine A nephrotoxicity in non-renal patients.
Topics: Administration, Oral; Adult; Analysis of Variance; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Kidney; Male; Middle Aged; Prospective Studies; Psoriasis; Uveitis | 1994 |
Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis.
Topics: Adult; Calcitriol; Cell Division; Chronic Disease; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Humans; In Vitro Techniques; Lymphocyte Culture Test, Mixed; Lymphocytes; Male; Psoriasis | 1994 |
A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study.
Topics: Adult; Aged; Calcitriol; Cyclosporine; Dermatologic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ointments; Psoriasis | 1994 |
Cyclical immunotherapy in patients with psoriasis.
Topics: Cyclosporine; Humans; Psoriasis | 1994 |
Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis.
Topics: Adult; Aged; Angiotensin II; Cyclosporine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Psoriasis; Renal Circulation; Renin-Angiotensin System; Risk Factors | 1994 |
Immunomodulation of psoriasis with a topical cyclosporin A formulation.
Topics: Administration, Cutaneous; Adult; Aged; Antigens, CD; CD3 Complex; Cell Adhesion Molecules; Chronic Disease; Cyclosporine; Double-Blind Method; HLA-DR Antigens; Humans; Immune Tolerance; Intercellular Adhesion Molecule-1; Keratinocytes; Lymphocyte Activation; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Pharmaceutical Vehicles; Psoriasis; Receptors, Interleukin-2; Skin | 1993 |
Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Neoplasms; Psoriasis; Remission Induction; Treatment Outcome | 1994 |
Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine.
Topics: Adult; Biopsy; Blood Pressure; Chronic Disease; Creatinine; Cyclosporine; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Prospective Studies; Psoriasis; Renal Plasma Flow; Risk Factors | 1994 |
Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Cyclosporine; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis | 1993 |
Effect of cyclosporine on genital psoriasis and lichen planus.
Topics: Administration, Cutaneous; Adult; Cyclosporine; Humans; Lichen Planus; Male; Penile Diseases; Psoriasis; Time Factors | 1993 |
Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
Topics: Adult; Aged; Aged, 80 and over; Clinical Protocols; Cyclosporine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Psoriasis; Recurrence; Remission Induction; Severity of Illness Index; Time Factors; Treatment Outcome | 1993 |
Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
Topics: Adult; Aged; Cyclosporine; Dermatitis, Exfoliative; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Psoriasis; Recurrence; Remission Induction; Severity of Illness Index; Time Factors; Treatment Outcome | 1993 |
Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
Topics: Adolescent; Adult; Aged; Cyclosporine; Etretinate; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Psoriasis; Recurrence; Remission Induction; Severity of Illness Index; Time Factors | 1993 |
Treatment of psoriasis with cyclosporin. Experience at Johannesburg Hospital.
Topics: Adult; Aged; Cyclosporine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; South Africa | 1995 |
Long-term safety of cyclosporine in the treatment of psoriasis.
Topics: Adolescent; Adult; Aged; Cyclosporine; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney; Male; Middle Aged; Neoplasms; Psoriasis; Time Factors | 1996 |
Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
Topics: Cyclosporine; Dose-Response Relationship, Drug; Female; Fluorescence Polarization Immunoassay; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 1996 |
Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis.
Topics: Chemistry, Pharmaceutical; Cross-Over Studies; Cyclosporine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Individuality; Male; Psoriasis; Regression Analysis | 1995 |
Delayed-type hypersensitivity in palmoplantar pustulosis: effect of cyclosporin A treatment on skin testing with recall antigens.
Topics: Adult; Antigens; Antigens, Bacterial; Antigens, Fungal; Cyclosporine; Diphtheria Toxoid; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Immunosuppressive Agents; Injections, Intradermal; Male; Middle Aged; Pharmaceutical Vehicles; Placebos; Psoriasis; Skin; Skin Tests; T-Lymphocytes; Tetanus Toxoid; Tuberculin Test | 1996 |
Clinical aspects: preliminary experience with a novel oral formulation of cyclosporin (Neoral).
Topics: Chemistry, Pharmaceutical; Chronic Disease; Cyclosporine; Dermatologic Agents; Emulsions; Follow-Up Studies; Humans; Psoriasis; Recurrence | 1996 |
Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin.
Topics: Adult; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Cyclosporine; Dermatologic Agents; Emulsions; Female; Humans; Male; Psoriasis | 1996 |
Blood concentrations and clinical effect of cyclosporin in psoriasis.
Topics: Adult; Aged; Blood Pressure; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Treatment Outcome | 1996 |
Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure.
Topics: Adult; Aged; Biopsy; Blood Pressure; Cyclosporine; Female; Humans; Immunosuppressive Agents; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Time Factors | 1996 |
Description of blood pressure changes in patients beginning cyclosporin A therapy.
Topics: Adult; Age Factors; Blood Pressure; Body Weight; Cyclosporine; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Psoriasis | 1997 |
Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis.
Topics: Administration, Oral; Adult; Chemistry, Pharmaceutical; Cross-Over Studies; Cyclosporine; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Psoriasis | 1997 |
Cyclosporine as maintenance therapy in patients with severe psoriasis.
Topics: Administration, Oral; Adult; Aged; Cyclosporine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 1997 |
Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
Topics: Adolescent; Adult; Aged; Cholesterol; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Lipids; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome; Triglycerides | 1997 |
Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
Topics: Adult; Aged; Chronic Disease; Cyclosporine; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome | 1997 |
Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Calcitriol; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Treatment Outcome | 1998 |
Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Chemistry, Pharmaceutical; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Drug Evaluation; Emulsions; Female; Humans; Immunosuppressive Agents; Kidney Calculi; Leg; Male; Menorrhagia; Middle Aged; Pain; Psoriasis; Treatment Outcome | 1998 |
A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
Topics: Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Chronic Disease; Cyclosporine; Double-Blind Method; Drug Administration Schedule; Humans; Immunosuppressive Agents; Middle Aged; Prospective Studies; Psoriasis | 1998 |
Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cyclosporine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kallikreins; Kidney; Longitudinal Studies; Male; Middle Aged; Psoriasis; Renin | 1998 |
Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A.
Topics: Blood Proteins; Cyclosporine; Dermatologic Agents; Eosinophil Granule Proteins; Eosinophils; Etretinate; Humans; Immunosuppressive Agents; Inflammation Mediators; Keratolytic Agents; Leukocyte Count; Pruritus; Psoriasis; Ribonucleases | 1998 |
Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
Topics: Adult; Aged; Blood Pressure Determination; Calcium Channel Blockers; Cyclosporine; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Gingival Hyperplasia; Humans; Hyperlipidemias; Hypertension; Kidney Function Tests; Long-Term Care; Male; Middle Aged; Nifedipine; Psoriasis; Treatment Outcome | 1998 |
Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis.
Topics: Adolescent; Adult; Aged; Blood Pressure; Creatinine; Cyclosporine; Dermatologic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Treatment Outcome | 1998 |
Red blood cell rigidification during cyclosporin therapy: a possible early warning signal for adverse reactions.
Topics: Cyclosporine; Erythrocyte Aggregation; Erythrocyte Deformability; Hematology; Humans; Immunosuppressive Agents; Kidney Diseases; Postoperative Complications; Predictive Value of Tests; Prospective Studies; Psoriasis | 1998 |
Expression of the psoriasis-associated antigen, Pso p27, is inhibited by cyclosporin A.
Topics: Adult; Antigens; Biopsy; Cyclosporine; Dermatologic Agents; Female; Fluorescent Antibody Technique; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Skin | 1999 |
Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Creatinine; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Hypertension; Middle Aged; Prospective Studies; Psoriasis; Recurrence; Treatment Outcome | 1999 |
Cyclin D1, B and A expression and cell turnover in psoriatic skin lesions before and after cyclosporin treatment.
Topics: Adult; Biomarkers; Cell Division; Cyclin A; Cyclin B; Cyclin D1; Cyclins; Cyclosporine; Dermatologic Agents; Epidermis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 2000 |
Selected cytokines and acute phase proteins in psoriatic patients treated with cyclosporin A or Re-PUVA methods.
Topics: Acute-Phase Proteins; Adult; Cyclosporine; Cytokines; Drug Therapy, Combination; Etretinate; Humans; Male; Middle Aged; Psoriasis; PUVA Therapy | 1999 |
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Cohort Studies; Creatinine; Cyclosporine; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Psoriasis; Time Factors | 2001 |
Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
Topics: Adult; Chronic Disease; Cyclosporine; Follow-Up Studies; Humans; Immunosuppressive Agents; Multivariate Analysis; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2001 |
The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis.
Topics: Administration, Oral; Adult; Chronic Disease; Cost-Benefit Analysis; Cyclosporine; Dermatologic Agents; Direct Service Costs; Drug Administration Schedule; Economics, Pharmaceutical; Female; Humans; Male; Multicenter Studies as Topic; Psoriasis; Treatment Outcome | 2001 |
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Pilot Projects; Psoriasis; Severity of Illness Index; Sirolimus; Treatment Outcome | 2001 |
Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels.
Topics: Adult; Creatinine; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney; Male; Middle Aged; Prospective Studies; Psoriasis | 2002 |
Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease.
Topics: Adult; Blood Pressure; Cyclosporine; Female; Humans; Hyperlipidemias; Male; Psoriasis; Risk Factors | 1992 |
Differential effects of cyclosporine and etretinate on serum cytokine levels in patients with psoriasis.
Topics: Administration, Oral; Adult; Aged; Cyclosporine; Etretinate; Female; Humans; Interferon-gamma; Interleukin-1; Male; Middle Aged; Psoriasis; Recurrence; Remission Induction; Tumor Necrosis Factor-alpha | 1992 |
Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy.
Topics: Cyclosporine; Humans; Injections, Intradermal; Injections, Intralesional; Pain; Pharmaceutical Vehicles; Psoriasis; Skin | 1992 |
Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study.
Topics: Adolescent; Adult; Aged; Cyclosporine; Female; Humans; Male; Middle Aged; Psoriasis | 1992 |
462 other study(ies) available for cyclosporine and Psoriasis
| Article | Year |
|---|---|
A case of generalised pustular psoriasis with bullous pemphigoid showing spongiform pustule of Kogoj with eosinophils.
Topics: Adult; Cyclosporine; Dermatologic Agents; Eosinophilia; Female; Humans; Immunoglobulins, Intravenous; Pemphigoid, Bullous; Psoriasis | 2021 |
Risankizumab-induced paradoxical pustular psoriasis.
Topics: Antibodies, Monoclonal; Cyclosporine; Dermatologic Agents; Disease Progression; Female; Humans; Interleukin-23 Subunit p19; Middle Aged; Psoriasis | 2022 |
Successful treatment of recalcitrant facial sebopsoriasis with low-dose cyclosporine.
Topics: Cyclosporine; Dermatitis, Seborrheic; Humans; Immunosuppressive Agents; Psoriasis | 2022 |
Effects of Cyclosporine A and Adalimumab on the expression profiles histaminergic system-associated genes and microRNAs regulating these genes in HaCaT cells.
Topics: Adalimumab; Adult; Cyclosporine; gamma-Aminobutyric Acid; HaCaT Cells; Histamine N-Methyltransferase; Humans; Lipopolysaccharides; Matrix Metalloproteinase 2; MicroRNAs; Phosphatidylinositol 3-Kinases; Polycomb Repressive Complex 1; Psoriasis; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2022 |
Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records.
Topics: Acute Disease; Adult; Chronic Disease; Cohort Studies; Cyclosporine; Electronic Health Records; Female; Humans; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Skin Diseases, Vesiculobullous; Tacrolimus | 2022 |
'Transfersome-embedded-gel' for dual-mechanistic delivery of anti-psoriatic drugs to dermal lymphocytes.
Topics: Clobetasol; Cyclosporine; Humans; Lymphocytes; Pharmaceutical Preparations; Psoriasis; Tumor Necrosis Factor-alpha | 2022 |
Cyclosporine and Pentoxifylline laden tailored niosomes for the effective management of psoriasis: In-vitro optimization, Ex-vivo and animal study.
Topics: Animals; Cholesterol; Cyclosporine; Imiquimod; Liposomes; Mice; Particle Size; Pentoxifylline; Polysorbates; Psoriasis; Surface-Active Agents | 2022 |
Risk of malignancy in patients with psoriasis receiving systemic medications: A nested case-control study.
Topics: Adalimumab; Biological Products; Case-Control Studies; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Methotrexate; Neoplasms; Psoriasis; Ustekinumab | 2022 |
Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis.
Topics: Cyclosporine; Dermatologic Agents; Humans; Hydrogels; Nail Diseases; Ointments; Prospective Studies; Psoriasis | 2022 |
Protein network and pathway analysis in a pharmacogenetic study of cyclosporine treatment response in Greek patients with psoriasis.
Topics: Cyclosporine; Greece; Humans; Pharmacogenetics; Pharmacogenomic Testing; Psoriasis | 2023 |
Trends in prescriptions of oral medications for psoriasis: A single-center retrospective study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Etretinate; Humans; Methotrexate; Phosphodiesterase 4 Inhibitors; Psoriasis; Retrospective Studies; Severity of Illness Index | 2023 |
Risk of malignancy in patients with psoriasis according to treatment modalities in Korea: a nationwide cohort study.
Topics: Cohort Studies; Cyclosporine; Humans; Psoriasis; Republic of Korea; Skin Neoplasms | 2022 |
Conventional therapy in psoriasis. Lost in translation?
Topics: Acitretin; Cohort Studies; Cyclosporine; Fumarates; Humans; Methotrexate; Psoriasis | 2023 |
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Topics: Acitretin; Adjuvants, Immunologic; Biological Factors; Cohort Studies; Cyclosporine; Dermatologic Agents; Fumarates; Humans; Immunologic Factors; Male; Methotrexate; Prospective Studies; Psoriasis; Treatment Outcome | 2023 |
Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
Topics: Arthritis, Psoriatic; Biological Products; Cyclosporine; Humans; Japan; Psoriasis; Registries; Retrospective Studies; Survival Rate | 2023 |
Variances in the Expression Profile of DUSP1-7 and miRNAs Regulating their Expression in the HaCat Line under LPS and Cyclosporine A.
Topics: Adult; Cyclosporine; Dual Specificity Phosphatase 1; Dual-Specificity Phosphatases; Humans; Lipopolysaccharides; MicroRNAs; Mitogen-Activated Protein Kinases; Psoriasis | 2023 |
The real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for treating moderate-to-severe psoriasis.
Topics: Acitretin; Cohort Studies; Cyclosporine; Fumarates; Humans; Methotrexate; Psoriasis | 2023 |
Transcriptomic responses of peripheral blood mononuclear cells to cyclosporin and etanercept in a female infant with juvenile generalized pustular psoriasis.
Topics: Acute Disease; CARD Signaling Adaptor Proteins; Chronic Disease; Cyclosporine; Etanercept; Female; Guanylate Cyclase; Humans; Infant; Interleukins; Leukocytes, Mononuclear; Membrane Proteins; Psoriasis; Transcriptome; Tumor Necrosis Factor Inhibitors | 2023 |
Outcomes of prolonged and low-dose ciclosporin in an Asian population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Child; Cyclosporine; Eczema; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2021 |
Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
Topics: Acitretin; Adalimumab; Adult; Anti-Inflammatory Agents; Cyclosporine; Cytokine TWEAK; Dermatologic Agents; Etanercept; Female; Humans; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2020 |
BMI changes and concentration of selected morphological and biochemical indices during cyclosporin A therapy.
Topics: Adult; Body Mass Index; Body Weight; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 2019 |
Evaluation of expression pattern of selected genes associated with IL12/23 signaling paths in psoriatic patients during cyclosporine A therapy.
Topics: Cyclosporine; Dermatologic Agents; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-12; Interleukin-23; Psoriasis; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha | 2019 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Topics: Adolescent; Adrenal Cortex Hormones; Anthralin; Biological Products; Calcineurin Inhibitors; Cardiovascular Diseases; Child; Child, Preschool; Coal Tar; Comorbidity; Cyclosporine; Dermatologic Agents; Dyslipidemias; Evidence-Based Medicine; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Insulin Resistance; Mental Health; Metabolic Syndrome; Methotrexate; Nicotinic Acids; Obesity; Photochemotherapy; Psoriasis; Retinoids | 2020 |
Characteristics and Management of Autoimmune Bullous Disease in Psoriasis Patients.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Cyclosporine; Disease Management; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Hydroxyurea; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Pemphigoid, Bullous; Pemphigus; Psoriasis; Retrospective Studies; Ultraviolet Therapy | 2019 |
Cyclosporine laden tailored microemulsion-gel depot for effective treatment of psoriasis: In vitro and in vivo studies.
Topics: Administration, Topical; Animals; Cyclosporine; Emulsions; Gels; Hydrogen-Ion Concentration; Particle Size; Psoriasis; Rabbits; Skin Absorption; Solubility; Surface Properties; Thermodynamics; Viscosity | 2020 |
Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2/STAT3 signal pathways.
Topics: Animals; Cell Line; Cell Proliferation; Cyclosporine; Cytokines; Dermatitis; Humans; Imiquimod; Inflammation; Janus Kinase 2; Keratinocytes; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Models, Animal; Psoriasis; Quercetin; Receptor, Notch1; Signal Transduction; Skin; STAT3 Transcription Factor; T-Lymphocytes; Transcription Factors | 2020 |
A Long-Term Follow-up of Retinal Vasculitis - Do They Develop Systemic Disease?
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Azathioprine; Colitis, Ulcerative; Cyclosporine; Drug Therapy, Combination; Female; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Psoriasis; Recurrence; Retinal Vasculitis; Retrospective Studies; Tuberculin Test; Tuberculosis, Ocular; Visual Acuity; Vitreous Hemorrhage | 2020 |
Adverse event monitoring in patients on oral systemic medications for inflammatory skin disease.
Topics: Azathioprine; Cross-Sectional Studies; Cyclosporine; Dermatitis, Atopic; Drug Eruptions; Drug Monitoring; Humans; Methotrexate; Mycophenolic Acid; Psoriasis; United States | 2020 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Topics: Acitretin; Cyclosporine; Drug Monitoring; Humans; Methotrexate; Piperidines; Psoriasis; Pyrimidines; Thalidomide | 2020 |
Two cases of refractory nail psoriasis successfully treated with calcipotriol plus betamethasone dipropionate gel.
Topics: Administration, Oral; Aged; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Combinations; Drug Resistance; Female; Gels; Humans; Male; Middle Aged; Nail Diseases; Ointments; Psoriasis; Severity of Illness Index; Thalidomide; Treatment Outcome | 2020 |
Combination Therapy of Acarbose and Cyclosporine a Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice.
Topics: Acarbose; Animals; Anti-Inflammatory Agents; Cyclosporine; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Humans; Imiquimod; Male; Mice; Psoriasis; T-Lymphocytes, Regulatory; Tumor Necrosis Factor-alpha | 2020 |
Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study.
Topics: Cross-Sectional Studies; Cyclosporine; Female; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2022 |
Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Australia; Cyclosporine; Dermatologic Agents; Female; Headache; Humans; Hypertension; Male; Middle Aged; Nausea; Psoriasis; Registries; Renal Insufficiency; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2020 |
Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case.
Topics: Adult; Cyclosporine; Female; Humans; Infliximab; Pregnancy; Psoriasis; Skin Diseases, Vesiculobullous; Young Adult | 2020 |
Covid-19 infection in psoriasis patients treated with cyclosporin.
Topics: Adolescent; Adult; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Psoriasis; SARS-CoV-2; Young Adult | 2020 |
Le choix thérapeutique : médicaments du psoriasis et grossesse avant, pendant et après la grossesse.
Topics: Acitretin; Biological Factors; Breast Feeding; Contraindications, Drug; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Psoriasis; Risk Factors; Ultraviolet Therapy | 2020 |
The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cardiovascular Diseases; Cyclosporine; Female; Humans; Incidence; Male; Methotrexate; Middle Aged; Phototherapy; Proportional Hazards Models; Psoriasis; Republic of Korea; Severity of Illness Index; Young Adult | 2021 |
A case of psoriasis successfully treated by extracorporeal photopheresis during COVID-19 pandemic.
Topics: Acitretin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Contraindications, Drug; COVID-19; Cyclosporine; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Nails; Pandemics; Photopheresis; Psoriasis; Quality of Life; SARS-CoV-2; Severity of Illness Index; Ultraviolet Therapy | 2021 |
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Argentina; Arthritis, Psoriatic; Biological Products; Body Mass Index; Cyclosporine; Electronic Health Records; Etanercept; Female; Humans; Incidence; Infliximab; Male; Methotrexate; Middle Aged; Nail Diseases; Phototherapy; Psoriasis; Retrospective Studies; Risk Factors; Sex Factors; Ustekinumab; Young Adult | 2022 |
Management of patients with psoriasis.
Topics: Acitretin; Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Disease Management; Emollients; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Thalidomide | 2017 |
Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action.
Topics: Administration, Topical; Adult; Animals; Coconut Oil; Cyclosporine; Dermatologic Agents; Diffusion; Drug Evaluation, Preclinical; Emulsions; Female; Humans; Myristica; Nanostructures; Particle Size; Plant Oils; Polysaccharides, Bacterial; Psoriasis; Rats; Skin; Solubility; Surface-Active Agents; Viscosity | 2017 |
The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients.
Topics: Adolescent; Adult; Cyclosporine; Female; Gonadal Steroid Hormones; Humans; Incidence; Italy; Male; Middle Aged; Postmenopause; Prospective Studies; Psoriasis; Severity of Illness Index; Sex Factors; Young Adult | 2017 |
Generalized Pustular Psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Child; Cyclosporine; Humans; Japan; Male; Prognosis; Psoriasis; Rare Diseases; Risk Assessment; Severity of Illness Index; Skin Diseases, Vesiculobullous; Treatment Outcome | 2017 |
Acquired hemophilia A following generalized pustular psoriasis of pregnancy.
Topics: Adult; Blood Component Removal; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Female; Hemophilia A; Humans; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Psoriasis | 2017 |
Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Topics: Acitretin; Adalimumab; Austria; Biological Products; Combined Modality Therapy; Cyclosporine; Czech Republic; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Fumarates; Humans; Infliximab; Israel; Italy; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Netherlands; Psoriasis; PUVA Therapy; Registries; Severity of Illness Index; Ustekinumab | 2018 |
Interleukin Antagonists: Have We Found the Right One to Block? Are Cardiovascular Effects of Biologic Therapies Similar?
Topics: Biological Therapy; Cyclosporine; Humans; Interleukin-12; Interleukins; Psoriasis | 2017 |
Abrupt generalized pustules in patients with rheumatoid arthritis and interstitial lung disease.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Arthritis, Rheumatoid; Biopsy; Chromones; Cyclosporine; Diagnosis, Differential; Exanthema; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Paeonia; Plant Extracts; Prednisone; Psoriasis; Skin; Sulfonamides | 2018 |
Cyclosporine in clinical practice: a retrospective study comparing fixed dose and body weight-based dose regimens in psoriatic patients.
Topics: Adult; Aged; Body Weight; Cyclosporine; Dermatologic Agents; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies | 2020 |
Rapid response to cyclosporine in a rare case of pityriasis rubra pilaris with autoantibodies and systemic symptoms.
Topics: Adult; Arthralgia; Autoantibodies; Celiac Disease; Cyclosporine; Diagnostic Errors; Drug Therapy, Combination; Emollients; Female; Gastrointestinal Diseases; Humans; Immunosuppressive Agents; Pityriasis Rubra Pilaris; Psoriasis; Symptom Assessment | 2019 |
ARDS complicating pustular psoriasis: treatment with low-dose corticosteroids, vitamin C and thiamine.
Topics: Adrenal Cortex Hormones; Continuous Positive Airway Pressure; Critical Illness; Cyclosporine; Drug Therapy, Combination; Electrocardiography; Female; Humans; Immunosuppressive Agents; Middle Aged; Psoriasis; Radiography; Respiratory Distress Syndrome; Severity of Illness Index | 2018 |
Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: A treatment approach.
Topics: Adolescent; Baths; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Humans; Immunosuppressive Agents; Occlusive Dressings; Psoriasis; Skin Diseases, Vesiculobullous | 2017 |
Clinical improvement of a patient with both amyopathic dermatomyositis and psoriasis following treatment with cyclosporine.
Topics: Cyclosporine; Dermatologic Agents; Dermatomyositis; Female; Humans; Middle Aged; Psoriasis; Retreatment | 2017 |
Comparison of clinical effects, trough and peak levels between branded and generic formulation of Cyclosporine in stable psoriatic patients.
Topics: Adult; Cross-Over Studies; Cyclosporine; Dermatologic Agents; Drugs, Generic; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Therapeutic Equivalency; Treatment Outcome | 2020 |
Psoriasis management in actual clinical practice: a 6-year retrospective study of 845 patients.
Topics: Biological Products; Cyclosporine; Dermatologic Agents; Female; Hospitalization; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies | 2018 |
Two cases of generalized pustular psoriasis complicated by IgG4-related disease.
Topics: Adalimumab; Aged; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etretinate; Female; Humans; Immunoglobulin G; Immunoglobulin G4-Related Disease; Magnetic Resonance Imaging; Male; Prednisolone; Psoriasis; Skin; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis.
Topics: Aged; Ankle Joint; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Eruptions; Drug Substitution; Edema; Female; Humans; Knee Joint; Male; Middle Aged; Myalgia; Psoriasis; Skin | 2018 |
Clinical and molecular evaluation of therapy with the use of cyclosporine A in patients with psoriasis vulgaris.
Topics: Cyclosporine; Diabetes Complications; Female; Gene Expression; Humans; Immunosuppressive Agents; Male; Metabolic Syndrome; Proteoglycans; Psoriasis; Quality of Life; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; RNA, Messenger; Severity of Illness Index; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factor beta2; Transforming Growth Factor beta3; Treatment Outcome | 2019 |
Compounded topical preparations in plaque psoriasis: Still a place for it in 2018?
Topics: Administration, Cutaneous; Adult; Chronic Disease; Cyclosporine; Dermatologic Agents; Drug Compounding; Drug Substitution; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Remission Induction; Skin; Time Factors; Treatment Outcome | 2019 |
Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Therapy; Comorbidity; Cyclosporine; Etanercept; Female; Hepatitis B; Hepatitis C; Humans; Infliximab; Interleukin-17; Latent Tuberculosis; Male; Methotrexate; Middle Aged; Non-alcoholic Fatty Liver Disease; Psoriasis; Ustekinumab | 2018 |
TNF-α inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Child; Cyclosporine; Female; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Male; Methotrexate; Middle Aged; Psoriasis; Recurrence; Retrospective Studies; Risk Factors; Sex Factors; Spondylitis, Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2020 |
Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.
Topics: Adult; Cyclosporine; Dermatologic Agents; Female; Folic Acid; France; Humans; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prospective Studies; Psoriasis; Treatment Outcome | 2019 |
Trough (C0) and 2-hour postdose (C2) cyclosporine monitoring in patients with moderate-to-severe psoriasis.
Topics: Administration, Oral; Adult; Cyclosporine; Drug Monitoring; Female; Humans; Immunosuppressive Agents; Male; Memory, Episodic; Psoriasis; Severity of Illness Index | 2019 |
Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real-world practice.
Topics: Adult; Age Factors; Aged; Creatinine; Cyclosporine; Diabetes Mellitus; Female; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Middle Aged; Obesity; Psoriasis; Retrospective Studies; Risk Factors | 2019 |
Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Age of Onset; Biological Products; Cyclosporine; Dermatologic Agents; Etanercept; Female; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Psoriasis; Spain; Ustekinumab | 2020 |
Preparation, characterization, and
Topics: Administration, Cutaneous; Animals; Cations; Cholesterol; Cyclosporine; Cytokines; Dermatologic Agents; Drug Compounding; Drug Liberation; Fatty Acids, Monounsaturated; Humans; Hydrogels; Liposomes; Male; Mice, Inbred BALB C; Nanocapsules; Psoriasis; Quaternary Ammonium Compounds; Skin; Skin Absorption; Treatment Outcome | 2020 |
The impact of diabetes and metabolic syndromes to the effectiveness of cyclosporine a pharmacotherapy in psoriatic patients.
Topics: Cyclosporine; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Psoriasis | 2019 |
A case of pustular psoriasis possibly precipitated by periodic oestrogen/gestagen therapy for Turner syndrome.
Topics: Adult; Cyclosporine; Dermatologic Agents; Estrogens; Female; Humans; Progestins; Psoriasis; Treatment Outcome; Turner Syndrome | 2019 |
Switching to secukinumab in difficult-to-treat psoriasis recalcitrant to methotrexate, cyclosporine and leflunomide, in a tuberculosis-endemic country.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Humans; Interleukin-17; Leflunomide; Male; Methotrexate; Middle Aged; Psoriasis; Treatment Failure; Tuberculosis | 2019 |
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse.
Topics: Adrenocorticotropic Hormone; Adult; Clobetasol; Cushing Syndrome; Cyclosporine; Dermatologic Agents; Female; Glucocorticoids; Humans; Iatrogenic Disease; Prescription Drug Overuse; Psoriasis | 2019 |
Pediatric-onset annular pustular psoriasis in a patient with Down syndrome.
Topics: Child; Cyclosporine; Down Syndrome; Dwarfism, Pituitary; Growth Hormone; Humans; Male; Psoriasis; Skin | 2019 |
Effects of psoriasis treatment on genital warts: a case report.
Topics: Adalimumab; Anti-Inflammatory Agents; Condylomata Acuminata; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Papillomaviridae; Psoriasis; Treatment Outcome | 2019 |
Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology.
Topics: Adrenal Cortex Hormones; Anthralin; Antibodies, Monoclonal; Brazil; Calcineurin Inhibitors; Comorbidity; Cyclosporine; Dermatologic Agents; Dermatology; Drug Combinations; Female; Humans; Male; Methotrexate; Phototherapy; Psoriasis; Severity of Illness Index; Societies, Medical; Time Factors; Vitamin D | 2019 |
Timing of quality of life improvements in psoriatic patients treated with different systemic therapies.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Biological Therapy; Cyclosporine; Dermatologic Agents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Retrospective Studies; Severity of Illness Index; Skin; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ustekinumab; Young Adult | 2019 |
A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis.
Topics: Adult; Combined Modality Therapy; Cyclosporine; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; India; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome | 2014 |
Ciclosporin A inhibits production of interleukin-12/23p40 and interleukin-23 by the human monocyte cell line, THP-1.
Topics: Cell Line; Cyclosporine; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-12; Interleukin-23; Monocytes; Psoriasis | 2013 |
Cancer-free survival of psoriasis patients treated with methotrexate and cyclosporine combination.
Topics: Adult; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Surveys and Questionnaires; Turkey | 2014 |
Mycobacterium poriferae infection in a psoriasis patient on anti-TNF-α therapy.
Topics: Adult; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Bacterial Typing Techniques; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Fishes; Humans; Immunocompromised Host; Immunoglobulin G; Immunosuppressive Agents; Interferon-gamma Release Tests; Leg Ulcer; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Porifera; Psoriasis; Receptors, Tumor Necrosis Factor; Species Specificity; Triamcinolone; Tuberculin Test; Tumor Necrosis Factor-alpha; Ustekinumab | 2013 |
Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Biological Products; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Psoriasis; Retinoids; Retrospective Studies; Tertiary Care Centers; Ustekinumab | 2013 |
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclosporine; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Psoriasis; Receptors, Tumor Necrosis Factor; Registries; Risk Assessment; Spain; Ustekinumab | 2015 |
Cutaneous cytomegalovirus complicating pustular psoriasis.
Topics: Aged; Cyclosporine; Cytomegalovirus Infections; Female; Ganciclovir; Humans; Immunocompromised Host; Immunosuppressive Agents; Opportunistic Infections; Psoriasis; Skin Diseases, Viral | 2014 |
A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Cyclosporine; Female; Greece; Humans; Male; Polymorphism, Single Nucleotide; Psoriasis | 2014 |
Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study.
Topics: Acitretin; Adalimumab; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Cyclosporine; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Prevalence; Psoriasis; Tumor Necrosis Factor-alpha | 2015 |
Methotrexate and cyclosporine in psoriasis revisited.
Topics: Cyclosporine; Humans; Methotrexate; Psoriasis | 2014 |
Ophthalmic cyclosporine for the treatment of psoriatic conjunctivitis.
Topics: Administration, Ophthalmic; Conjunctivitis; Cyclosporine; Female; Humans; Immunosuppressive Agents; Middle Aged; Psoriasis | 2014 |
Trends in systemic psoriasis treatment therapies from 1993 through 2010.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Cyclosporine; Dermatologic Agents; Dermatology; Humans; Methotrexate; Phototherapy; Psoriasis; Retinoids; Severity of Illness Index; Surveys and Questionnaires; United States | 2014 |
Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis.
Topics: Adult; Cyclosporine; End Stage Liver Disease; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Psoriasis; Recurrence; Risk Factors; Tacrolimus; Transplant Recipients; Treatment Outcome | 2014 |
Acquired ichthyosis during acitretin therapy for psoriasis vulgaris.
Topics: Acitretin; Aged; Cyclosporine; Dermatologic Agents; Female; Humans; Ichthyosis; Keratolytic Agents; Psoriasis | 2016 |
[Journal-Club].
Topics: Activating Transcription Factor 3; Animals; Carcinoma, Squamous Cell; Cyclosporine; Female; Human papillomavirus 16; Human papillomavirus 18; Human papillomavirus 6; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-23; Keratinocytes; Male; Neoplasms, Radiation-Induced; Nociceptors; Papillomavirus E7 Proteins; Papillomavirus Infections; Psoriasis; Sensory Receptor Cells; Skin; Skin Neoplasms; Ultraviolet Rays | 2014 |
Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference.
Topics: Adult; Child; Cyclosporine; Dermatitis, Atopic; Disease Susceptibility; Drug Administration Schedule; Drug Interactions; Female; Food-Drug Interactions; Humans; Hypertension; Immunosuppressive Agents; Infections; Kidney Diseases; Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Psoriasis; Quality of Life; Skin Diseases | 2014 |
Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy.
Topics: Adult; Antibodies, Monoclonal; Biopsy, Needle; CD8 Antigens; Cyclosporine; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Infliximab; Pseudolymphoma; Psoriasis; Risk Assessment; Severity of Illness Index; Skin Diseases; Treatment Outcome | 2014 |
A potentially rare and serious consequence of ciclosporin therapy for psoriasis.
Topics: Adult; Cyclosporine; Female; Humans; Immunosuppressive Agents; Intracranial Hypertension; Papilledema; Psoriasis | 2014 |
Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cross-Sectional Studies; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Young Adult | 2014 |
Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biological Products; Cardiovascular Diseases; Cause of Death; Climatotherapy; Cyclosporine; Denmark; Dermatologic Agents; Female; Follow-Up Studies; Humans; Incidence; Longitudinal Studies; Male; Methotrexate; Middle Aged; Myocardial Infarction; Phototherapy; Psoriasis; Registries; Retinoids; Severity of Illness Index; Stroke; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
Topics: Acitretin; Adalimumab; Adult; Aged; Biological Factors; Cyclosporine; Dermatologic Agents; Drug Substitution; Etanercept; Female; Humans; Infliximab; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Psoriasis; Ustekinumab; Young Adult | 2015 |
Varicella zoster virus-associated generalized pustular psoriasis in a baby with heterozygous IL36RN mutation.
Topics: Cyclosporine; Dermatologic Agents; Herpesvirus 3, Human; Heterozygote; Humans; Infant; Interleukins; Male; Mutation; Psoriasis; Recurrence | 2014 |
Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain.
Topics: Adult; Antimalarials; Antirheumatic Agents; Azathioprine; Cohort Studies; Cyclophosphamide; Cyclosporine; Female; Humans; Inflammatory Bowel Diseases; Isoxazoles; Leflunomide; Logistic Models; Male; Methotrexate; Middle Aged; Odds Ratio; Practice Patterns, Physicians'; Psoriasis; Retrospective Studies; Severity of Illness Index; Sex Factors; Spain; Spondylarthropathies; Sulfasalazine; Uveitis | 2015 |
How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practice.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Cyclosporine; Dapsone; Dermatologic Agents; Fumarates; Humans; Immunosuppressive Agents; Methotrexate; Practice Patterns, Physicians'; Psoriasis; United Kingdom | 2015 |
Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Fumarates; Germany; Humans; Infliximab; Isoxazoles; Keratolytic Agents; Leflunomide; Male; Methotrexate; Middle Aged; Prednisolone; Psoriasis; Retrospective Studies | 2015 |
Cutaneous pseudolymphoma: a rare side effect of cyclosporine.
Topics: Adult; Cyclosporine; Dermatologic Agents; Drug Eruptions; Humans; Male; Pseudolymphoma; Psoriasis | 2015 |
Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin.
Topics: Aged; Autoantibodies; Autoantigens; Collagen Type XVII; Cyclosporine; Dystonin; Humans; Immunosuppressive Agents; Laminin; Male; Non-Fibrillar Collagens; Pemphigoid, Bullous; Psoriasis | 2015 |
Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines.
Topics: Adult; Child; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Europe; Humans; Immunosuppressive Agents; Italy; Practice Guidelines as Topic; Psoriasis | 2016 |
Therapeutic and immunomodulatory effects of glucosamine in combination with low-dose cyclosporine a in a murine model of imiquimod-induced psoriasis.
Topics: Aminoquinolines; Animals; Cyclosporine; Dermatitis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosamine; Imiquimod; Immunomodulation; Mice; Mice, Inbred C57BL; Organ Size; Psoriasis; Spleen; T-Lymphocytes, Regulatory | 2015 |
Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Biological Factors; Causality; Cohort Studies; Comorbidity; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Isoxazoles; Male; Methotrexate; Middle Aged; Multivariate Analysis; Phototherapy; Psoriasis; Risk Factors; Sex Distribution; Ustekinumab | 2015 |
Periodontal management of a patient with severe psoriasis: A case report.
Topics: Administration, Oral; Cyclosporine; Dental Care for Chronically Ill; Dental Scaling; Gingival Overgrowth; Humans; Immunosuppressive Agents; Male; Middle Aged; Oral Hygiene; Psoriasis; Root Planing | 2015 |
Infant with generalized pustular psoriasis who responded to cyclosporin A therapy.
Topics: Cyclosporine; Dermatologic Agents; Female; Humans; Infant; Psoriasis | 2015 |
Cyclosporine A microemulsion in dermatological practice: is oral solution better tolerated than soft gelatin capsules?
Topics: Administration, Oral; Adolescent; Adult; Aged; Capsules; Cyclosporine; Dermatitis, Atopic; Dermatitis, Contact; Emulsions; Female; Gelatin; Humans; Immunosuppressive Agents; Middle Aged; Pharmaceutical Solutions; Psoriasis | 2015 |
Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis.
Topics: Acitretin; Adalimumab; Attitude of Health Personnel; Biological Products; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Infliximab; Methotrexate; Perception; Practice Patterns, Physicians'; Psoriasis | 2015 |
Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Aged; Antibodies, Monoclonal; Biological Products; Certolizumab Pegol; Cyclosporine; Dermatologic Agents; Drug Prescriptions; Drug Therapy, Combination; Etanercept; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Practice Patterns, Physicians'; Psoriasis; Retrospective Studies; Severity of Illness Index; Ultraviolet Therapy; Ustekinumab; Young Adult | 2015 |
The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Foot Dermatoses; Hand Dermatoses; Humans; Immunosuppressive Agents; Infliximab; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Psoriasis; Severity of Illness Index; Thalidomide; Ustekinumab; Young Adult | 2015 |
Subepidermal autoimmune blistering lesion in a case of psoriasis successfully treated with cyclosporin.
Topics: Autoimmune Diseases; Cyclosporine; Humans; Immunosuppressive Agents; Male; Middle Aged; Pemphigoid, Bullous; Psoriasis | 2015 |
Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Topics: Adalimumab; Biological Products; Biological Therapy; Cardiovascular Diseases; Cyclosporine; Dermatologic Agents; Etanercept; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Registries; Ustekinumab | 2015 |
Granulocyte and Monocyte Adsorption Apheresis for Generalized Pustular Psoriasis: Therapeutic Outcomes in Three Refractory Patients.
Topics: Adult; Blood Component Removal; Cyclosporine; Drug Resistance; Female; Granulocytes; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Monocytes; Phototherapy; Psoriasis; Severity of Illness Index; Treatment Outcome | 2015 |
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
Topics: Acitretin; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Drug Therapy, Combination; Etanercept; Fumarates; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; Ustekinumab | 2015 |
Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hypertension; Longitudinal Studies; Male; Middle Aged; Population Surveillance; Psoriasis; Risk Factors; Taiwan | 2016 |
Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis.
Topics: Adolescent; Child; Cyclosporine; Female; Humans; Immunosuppressive Agents; Italy; Male; Psoriasis; Retrospective Studies; Treatment Outcome | 2016 |
Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
Topics: Acitretin; Adolescent; Adult; Aged; Algorithms; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Systemic treatments in childhood psoriasis: a French multicentre study on 154 children.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; France; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Treatment Outcome | 2016 |
Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis.
Topics: Adolescent; Child; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Psoriasis; Retrospective Studies | 2016 |
Induction therapy with a combination of fumarates and cyclosporine: A benefit for the patient?
Topics: Cyclosporine; Drug Therapy, Combination; Fumarates; Humans; Patient Compliance; Psoriasis | 2016 |
Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Cyclosporine; Databases, Factual; Dermatologic Agents; Female; Humans; Infant; Italy; Male; Practice Patterns, Physicians'; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2017 |
Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study.
Topics: Acitretin; Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Italy; Male; Methotrexate; Middle Aged; Phototherapy; Psoriasis; Retrospective Studies; Treatment Outcome | 2016 |
Focus on five patients treated with cyclosporine up to 62 months.
Topics: Adult; Aged; Cyclosporine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Retrospective Studies; Time Factors | 2016 |
Cutaneous B-cell Pseudolymphoma in a Psoriatic Patient Treated with Cyclosporine.
Topics: Aged; Cyclosporine; Humans; Immunosuppressive Agents; Male; Pseudolymphoma; Psoriasis; Skin Diseases | 2016 |
[Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].
Topics: Acitretin; Adalimumab; Cost-Benefit Analysis; Cyclosporine; Etanercept; Health Care Costs; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Models, Economic; Psoriasis; PUVA Therapy; Severity of Illness Index; Spain; Time Factors; Treatment Outcome; Ultraviolet Therapy; Ustekinumab | 2016 |
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.
Topics: Acitretin; Biological Factors; Cyclosporine; Dermatology; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Psoriasis; Societies, Medical; Switzerland; Thalidomide | 2016 |
Generalized pustular psoriasis treated with ustekinumab.
Topics: Acitretin; Adalimumab; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Resistance; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; Skin Diseases, Vesiculobullous; Treatment Outcome; Ustekinumab | 2016 |
Facial hair growth in a patient with psoriasis.
Topics: Cyclosporine; Dermatologic Agents; Face; Female; Humans; Hypertrichosis; Middle Aged; Psoriasis | 2016 |
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.
Topics: Adalimumab; Adult; Aged; Bacterial Infections; Biological Products; Cyclosporine; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Poisson Distribution; Psoriasis; Registries | 2017 |
Systemic cyclosporine treatment in severe childhood psoriasis: A retrospective chart review.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Dermatitis, Exfoliative; Female; Humans; Male; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2017 |
Combination therapy of infliximab and ciclosporin in the treatment of recalcitrant psoriasis: a case series.
Topics: Adult; Chronic Disease; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infliximab; Infusions, Intravenous; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study.
Topics: Acitretin; Adolescent; Child; Cohort Studies; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Psoriasis; Treatment Outcome | 2017 |
Clinical experience of cyclosporin treatment in patients with psoriasis and psoriatic arthritis.
Topics: Adult; Arthritis, Psoriatic; Cyclosporine; Female; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome; Young Adult | 2018 |
Infections and Psoriasis Treatment: More "Real-World" Data Needed with Critical Appraisal.
Topics: Biological Products; Cyclosporine; Humans; Psoriasis; Registries | 2017 |
Acute Generalized Erythrodermic Pustular Psoriasis Associated with Bupropion/Naltrexone (Contrave
Topics: Acute Kidney Injury; Biopsy; Bupropion; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Middle Aged; Naltrexone; Psoriasis; Stevens-Johnson Syndrome | 2017 |
Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
Topics: Acitretin; Adult; Biological Products; Body Mass Index; Comorbidity; Coronary Disease; Cyclosporine; Czech Republic; Dermatologic Agents; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; Keratolytic Agents; Male; Methotrexate; Middle Aged; Obesity; Phototherapy; Prevalence; Psoriasis; Quality of Life; Registries; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index | 2017 |
Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia.
Topics: Acitretin; Acute Disease; Adolescent; Adult; Age of Onset; CARD Signaling Adaptor Proteins; Child; Child, Preschool; Chronic Disease; Cyclosporine; Dermatologic Agents; Female; Guanylate Cyclase; Humans; Interleukins; Keratolytic Agents; Malaysia; Male; Membrane Proteins; Pregnancy; Pregnancy Complications; Psoriasis; Respiratory Tract Infections; Retrospective Studies; Risk Factors; Severity of Illness Index; Steroids; Stress, Psychological; Tertiary Care Centers; Vaccination; Young Adult | 2017 |
Systemic and light therapies for the management of childhood psoriasis: part II.
Topics: Biological Products; Child; Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Phototherapy; Psoriasis; Retinoids | 2008 |
Voclosporin (ISA247) for plaque psoriasis.
Topics: Calcineurin Inhibitors; Cyclosporine; Humans; Placebos; Psoriasis; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides | 2008 |
Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Case-Control Studies; Cross-Sectional Studies; Cyclosporine; Dermatologic Agents; Female; Gene Frequency; Genotype; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Immune System; Interleukin-10; Male; Middle Aged; Polymorphism, Genetic; Psoriasis; T-Lymphocytes; Young Adult | 2008 |
Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection.
Topics: Aged; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Etanercept; Follow-Up Studies; Hepatitis C; Humans; Immunoglobulin G; Injections, Subcutaneous; Kidney Failure, Chronic; Liver Function Tests; Male; Polycystic Kidney Diseases; Psoriasis; Receptors, Tumor Necrosis Factor; Renal Dialysis; Severity of Illness Index; Treatment Outcome | 2008 |
Increased insulin-like growth factor binding protein-3 expression level in psoriatic tissue before and after systemic treatment with cyclosporine A and methotrexate.
Topics: Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Immunohistochemistry; Immunosuppressive Agents; Insulin-Like Growth Factor Binding Protein 3; Male; Methotrexate; Middle Aged; Psoriasis; Skin; Young Adult | 2008 |
Lichen planopilaris and psoriasis.
Topics: Adult; Alopecia; Betamethasone; Cyclosporine; Drug Therapy, Combination; Epidermis; Female; Granulocytes; Humans; Lichen Planus; Lymphocytes; Plasma Cells; Pruritus; Psoriasis; Scalp Dermatoses | 2008 |
A case of infliximab-induced psoriasis.
Topics: Adult; Antibodies, Monoclonal; Crohn Disease; Cyclosporine; Humans; Immunosuppressive Agents; Infliximab; Klebsiella Infections; Klebsiella oxytoca; Male; Pharyngitis; Psoriasis; Spondylitis, Ankylosing; Staphylococcal Infections; Streptococcal Infections; Streptococcus agalactiae; Tumor Necrosis Factor-alpha | 2008 |
Economic evaluation of systemic therapies for moderate to severe psoriasis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Statistics as Topic; Time Factors; Treatment Outcome | 2009 |
Inhibition of calcineurin by cyclosporine A exerts multiple effects on human melanoma cell lines HT168 and WM35.
Topics: Apoptosis; Calcineurin Inhibitors; Calcium; Calmodulin; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Cytosol; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Melanoma; Psoriasis; RNA, Messenger | 2009 |
Clinical usefulness of a supplementary cyclosporin administration with a topical application of maxacalcitol ointment for patients with moderate psoriasis vulgaris.
Topics: Administration, Topical; Adult; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Synergism; Female; Humans; Male; Ointments; Patient Satisfaction; Psoriasis; Remission Induction | 2009 |
Computerized quantification of psoriasis lesions with colour calibration: preliminary results.
Topics: Calibration; Color; Cyclosporine; Dermatologic Agents; Humans; Image Interpretation, Computer-Assisted; Photography; Psoriasis; Sensitivity and Specificity; Severity of Illness Index | 2009 |
Psoriasiform eruption associated with alopecia areata during infliximab therapy.
Topics: Aged; Alopecia Areata; Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis, Rheumatoid; Cyclosporine; Drug Eruptions; Female; Humans; Infliximab; Psoriasis | 2009 |
Comment on the letter by Sadighha and Zahed on Hair darkening after treatment with cyclosporin in a patient with psoriasis.
Topics: Adult; Cyclosporine; Female; Hair Color; Humans; Psoriasis | 2009 |
A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients.
Topics: Adolescent; Adult; Aged; Child; Cyclosporine; Female; Humans; Keratoderma, Palmoplantar; Male; Methotrexate; Middle Aged; Photochemotherapy; Psoriasis; Retinoids; Retrospective Studies; Treatment Outcome; Young Adult | 2009 |
European S3-guidelines on the systemic treatment of psoriasis vulgaris.
Topics: Adalimumab; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Retinoids | 2009 |
Childhood psoriasis: often favorable outcome.
Topics: Acitretin; Administration, Topical; Anthralin; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Emollients; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Plant Extracts; Psoriasis; Receptors, Tumor Necrosis Factor; Salicylates; Steroids; Tars; Treatment Outcome; Ultraviolet Therapy | 2009 |
Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease.
Topics: Child; Cyclosporine; Dermatologic Agents; Humans; Interferon-gamma; Interleukin-6; Male; Psoriasis; Time Factors; Tumor Necrosis Factor-alpha | 2009 |
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Drug Interactions; Female; Humans; Immunosuppressive Agents; Male; Managed Care Programs; Methotrexate; Middle Aged; Prevalence; Psoriasis; Retinoids | 2010 |
Case of anti-laminin-gamma1 pemphigoid associated with psoriatic erythroderma.
Topics: Autoantibodies; Cyclosporine; Dermatitis, Exfoliative; Humans; Immunoglobulin G; Laminin; Male; Middle Aged; Pemphigoid, Bullous; Prednisolone; Psoriasis; Treatment Outcome | 2010 |
Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?
Topics: Cyclosporine; Dermatologic Agents; Hepatitis C, Chronic; Humans; Practice Guidelines as Topic; Psoriasis; Risk Factors | 2010 |
Development of pemphigus vulgaris in a patient with psoriasis treated with cyclosporine.
Topics: Biopsy; Cyclosporine; Humans; Immunosuppressive Agents; Male; Middle Aged; Pemphigus; Psoriasis | 2010 |
Eruptive nevi in a patient receiving cyclosporine A for psoriasis treatment.
Topics: Adult; Cyclosporine; Diagnosis, Differential; Follow-Up Studies; Humans; Male; Nevus; Psoriasis; Skin Neoplasms | 2010 |
A preliminary examination of the role of NFAT 3 in human skin, cultured keratocytes and dermal fibroblasts.
Topics: Calcineurin Inhibitors; Calcium Signaling; Cell Nucleus; Cells, Cultured; Cyclosporine; Dermis; Fibroblasts; Gene Expression; Humans; Immunosuppressive Agents; Keratinocytes; Microscopy, Confocal; NFATC Transcription Factors; Psoriasis; RNA, Messenger; Skin; Tacrolimus | 2010 |
Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cyclosporine; Dermatologic Agents; Female; Humans; Infliximab; Psoriasis; PUVA Therapy; Skin Neoplasms; Time Factors; Tumor Necrosis Factor-alpha | 2011 |
The value of monitoring ciclosporin concentration 2 hours post-dose (C2) in dermatology: a prospective cohort study.
Topics: Adult; Aged; Blood Pressure; Creatinine; Cyclosporine; Dermatologic Agents; Drug Monitoring; Female; Humans; Male; Middle Aged; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Time Factors; Young Adult | 2011 |
Successful treatment of hand and foot psoriasis with infliximab.
Topics: Adult; Antibodies, Monoclonal; Cyclosporine; Dermatologic Agents; DiGeorge Syndrome; Fatty Liver, Alcoholic; Female; Foot Dermatoses; Hand Dermatoses; Hepatitis C, Chronic; Humans; Infliximab; Male; Methotrexate; Middle Aged; Psoriasis; Retinoids; Retrospective Studies; Treatment Outcome | 2010 |
Circulating level of chemerin is upregulated in psoriasis.
Topics: Adult; Chemokines; Chronic Disease; Cyclosporine; Dermatitis; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; Intercellular Signaling Peptides and Proteins; Leptin; Male; Metabolic Syndrome; Psoriasis; Skin; Up-Regulation | 2010 |
Adherence to treatment: still the forgotten variable.
Topics: Cyclosporine; Dermatologic Agents; Humans; Medication Adherence; Obesity; Psoriasis | 2010 |
Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants.
Topics: Adult; Antibiotics, Antineoplastic; Biopsy; Cyclosporine; Doxorubicin; Etanercept; Fatal Outcome; Humans; Immunoglobulin G; Immunosuppressive Agents; Leg; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasm Invasiveness; Neoplasm Staging; Polyethylene Glycols; Psoriasis; Receptors, Tumor Necrosis Factor; Skin Neoplasms; Treatment Failure | 2010 |
Treatment of psoriasis in patients with hepatitis C virus infection.
Topics: Acitretin; Antiviral Agents; Cyclosporine; Drug Eruptions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Methotrexate; Psoriasis; Ribavirin | 2011 |
Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).
Topics: Adalimumab; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Therapy; Cyclosporine; Dermatologic Agents; Female; Humans; Infliximab; Male; Middle Aged; Nail Diseases; Psoriasis; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Cyclosporin A induces the unfolded protein response in keratinocytes.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclophilins; Cyclosporine; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Keratinocytes; Psoriasis; RNA, Small Interfering; Transcription Factor CHOP; Transforming Growth Factor beta1; Unfolded Protein Response | 2011 |
Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
Topics: Adalimumab; Adipokines; Adult; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cyclosporine; Etanercept; Female; Fumarates; Humans; Immunoglobulin G; Longitudinal Studies; Male; Methotrexate; Middle Aged; Prospective Studies; Psoriasis; Receptors, Tumor Necrosis Factor; Resistin; Risk Factors; Severity of Illness Index; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.
Topics: Adult; Aged; Cyclosporine; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Patient Satisfaction; Psoriasis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2011 |
Improvement of quality of life and clinical usefulness of cyclosporin administration in patients with nail psoriasis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cyclosporine; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Nail Diseases; Psoriasis; Quality of Life; Treatment Outcome; Young Adult | 2011 |
Use of conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists.
Topics: Cyclosporine; Dermatology; Humans; Methotrexate; Practice Patterns, Physicians'; Psoriasis; Retinoids | 2011 |
[Meetings of the Psoriasis Experts: recommendations for daily practice].
Topics: Consensus Development Conferences as Topic; Cyclosporine; Delphi Technique; Evidence-Based Medicine; Expert Testimony; Humans; Methotrexate; Practice Guidelines as Topic; Professional Practice; Psoriasis; Retinoids | 2011 |
In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?".
Topics: Cyclosporine; Dermatologic Agents; Evidence-Based Medicine; Hepatitis C, Chronic; Humans; Psoriasis; Risk Factors | 2011 |
Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; Dermatomyositis; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Methotrexate; Methylprednisolone; Mycophenolic Acid; Phototherapy; Prednisone; Psoriasis; Receptors, Tumor Necrosis Factor; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Statistical evaluation and experimental design of a psoriasis xenograft transplantation model treated with cyclosporin A.
Topics: Adult; Aged; Analysis of Variance; Animals; Computer Simulation; Cyclosporine; Data Interpretation, Statistical; Disease Models, Animal; Humans; Mice; Mice, SCID; Middle Aged; Psoriasis; Research Design; Skin Transplantation; Transplantation, Heterologous; Treatment Outcome | 2011 |
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Safety-Based Drug Withdrawals; Severity of Illness Index; Treatment Outcome; Withholding Treatment; Young Adult | 2011 |
Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Topics: Acitretin; Adalimumab; Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Tacrolimus; Treatment Outcome; Ustekinumab | 2011 |
Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Cyclosporine; Drug Utilization; Female; Fumarates; General Practice; Germany; Guideline Adherence; Humans; Internal Medicine; Male; Methotrexate; Off-Label Use; Psoriasis; Retinoids | 2011 |
Pemphigus vulgaris with plaque-type psoriasis successfully treated with cyclosporine monotherapy.
Topics: Aged; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Pemphigus; Psoriasis; Treatment Outcome | 2011 |
[Update on psoriasis at the Dermatology Day conference, Paris 2010].
Topics: Comorbidity; Creatinine; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Kidney Diseases; Liver Cirrhosis; Methotrexate; Psoriasis; Risk Factors; Severity of Illness Index | 2011 |
[News on psoriasis from the 2010 Dermatology Days in Paris].
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cyclosporine; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Evidence-Based Medicine; Humans; Immunoglobulin G; Methotrexate; Practice Guidelines as Topic; Psoriasis; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Treatment Outcome; Ustekinumab | 2011 |
Severe generalized pustular psoriasis accompanied by bullae formation with increased serum vascular endothelial growth factor level.
Topics: Blister; Cholecalciferol; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etretinate; Female; Humans; Middle Aged; Psoriasis; Treatment Outcome; Ultraviolet Therapy; Vascular Endothelial Growth Factor A | 2012 |
Superimposed linear psoriasis: low effectiveness of biologic therapy.
Topics: Acitretin; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Biological Therapy; Cyclosporine; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Loss of Heterozygosity; Male; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor | 2011 |
Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Alefacept; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Crohn Disease; Cyclosporine; Etanercept; Female; Humans; Immunoglobulin G; Methotrexate; Middle Aged; Mycophenolic Acid; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Treatment Outcome; Ustekinumab | 2011 |
Translating clinical activity and gene expression signatures of etanercept and ciclosporin to the psoriasis xenograft SCID mouse model.
Topics: Animals; Biomarkers; Chemokines; Cyclosporine; Cytokines; Dermatologic Agents; Disease Models, Animal; Down-Regulation; Etanercept; Gene Expression; Gene Expression Profiling; Humans; Immunoglobulin G; Mice; Mice, SCID; Psoriasis; Receptors, Tumor Necrosis Factor; Transplantation, Heterologous | 2012 |
New-onset psoriasis in a maintenance hemodialysis patient.
Topics: Adult; Cyclosporine; Female; Humans; Kidney; Psoriasis; Renal Dialysis | 2012 |
[Choice of therapy based on clinical setting].
Topics: Age Factors; Comorbidity; Contraindications; Cyclosporine; Decision Making; Dermatologic Agents; Female; Hepatic Insufficiency; Humans; Kidney Diseases; Latent Tuberculosis; Mental Disorders; Methotrexate; Pregnancy; Psoriasis; Risk Factors; Skin Neoplasms | 2011 |
[Cyclosporine].
Topics: Cyclosporine; Drug Monitoring; Humans; Immunosuppressive Agents; Psoriasis | 2011 |
[Organisation of combined follow-up by hospitals and private dermatologists].
Topics: Biological Products; Cyclosporine; Drug Monitoring; Humans; Immunosuppressive Agents; Patient Care Team; Psoriasis | 2011 |
[Patient education. Information letter on treatment of psoriasis with oral cyclosporine].
Topics: Abdominal Pain; Administration, Oral; Cyclosporine; Diarrhea; Fatigue; Headache; Humans; Immunosuppressive Agents; Nausea; Psoriasis; Tremor | 2011 |
Interleukin-17- and protease-activated receptor 2-mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes.
Topics: Cells, Cultured; Chemokine CXCL1; Clobetasol; Cyclosporine; Dexamethasone; Dihydroxycholecalciferols; Glucocorticoids; Humans; Inflammation Mediators; Interleukin-17; Interleukin-8; Keratinocytes; Oligopeptides; Psoriasis; Receptor, PAR-2; RNA, Messenger; RNA, Small Interfering | 2012 |
Estimation of tissue osteopontin levels before and after different traditional therapeutic modalities in psoriatic patients.
Topics: Cyclosporine; Humans; Methotrexate; Osteopontin; Psoriasis; PUVA Therapy | 2013 |
Femoral head osteonecrosis after long-term topical corticosteroid treatment in a psoriasis patient.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthroplasty, Replacement, Hip; Calcitriol; Clobetasol; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Femur Head; Hip; Humans; Male; Middle Aged; Osteonecrosis; Psoriasis; Quality of Life; Range of Motion, Articular; Severity of Illness Index; Treatment Outcome | 2012 |
Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin.
Topics: Adipokines; Adiponectin; Adult; Case-Control Studies; Cyclosporine; Female; Ghrelin; Humans; Immunosuppressive Agents; Leptin; Male; Middle Aged; Psoriasis; Resistin | 2012 |
The psoriasis xenograft SCID mouse model: a tool in translational research.
Topics: Animals; Cyclosporine; Dermatologic Agents; Etanercept; Gene Expression; Humans; Immunoglobulin G; Mice, SCID; Psoriasis; Receptors, Tumor Necrosis Factor | 2012 |
Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Male; Melanoma; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Downregulation of circulating CD4+ CD25(bright) Foxp3+ T cells by cyclosporine therapy and correlation with clinical response in psoriasis patients: report of three cases.
Topics: CD4 Antigens; Cyclosporine; Down-Regulation; Female; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Male; Psoriasis; Severity of Illness Index; T-Lymphocytes, Regulatory | 2013 |
Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cyclosporine; Drug Substitution; Humans; Immunosuppressive Agents; Knee Injuries; Male; Methotrexate; Osteoarthritis, Knee; Psoriasis; Spondylarthritis; Tumor Necrosis Factor-alpha; Ustekinumab; Withholding Treatment | 2014 |
Low-dose cyclosporin improves the health-related quality of life in Japanese psoriasis patients dissatisfied with topical corticosteroid monotherapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Cyclosporine; Female; Humans; Immunosuppressive Agents; Japan; Male; Middle Aged; Patient Satisfaction; Psoriasis; Quality of Life; Severity of Illness Index | 2012 |
Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cross-Sectional Studies; Cyclosporine; Dermatology; Etanercept; Humans; Immunoglobulin G; Infliximab; Perception; Physicians; Practice Patterns, Physicians'; Psoriasis; Receptors, Tumor Necrosis Factor; Ustekinumab | 2013 |
Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Treatment Outcome; Young Adult | 2012 |
Generalized pustular psoriasis of Zambusch: case report of successful disease control with cyclosporine and etanercept.
Topics: Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Psoriasis; Receptors, Tumor Necrosis Factor; Treatment Outcome; Young Adult | 2012 |
Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients.
Topics: Adult; Aged; Cyclosporine; Drug Resistance; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Prognosis; Psoriasis; Retrospective Studies; Risk Factors; Severity of Illness Index; Young Adult | 2012 |
Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model.
Topics: Administration, Topical; Adolescent; Adult; Cell Survival; Cyclosporine; Cytokines; Dermatitis; Dermatologic Agents; Emulsions; Female; Humans; Middle Aged; Nanoparticles; Organ Culture Techniques; Psoriasis; Skin; Young Adult | 2012 |
[Generalized pustular psoriasis of pregnancy].
Topics: Administration, Intravenous; Biopsy; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Female; Glucocorticoids; Humans; Prednisolone; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimester, Third; Pruritus; Psoriasis; Skin; Treatment Outcome; Ultraviolet Therapy; Young Adult | 2012 |
Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Child; Cholecalciferol; Cyclosporine; Dermatologic Agents; Drug Combinations; Etretinate; Female; Follow-Up Studies; Glucocorticoids; Humans; Japan; Male; Middle Aged; Phototherapy; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2013 |
Secondary syphilis on a psoriatic patient under cyclosporine: a challenging case.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Syphilis | 2014 |
Levels of cyclosporine in breast milk and passage into the circulation of the infant of a mother with psoriasis.
Topics: Breast Feeding; Cyclosporine; Female; Humans; Immunosuppressive Agents; Infant, Newborn; Milk, Human; Pregnancy; Psoriasis; Young Adult | 2014 |
Use of basiliximab as a cyclosporin-sparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect.
Topics: Aged; Antibodies, Monoclonal; Basiliximab; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Male; Psoriasis; Recombinant Fusion Proteins | 2002 |
Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-density [correction for destiny] lipoprotein.
Topics: Administration, Oral; Anticholesteremic Agents; Cyclosporine; Dermatologic Agents; Drug Synergism; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hyperlipoproteinemia Type II; Immunosuppressive Agents; Indoles; Lipoproteins, LDL; Middle Aged; Obesity; Psoriasis | 2002 |
Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Cyclosporine; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2002 |
Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.
Topics: Adult; Cyclosporine; ErbB Receptors; Humans; Immunosuppressive Agents; Lymphocyte Activation; Male; Middle Aged; Psoriasis; Receptors, Interleukin-2; T-Lymphocytes | 1989 |
Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin.
Topics: Acitretin; Alcoholism; Carcinoma, Squamous Cell; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Leg; Male; Middle Aged; Psoriasis; PUVA Therapy; Skin Neoplasms; Ultraviolet Rays | 2003 |
Erythromelalgia induced by possible calcium channel blockade by ciclosporin.
Topics: Adult; Calcium Channels; Cyclosporine; Dermatologic Agents; Erythromelalgia; Humans; Male; Psoriasis | 2003 |
Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine.
Topics: Biomarkers, Tumor; Cyclosporine; Etretinate; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Middle Aged; Psoriasis; Risk Factors; Skin Neoplasms | 2003 |
Cyclosporin in childhood psoriasis.
Topics: Administration, Oral; Child; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Male; Psoriasis; Severity of Illness Index | 2003 |
Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Topics: Aged; Cyclosporine; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Psoriasis; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2003 |
Psoriasiform-lichenoid-like dermatosis in three dogs treated with microemulsified cyclosporine A.
Topics: Animals; Cyclosporine; Dermatitis, Seborrheic; Dermatologic Agents; Diagnosis, Differential; Dog Diseases; Dogs; Lichen Planus; Male; Psoriasis | 2003 |
Subclinical impairment of distal renal acidification induced by low-dose cyclosporin A therapy.
Topics: Adult; Creatinine; Cyclosporine; Female; Furosemide; Humans; Hydrogen-Ion Concentration; Immunosuppressive Agents; Kidney Function Tests; Male; Middle Aged; Psoriasis; Urine | 1992 |
Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol.
Topics: Calcitriol; Cyclosporine; Dermatologic Agents; Epidermal Cells; Epidermis; Gene Expression; Genes, Tumor Suppressor; Humans; Interleukin-10; Interleukins; Keratinocytes; Psoriasis; Receptors, Interleukin; RNA, Messenger; T-Lymphocytes | 2003 |
The evaluation of the effectiveness and side-effects of a 200-mg/day constant dose of cyclosporin in chronic plaque-type psoriasis: can a constant dose be an alternative?
Topics: Administration, Oral; Adult; Aged; Chi-Square Distribution; Chronic Disease; Cyclosporine; Female; Humans; Male; Middle Aged; Psoriasis; Treatment Outcome | 2004 |
A case of generalized pustular psoriasis associated with Turner syndrome.
Topics: Adult; Biopsy, Needle; Cyclosporine; Female; Follow-Up Studies; Humans; Immunohistochemistry; Psoriasis; Risk Assessment; Severity of Illness Index; Treatment Outcome; Turner Syndrome | 2004 |
Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series.
Topics: Adolescent; Adult; Aged; Chronic Disease; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Retrospective Studies | 2004 |
A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis.
Topics: Adolescent; Adult; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Multicenter Studies as Topic; Netherlands; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2004 |
Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
Topics: Adolescent; Adult; Chronic Disease; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psoriasis; Quality of Life; Recurrence; Severity of Illness Index; Sickness Impact Profile; Treatment Outcome; United Kingdom | 2004 |
Cyclosporin in psoriasis: how?
Topics: Autoimmune Diseases; Clinical Trials as Topic; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Male; Prognosis; Psoriasis; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Psoriasis coexisting with subacute cutaneous lupus erythematosus.
Topics: Biopsy, Needle; Cyclosporine; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lupus Erythematosus, Cutaneous; Middle Aged; Psoriasis; Risk Assessment; Treatment Outcome | 2004 |
Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
Topics: Adult; Aged; Cyclosporine; Dermatologic Agents; Drug Interactions; Drug Therapy, Combination; Esters; Female; Flushing; Fumarates; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies; Time Factors; Treatment Outcome | 2004 |
Use of infliximab in the treatment of psoriasis.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Infliximab; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Psoriasis; Remission Induction; Time Factors | 2004 |
Cyclosporine enhances salt sensitivity of body water composition as assessed by impedance among psoriatic patients with normal renal function.
Topics: Adult; Blood Pressure; Body Water; Creatinine; Cyclosporine; Diet, Sodium-Restricted; Electric Impedance; Energy Intake; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Osmolar Concentration; Potassium; Psoriasis; Sodium; Sodium, Dietary; Urine | 2004 |
Severe extra-palmoplantar pustulation associated with palmoplantar pustulosis.
Topics: Cyclosporine; Diagnosis, Differential; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 2004 |
Sequential therapy using cyclosporine and acitretin for treatment of total body psoriasis.
Topics: Acitretin; Administration, Cutaneous; Adult; Cyclosporine; Dermatologic Agents; Humans; Keratolytic Agents; Male; Psoriasis; Skin; Treatment Outcome | 2004 |
Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing.
Topics: Acitretin; Cyclosporine; Female; Ficusin; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Patient Satisfaction; Photosensitizing Agents; Psoriasis; PUVA Therapy; Treatment Outcome | 2005 |
Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression.
Topics: B-Lymphocytes; Cyclosporine; Epstein-Barr Virus Infections; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Psoriasis; Remission, Spontaneous; Time Factors | 2005 |
A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.
Topics: Angiopoietins; Animals; Blotting, Western; Cell Line; Cyclosporine; Doxycycline; Enzyme-Linked Immunosorbent Assay; Epidermis; Gene Expression Regulation; Genotype; Humans; Immunohistochemistry; Immunoprecipitation; Immunosuppressive Agents; Inflammation; Keratinocytes; Lac Operon; Lectins; Mice; Mice, Transgenic; Models, Genetic; Phenotype; Psoriasis; Receptor, TIE-2; Signal Transduction; Skin; Tetracycline; Time Factors; Transgenes; Vascular Endothelial Growth Factor A | 2005 |
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
Topics: Acitretin; Adult; Aged; Cyclosporine; Dermatologic Agents; Female; Ficusin; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Patient Satisfaction; Psoriasis; PUVA Therapy; Treatment Outcome; United States | 2005 |
Pustular psoriasis and the Kobner phenomenon caused by allergic contact dermatitis from zinc pyrithione-containing shampoo.
Topics: Adult; Cyclosporine; Dermatitis, Allergic Contact; Female; Hair Preparations; Humans; Immunosuppressive Agents; Psoriasis; Pyridines; Risk Factors; Scalp Dermatoses; Zinc Compounds | 2005 |
Salt sensitivity of blood pressure in patients with psoriasis on ciclosporin therapy.
Topics: Adult; Blood Pressure; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Natriuresis; Norepinephrine; Psoriasis; Sodium, Dietary | 2005 |
Ciclosporin in psoriasis consensus statement.
Topics: Consensus; Cyclosporine; Humans; Immunosuppressive Agents; Psoriasis | 2005 |
Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Topics: Acitretin; Adult; Costs and Cost Analysis; Cyclosporine; Dermatologic Agents; Female; Health Care Costs; Humans; Male; Managed Care Programs; Methotrexate; Middle Aged; New England; Phototherapy; Psoriasis; PUVA Therapy; Treatment Failure; United States | 2005 |
Psoriasis: TNF-alpha inhibitors and beyond.
Topics: Cyclosporine; Drug Industry; Humans; Insulin-Like Growth Factor I; Neoplasm Proteins; Psoriasis; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Technology, Pharmaceutical; Tumor Necrosis Factor Decoy Receptors | 2005 |
Pustular psoriasis of pregnancy treated with ciclosporin and high-dose prednisolone.
Topics: Adult; Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Prednisolone; Pregnancy; Pregnancy Complications; Psoriasis; Treatment Outcome | 2005 |
The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis.
Topics: Adult; Aged; Calcitriol; Chronic Disease; Cyclosporine; Dermatologic Agents; Female; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-10; Interleukins; Male; Middle Aged; Psoriasis; Receptors, Interleukin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin | 2005 |
Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
Topics: Adult; Aged; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 2005 |
Evaluation of psoriatic patients with HCV infection.
Topics: Adult; Aged; Cyclosporine; Drug Therapy, Combination; Etretinate; Evaluation Studies as Topic; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis.
Topics: Adolescent; Arthritis, Psoriatic; Child; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Psoriasis; Treatment Outcome | 2006 |
Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
Topics: Adult; Cyclosporine; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor | 2006 |
Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine.
Topics: Administration, Oral; Aged; Cyclosporine; Dermatologic Agents; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Psoriasis | 2006 |
Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A.
Topics: Adult; Cells, Cultured; Cyclosporine; Dose-Response Relationship, Immunologic; Female; Flow Cytometry; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-12; Lipopolysaccharides; Male; Middle Aged; Monocytes; Psoriasis; Recombinant Proteins; Up-Regulation | 2006 |
Methotrexate and ciclosporin combination for the treatment of severe psoriasis.
Topics: Adult; Aged; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome | 2006 |
Musculoskeletal and myotoxic side-effects in a patient treated for psoriasis.
Topics: Adult; Cyclosporine; Humans; Immunosuppressive Agents; Male; Muscle Weakness; Musculoskeletal Diseases; Psoriasis | 2006 |
Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Chemokine CCL17; Chemokine CCL22; Chemokines, CC; Cyclosporine; Dendritic Cells; Dermatitis, Atopic; Dermatologic Agents; Dexamethasone; Female; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-12; Interleukin-18; Male; Middle Aged; Monocytes; Psoriasis; Severity of Illness Index; Tacrolimus | 2006 |
Cyclosporine resolves generalized pustular psoriasis of pregnancy.
Topics: Adult; Cyclosporine; Diagnosis, Differential; Female; Humans; Immunosuppressive Agents; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Prenatal Diagnosis; Psoriasis | 2006 |
Adverse events from systemic therapies for psoriasis are common in clinical practice.
Topics: Adult; Aged; Biological Products; Cyclosporine; Dermatologic Agents; Female; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Retinoids; Retrospective Studies | 2006 |
Anti-TNF-alpha therapy in childhood pustular psoriasis.
Topics: Antibodies, Monoclonal; Child, Preschool; Cyclosporine; Dermatologic Agents; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Psoriasis; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
Photosensitive psoriasis in a vitiligo patient.
Topics: Adolescent; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Photosensitivity Disorders; Psoriasis; Sunlight; Vitiligo | 2006 |
Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
Topics: Adult; Aged; Alefacept; CD2 Antigens; CD4-Positive T-Lymphocytes; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Flow Cytometry; Humans; Immunologic Memory; Immunosuppressive Agents; Killer Cells, Natural; Lymphocyte Count; Methotrexate; Middle Aged; Psoriasis; Recombinant Fusion Proteins; Severity of Illness Index; T-Lymphocyte Subsets; Treatment Outcome | 2007 |
Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C.
Topics: Antiviral Agents; Cyclosporine; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Psoriasis; Recombinant Proteins | 2007 |
Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
Topics: Acitretin; Administration, Oral; Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Keratolytic Agents; Male; Methotrexate; Patient Satisfaction; Psoriasis; PUVA Therapy; Surveys and Questionnaires; Treatment Outcome; Ultraviolet Therapy | 2007 |
Comparative study of the effects of betamethasone butyrate propionate, vitamin D3 derivatives, and cyclosporine on human lymphocyte-proliferation stimulated with a hemolytic streptococci-derived superantigen.
Topics: Adult; Betamethasone; Cell Proliferation; Cells, Cultured; Cholecalciferol; Concanavalin A; Cyclosporine; Dose-Response Relationship, Drug; Enterotoxins; Female; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukins; Lymphocyte Activation; Lymphocytes; Male; Mitogens; Psoriasis; Streptococcus; Superantigens; Tumor Necrosis Factor-alpha | 2007 |
Juvenile generalized pustular psoriasis.
Topics: Anti-Infective Agents; Child; Child, Preschool; Cyclosporine; Dermatitis, Exfoliative; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Infant; Male; Psoriasis; Skin | 2007 |
Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Drug Therapy, Combination; Etanercept; Glucocorticoids; Humans; Immunoglobulin G; Immunosuppressive Agents; Injections, Subcutaneous; Male; Psoriasis; Receptors, Tumor Necrosis Factor; Skin; Skin Diseases, Vesiculobullous; Treatment Outcome; Triamcinolone | 2007 |
Conventional therapies for psoriasis.
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Italy; Keratolytic Agents; Methotrexate; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cryptococcosis; Cryptococcus neoformans; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Methotrexate; Psoriasis | 2007 |
Instability of topical ciclosporin emulsion for nail psoriasis.
Topics: Administration, Topical; Cell Proliferation; Cyclosporine; Dermatologic Agents; Drug Stability; Emulsions; Humans; Immunoassay; Keratinocytes; Male; Middle Aged; Nail Diseases; Psoriasis | 2007 |
Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Male; Psoriasis; Recurrence; Remission Induction; Time Factors; Withholding Treatment | 2007 |
[Therapeutic strategies against psoriasis. Skin to hide -- and how do you free your patients from it].
Topics: Adrenal Cortex Hormones; Anthralin; Arthritis, Psoriatic; Biological Products; Cyclosporine; Dermatologic Agents; Female; Fumarates; Humans; Male; Methotrexate; Phototherapy; Psoriasis; PUVA Therapy; Retinoids; Sex Factors | 2007 |
Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept.
Topics: Adult; Cyclosporine; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Psoriasis; Receptors, Tumor Necrosis Factor; Schizophrenia, Paranoid | 2007 |
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.
Topics: Animals; Antibodies, Monoclonal; Cells, Cultured; Cyclosporine; Dermis; Gene Expression; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-17; Interleukin-22; Interleukins; Keratin-16; Psoriasis; Rats; RNA, Messenger; Th1 Cells | 2008 |
Generalized pustular psoriasis and cryptogenic organizing pneumonia.
Topics: Acitretin; Adult; Arthritis, Psoriatic; Cryptogenic Organizing Pneumonia; Cyclosporine; Dermatologic Agents; Etanercept; Fatal Outcome; Female; Humans; Immunoglobulin G; Protein C Inhibitor; Psoriasis; Receptors, Tumor Necrosis Factor | 2008 |
Hair darkening after treatment with cyclosporin in a patient with psoriasis.
Topics: Cyclosporine; Hair Color; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 2008 |
FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; CD28 Antigens; Cell Proliferation; Cyclosporine; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Immunoglobulin G; Immunosuppressive Agents; Mice; Mice, SCID; Psoriasis; T-Lymphocytes; Transplantation, Heterologous | 2008 |
[Clinical experience with efalizumab in the Hospital of Cruces].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Combined Modality Therapy; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Female; Hospitals, Urban; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; PUVA Therapy; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2008 |
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Topics: Acitretin; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cyclosporine; Depression; Etanercept; Humans; Immunoglobulin G; Interleukin-12; Interleukin-23; Lymphoma; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Smoking; Tumor Necrosis Factor-alpha | 2008 |
Erythroderma in a patient taking acitretin for plaque psoriasis.
Topics: Acitretin; Cyclosporine; Dermatitis, Exfoliative; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis | 2008 |
[Psoriatic arthritis].
Topics: Arthritis, Psoriatic; Cyclosporine; Diagnosis, Differential; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Psoriasis | 2008 |
Effects of cyclosporine on cytokines and cytokine receptors in psoriasis.
Topics: Administration, Oral; Adult; Biopsy, Needle; Cells, Cultured; Cyclosporine; Cytokines; Female; Flow Cytometry; Humans; Immunohistochemistry; Inflammation Mediators; Male; Middle Aged; Psoriasis; Receptors, Cytokine; Skin; Statistics, Nonparametric; Time Factors | 1995 |
Response of the clinically uninvolved skin of psoriatic patients to repeated tape stripping during cyclosporin A treatment.
Topics: Cell Adhesion Molecules, Neuronal; Cell Differentiation; Cell Division; Cyclosporine; Epidermis; Extracellular Matrix Proteins; Filaggrin Proteins; Humans; Immunohistochemistry; Intermediate Filament Proteins; Keratinocytes; Ki-67 Antigen; Neoplasm Proteins; Nuclear Proteins; Protein Precursors; Psoriasis; T-Lymphocytes; Tenascin | 1994 |
PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy.
Topics: Adult; Aged; Antigens, CD; Antigens, CD1; Cells, Cultured; Cyclosporine; Epidermis; Filaggrin Proteins; HLA-DR Antigens; Humans; Ki-67 Antigen; Lymphocyte Activation; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Psoriasis; PUVA Therapy; Skin | 1994 |
Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.
Topics: Anthralin; Cell Line; Cyclosporine; Humans; Immunohistochemistry; Indoles; Intracellular Fluid; Keratinocytes; Organ Culture Techniques; Phosphorylation; Phosphotyrosine; Protein Kinase C; Protein-Tyrosine Kinases; Proteins; Psoriasis; Signal Transduction; Skin; Tacrolimus; Tyrosine | 1995 |
Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Anthralin; CD8-Positive T-Lymphocytes; Cell Division; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Epidermis; Female; Humans; Keratinocytes; Keratins; Lymphocyte Count; Lymphokines; Male; Middle Aged; Psoriasis; Remission Induction; Skin; T-Lymphocytes | 1995 |
Successful treatment of severe arthralgia associated with palmoplantar pustulosis with low-dose oral cyclosporine A.
Topics: Administration, Oral; Adult; Arthralgia; Arthritis, Psoriatic; Cyclosporine; Female; Humans; Immunosuppressive Agents; Middle Aged; Psoriasis | 1995 |
[Psoriasis--an immunologic disorder? Symposium, 14 July 1993, Düsseldorf].
Topics: Autoimmune Diseases; Cyclosporine; Humans; Psoriasis | 1993 |
Multiple benign keratoses during cyclosporin therapy for psoriasis.
Topics: Cyclosporine; Humans; Keratosis; Male; Middle Aged; Psoriasis | 1995 |
Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels.
Topics: Adult; Aldosterone; Arthritis, Rheumatoid; Atrial Natriuretic Factor; Blood Pressure; Cyclosporine; Endothelins; Female; Humans; Hypertension; Male; Middle Aged; Psoriasis; Renin; Vasopressins | 1995 |
Cyclosporine in dermatology. Fears and opportunities.
Topics: Cyclosporine; Humans; Psoriasis | 1995 |
Oral and intravenous disposition of cyclosporine in psoriatic patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cyclosporine; Female; Humans; Injections, Intravenous; Male; Middle Aged; Psoriasis | 1995 |
Cyclosporin A in severe, therapy-resistant atopic dermatitis: report of an international workshop, April 1993.
Topics: Adult; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Drug Interactions; Drug Monitoring; Guidelines as Topic; Humans; Patient Selection; Placebos; Psoriasis; Randomized Controlled Trials as Topic; Safety | 1993 |
Should atypical lymphocytes and plasma cells in well patients with psoriasis on cyclosporin cause concern?
Topics: Cyclosporine; Cytomegalovirus; Herpesvirus 4, Human; Humans; Lymphocytes; Lymphoma; Plasma Cells; Psoriasis; Risk Factors; Virus Activation | 1993 |
Transient monoclonal gammopathy associated with cyclosporin treatment of psoriasis.
Topics: Aged; Cyclosporine; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Paraproteinemias; Psoriasis | 1995 |
Changes in numbers of epidermal cell adhesion molecules caused by oral cyclosporin in psoriasis.
Topics: Antigens, CD; CD18 Antigens; Cell Adhesion Molecules; Cyclosporine; Humans; Integrin beta1; Intercellular Adhesion Molecule-1; Psoriasis; Skin | 1993 |
Interrelationship between serum concentrations of 1,25-dihydroxyvitamin D, parathyroid hormone and renal haemodynamics after low dose cyclosporin.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Biomarkers; Blood Pressure; Calcitriol; Cyclosporine; Glomerular Filtration Rate; Humans; Middle Aged; Parathyroid Hormone; Pilot Projects; Psoriasis; Renal Circulation | 1994 |
Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis.
Topics: Biomarkers; Cholestasis; Cholesterol, LDL; Cyclosporine; Drug Administration Schedule; Humans; Lipoproteins; Liver Function Tests; Psoriasis | 1995 |
Cyclosporine: a new therapeutic option for severe, recalcitrant psoriasis.
Topics: Adult; Cyclosporine; Drug Monitoring; Humans; Male; Patient Education as Topic; Psoriasis; Treatment Failure | 1994 |
HIV results in the frame. Cyclosporin A.
Topics: Adult; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclosporine; HIV-1; Humans; Lymphocyte Activation; Male; Psoriasis; RNA, Viral; Viremia; Virus Replication | 1995 |
Renal structure and function effects after low dose cyclosporine in psoriasis patients: a preliminary report.
Topics: Adult; Biopsy; Cyclosporine; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Prospective Studies; Psoriasis | 1995 |
[Psoriasis: diagnosis and therapy].
Topics: Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Psoriasis; Psychotherapy; PUVA Therapy; Retinoids | 1995 |
Regulatory effects of antipsoriatic agents on interleukin-1 alpha production by human keratinocytes stimulated with gamma interferon in vitro.
Topics: Calcitriol; Cells, Cultured; Cyclosporine; Humans; Hydrocortisone; Interferon-gamma; Interleukin-1; Keratinocytes; Psoriasis; Recombinant Proteins; RNA, Messenger | 1995 |
Ultrasound imaging of psoriatic skin: a noninvasive technique to evaluate treatment of psoriasis.
Topics: Adult; Aged; Cell Division; Cyclosporine; Drug Combinations; Epidermis; Female; Follow-Up Studies; Glucosamine; Humans; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Skin; Sulfasalazine; Ultrasonography | 1994 |
Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A.
Topics: Adolescent; Adult; Aged; Biomarkers; Child; Child, Preschool; Cyclosporine; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Proteinase Inhibitory Proteins, Secretory; Proteins; Psoriasis; Serine Proteinase Inhibitors; Severity of Illness Index | 1995 |
[Failure of cyclosporine in the treatment of psoriasis: role of lithium?].
Topics: Cyclosporine; Drug Interactions; Female; Humans; Lithium; Middle Aged; Psoriasis | 1995 |
Changes in numbers of epidermal cell adhesion molecules caused by oral cyclosporin in psoriasis.
Topics: Cell Adhesion Molecules; Cyclosporine; Dendritic Cells; Humans; Intercellular Adhesion Molecule-1; Psoriasis | 1994 |
Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis.
Topics: Animals; Cell Differentiation; Cyclooxygenase Inhibitors; Cyclosporine; Dose-Response Relationship, Drug; Epidermis; Fluorouracil; Lipoxygenase Inhibitors; Male; Mice; Psoriasis; Tail; Triamcinolone | 1994 |
Cyclosporin A and vitamin D metabolism: studies in patients with psoriasis and in rats.
Topics: Animals; Arthritis; Calcitriol; Cells, Cultured; Cyclosporine; Glomerular Filtration Rate; Humans; Macrophages; Male; Psoriasis; Rats; Rats, Wistar; Synovial Fluid | 1994 |
Development of human papillomavirus-associated Buschke-Löwenstein penile carcinoma during cyclosporine therapy for generalized pustular psoriasis.
Topics: Carcinoma, Squamous Cell; Carcinoma, Verrucous; Cyclosporine; Humans; Male; Papillomaviridae; Papillomavirus Infections; Penile Neoplasms; Psoriasis; Tumor Virus Infections | 1994 |
Reversibility of impaired renal function after long-term cyclosporin for psoriasis.
Topics: Adolescent; Adult; Aged; Cyclosporine; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Psoriasis; Time Factors | 1994 |
Excess granulation tissue development during treatment with cyclosporin.
Topics: Adolescent; Cyclosporine; Granulation Tissue; Humans; Hyperplasia; Male; Psoriasis | 1994 |
Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Coal Tar; Cyclosporine; Humans; Interferon Type I; Interferon-alpha; Middle Aged; Pregnancy Proteins; Psoriasis; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 1994 |
Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
Topics: Adult; Aged; Cyclosporine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psoriasis | 1994 |
Short-term treatment with cyclosporin in severe psoriasis: four years of experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Cyclosporine; Female; Humans; Male; Middle Aged; Psoriasis; Recurrence; Remission Induction | 1994 |
Psoriasis and cyclosporin: immunohistochemical aspects of the basement membrane.
Topics: Basement Membrane; Collagen; Cyclosporine; Humans; Immunohistochemistry; Laminin; Psoriasis; Skin | 1994 |
[Cyclosporine and psoriasis: experience with 14 patients].
Topics: Adult; Chronic Disease; Cyclosporine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Psoriasis | 1993 |
The interleukin-8 receptor: a potential target for antipsoriatic therapy?
Topics: Anthralin; Calcitriol; Cells, Cultured; Cyclosporine; Flow Cytometry; HLA-DR Antigens; Humans; Interleukin-8; Keratinocytes; Neutrophils; Psoriasis; Receptors, Interleukin; Receptors, Interleukin-8A; Recombinant Proteins | 1994 |
Acitretin does not prevent psoriasis relapse related to cyclosporin A tapering.
Topics: Acitretin; Chronic Disease; Cyclosporine; Female; Humans; Male; Middle Aged; Pilot Projects; Psoriasis; Recurrence; Remission Induction | 1994 |
Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients.
Topics: Adult; Arginine; Arthritis; Blood Glucose; C-Peptide; Cyclosporine; Diabetes Mellitus, Type 1; Female; Glucose; Humans; Immunosuppressive Agents; Insulin; Insulin Secretion; Islets of Langerhans; Kidney Transplantation; Male; Pancreas Transplantation; Prednisone; Psoriasis; Transplantation, Homologous | 1994 |
[Symposium report: "Therapy of severe psoriasis with Sandimmune". Symposium of Nurnberg Sandoz AG 13 February 1993, Nurnberg].
Topics: Clinical Trials as Topic; Cyclosporine; Germany; Humans; Psoriasis | 1994 |
Evaluation of plasma fibronectin levels before and after PUVA and cyclosporin A treatments in patients with psoriasis.
Topics: Adult; Aged; Cyclosporine; Female; Fibronectins; Humans; Male; Middle Aged; Psoriasis; PUVA Therapy; Severity of Illness Index; Time Factors | 1994 |
Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis.
Topics: Aged; Cyclosporine; Drug Combinations; Drug Tolerance; Etretinate; Female; Humans; Middle Aged; Psoriasis | 1994 |
Psoriasis and cigarettes. Another nail in the coffin.
Topics: Cyclosporine; Humans; Psoriasis; Smoking | 1993 |
Carcinoembryonic antigen and related glycoproteins in psoriasis.
Topics: Antibodies, Monoclonal; Biopsy; Carcinoembryonic Antigen; Cyclosporine; Endothelium; Humans; Immunohistochemistry; Psoriasis; PUVA Therapy; Reference Values; Skin; Skin Diseases; Sweat Glands | 1993 |
The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin.
Topics: Acitretin; Aged; Antifungal Agents; Cyclosporine; Drug Therapy, Combination; Etretinate; Female; Humans; In Vitro Techniques; Isotretinoin; Male; Microsomes, Liver; Middle Aged; Naphthalenes; Psoriasis; Retinoids; Terbinafine | 1993 |
Köbner phenomenon in a psoriatic patient under cyclosporin therapy after contusion trauma and local application of hyperaemic ointment.
Topics: Adult; Contusions; Cyclosporine; Drug Combinations; Humans; Hyperemia; Male; Niacin; Ointments; Psoriasis; Salicylates; Skin | 1993 |
Cyclosporin A rapidly inhibits epidermal cytokine expression in psoriasis lesions, but not in cytokine-stimulated cultured keratinocytes.
Topics: Blotting, Northern; Cells, Cultured; Cyclosporine; Cytokines; Enzyme-Linked Immunosorbent Assay; Gene Expression; Humans; Interleukin-1; Keratinocytes; Psoriasis; RNA, Messenger; Skin; Triamcinolone Acetonide | 1993 |
GRO-alpha mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes.
Topics: Base Sequence; Blotting, Northern; Cells, Cultured; Chemokine CXCL1; Chemokines, CXC; Cyclosporine; Gene Expression; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-1; Interleukin-8; Isomerism; Keratinocytes; Molecular Sequence Data; Polymerase Chain Reaction; Proto-Oncogene Proteins; Psoriasis; RNA, Messenger; Skin | 1993 |
Modulation of abnormalities in renal haemodynamics and vasoactive mediators by nifedipine in patients with psoriasis on low-dose cyclosporin.
Topics: Adolescent; Adult; Aged; Angiotensin II; Atrial Natriuretic Factor; Cyclosporine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemodynamics; Hormones; Humans; Male; Middle Aged; Nifedipine; Psoriasis; Renal Circulation | 1993 |
Response of nail psoriasis to cyclosporin.
Topics: Adult; Cyclosporine; Female; Humans; Nail Diseases; Psoriasis | 1993 |
Cyclosporin A does not affect epidermal proliferation following standardized injury.
Topics: Cell Division; Cyclosporine; Epidermis; Female; Humans; Male; Middle Aged; Psoriasis | 1993 |
Urinary acidification response to furosemide administration in patients on low-dose cyclosporine therapy.
Topics: Adult; Cyclosporine; Female; Follow-Up Studies; Furosemide; Humans; Kidney Function Tests; Kidney Tubules, Distal; Male; Prospective Studies; Proton-Translocating ATPases; Psoriasis; Time Factors | 1993 |
Cyclosporin therapy in psoriasis: recommendations for treatment. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
Topics: Blood Pressure Determination; Clinical Protocols; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Humans; Italy; Psoriasis; Remission Induction; Risk Factors; Time Factors; Treatment Outcome | 1993 |
Development of human papillomavirus-associated Buschke-Löwenstein penile carcinoma during cyclosporine therapy for generalized pustular psoriasis.
Topics: Adult; Condylomata Acuminata; Cyclosporine; DNA Probes, HPV; Humans; Male; Papillomaviridae; Penile Neoplasms; Polymerase Chain Reaction; Psoriasis; Time Factors; Tumor Virus Infections | 1993 |
Cutaneous malignancy related to cyclosporin A therapy.
Topics: Adult; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cyclosporine; Humans; Male; Methotrexate; Psoriasis; Skin Neoplasms | 1993 |
The annual cost of psoriasis.
Topics: Adult; Cyclosporine; Etretinate; Female; Health Care Costs; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Phototherapy; Psoriasis; PUVA Therapy; Retrospective Studies; Ultraviolet Therapy | 1993 |
Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis.
Topics: Adult; Creatinine; Cyclosporine; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Kidney; Kidney Diseases; Long-Term Care; Male; Middle Aged; Psoriasis | 1993 |
The effect of short-term low-dose cyclosporin on renal function and blood pressure in patients with psoriasis.
Topics: Adult; Blood Pressure; Blood Pressure Determination; Cyclosporine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Potassium; Psoriasis; Sodium | 1993 |
Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Cells, Cultured; Chloroquine; Cyclosporine; Ethanol; Female; Humans; Immunosuppressive Agents; Irritants; Lithium; Lymphocyte Activation; Male; Middle Aged; Phosphorylation; Phytohemagglutinins; Propranolol; Protein-Tyrosine Kinases; Psoriasis; T-Lymphocytes; Tacrolimus; Time Factors; Tyrosine | 1995 |
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994.
Topics: Administration, Cutaneous; Anti-Bacterial Agents; Cyclosporine; Dermatologic Agents; Drug Administration Schedule; Drug Combinations; Humans; Immunosuppressive Agents; Methotrexate; Photochemotherapy; Psoriasis; PUVA Therapy; Retinoids | 1996 |
Long-term use of cyclosporine in dermatology.
Topics: Cyclosporine; Dermatitis, Atopic; Humans; Psoriasis; Time Factors | 1996 |
A therapeutic approach to erythrodermic psoriasis: report of a case and a discussion of therapeutic options.
Topics: Aged; Calcitriol; Combined Modality Therapy; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Psoriasis; Ultraviolet Therapy | 1996 |
Discoid lupus erythematosus during treatment with cyclosporine.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Male; Middle Aged; Psoriasis | 1996 |
Cyclosporine A inhibits tPA mRNA transcription in A431 cell line.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Plasminogen; Psoriasis; RNA, Messenger; Tissue Plasminogen Activator; Tumor Cells, Cultured | 1996 |
A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses.
Topics: Adult; Chemistry, Pharmaceutical; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Drug Resistance; Emulsions; Humans; Male; Middle Aged; Psoriasis | 1996 |
Inhibition of T cell cAMP formation by cyclosporin A and FK506.
Topics: Adult; Aged; Colforsin; Cyclic AMP; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Isoproterenol; Male; Middle Aged; Psoriasis; T-Lymphocytes; Tacrolimus | 1996 |
Increased epidermal growth factor receptor in fsn/fsn mice.
Topics: Animals; Cyclosporine; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Immunohistochemistry; Mice; Mice, Mutant Strains; Psoriasis; Skin; Ultraviolet Rays; Wounds and Injuries | 1996 |
[Therapeutic management of psoriasis].
Topics: Adrenal Cortex Hormones; Calcitriol; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Retinoids | 1996 |
[Cyclosporine and severe psoriasis].
Topics: Cyclosporine; Drug Interactions; Humans; Hypertension; Immunosuppressive Agents; Kidney Diseases; Psoriasis | 1996 |
Cervical intraepithelial neoplasia in a patient receiving long-term cyclosporin for the treatment of severe plaque psoriasis.
Topics: Cyclosporine; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Psoriasis; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms | 1996 |
Dynamics of psoriatic trachyonychia during low-dose cyclosporin A treatment: a pilot study on onychochronobiology using optical profilometry.
Topics: Adult; Cyclosporine; Dose-Response Relationship, Drug; Humans; Image Processing, Computer-Assisted; Nail Diseases; Nails; Optics and Photonics; Pilot Projects; Psoriasis; Treatment Outcome | 1996 |
Treatment of psoriasis by cyclosporine and grapefruit juice.
Topics: Adult; Beverages; Citrus; Cyclosporine; Food-Drug Interactions; Humans; Male; Middle Aged; Psoriasis | 1996 |
Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1.
Topics: Adolescent; Adult; Aged; Biomarkers; CD4 Antigens; CD8 Antigens; Cyclosporine; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Middle Aged; Monitoring, Physiologic; Psoriasis; Receptors, Interleukin-2; Severity of Illness Index; Tacrolimus; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1996 |
The effect of cyclosporin A and FK 506 on the cAMP content in psoriatic keratinocytes.
Topics: Adult; Aged; Cyclic AMP; Cyclosporine; Female; Humans; Keratinocytes; Male; Middle Aged; Psoriasis; Signal Transduction; Tacrolimus | 1996 |
Alterations in ICAM-1 and ELAM-1 expression in psoriatic lesions following various treatments.
Topics: Adrenal Cortex Hormones; Cyclosporine; E-Selectin; Eicosapentaenoic Acid; Etretinate; Humans; Immunohistochemistry; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Keratolytic Agents; Psoriasis; PUVA Therapy; Skin; Ultraviolet Therapy | 1996 |
Changes in T-cell phenotype and adhesion molecules expression in psoriatic lesions after low-dose cyclosporin therapy.
Topics: Adult; Cell Adhesion Molecules; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Lymphocyte Count; Male; Middle Aged; Phenotype; Psoriasis; T-Lymphocytes | 1996 |
Cyclosporine and angiogenesis in psoriasis.
Topics: Cyclosporine; Humans; Neovascularization, Pathologic; Psoriasis; Skin | 1996 |
Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures.
Topics: 8,11,14-Eicosatrienoic Acid; Anti-Inflammatory Agents; Antineoplastic Agents; Calcitriol; Cells, Cultured; Cyclosporine; Dexamethasone; Down-Regulation; Epoxide Hydrolases; Humans; Interferon-gamma; Keratinocytes; Leukotriene B4; Methotrexate; Psoriasis; Thiophenes; Tretinoin | 1996 |
Plasma endothelin in psoriasis: possible relations to therapy and toxicity.
Topics: Acitretin; Cyclosporine; Endothelins; Humans; Hydroxyurea; Keratolytic Agents; Methotrexate; Psoriasis; Ranitidine | 1996 |
Beneficial clinical effects of cyclosporin A on severe psoriasis and its dissociation from serum concentration of soluble interleukin-2 receptor, soluble interleukin-6 receptor, soluble CD14 antigen, soluble intercellular adhesion molecule-1, and soluble
Topics: Adult; Aged; Antigens, CD; Cyclosporine; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interleukin-6; Lipopolysaccharide Receptors; Male; Middle Aged; Psoriasis; Receptors, Interleukin; Receptors, Interleukin-2; Receptors, Interleukin-6; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance.
Topics: Acitretin; Carcinoma, Squamous Cell; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Middle Aged; Neoplasms, Multiple Primary; Psoriasis; PUVA Therapy; Skin Neoplasms | 1997 |
Effects of cyclosporine on cytokines and cytokine receptors in psoriasis.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Interleukin-1; Interleukin-8; Psoriasis | 1997 |
Maintenance treatment with cyclosporin in psoriasis.
Topics: Adult; Cyclosporine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Psoriasis | 1997 |
[Pathogenesis and therapy of inflammatory dermatoses. Cyclosporin, an advance in the therapy of psoriasis].
Topics: Anti-Inflammatory Agents; Cyclosporine; Dermatitis; Humans; Inflammation; Psoriasis | 1995 |
Renal biopsy findings in long-term cyclosporin treatment of psoriasis.
Topics: Adult; Aged; Biopsy, Needle; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney; Kidney Diseases; Male; Middle Aged; Psoriasis | 1997 |
Allergic contact dermatitis caused by zinc pyrithione associated with pustular psoriasis.
Topics: Adult; Cyclosporine; Dermatitis, Allergic Contact; Female; Hair Preparations; Humans; Immunosuppressive Agents; Organometallic Compounds; Psoriasis; Pyridines; Scalp Dermatoses; Zinc | 1997 |
Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine.
Topics: Adult; Arthritis, Psoriatic; Cyclosporine; HIV Infections; Humans; Male; Psoriasis | 1997 |
Long-term low-dose cyclosporine therapy for psoriasis.
Topics: Age Factors; Biopsy; Creatinine; Cyclosporine; Fibrosis; Glomerular Filtration Rate; Humans; Hypertension; Immunosuppressive Agents; Kidney; Middle Aged; Psoriasis | 1997 |
Generalized pustular psoriasis responsive to PUVA and oral cyclosporin therapy.
Topics: Acute Disease; Administration, Oral; Biopsy, Needle; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Methoxsalen; Middle Aged; Psoriasis; PUVA Therapy | 1997 |
Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy.
Topics: Adult; Anti-Inflammatory Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Lymphocyte Activation; Lymphocytes; Male; Methylprednisolone; Middle Aged; Nephrosis; Prednisolone; Psoriasis | 1997 |
New method for determining prognosis of patients with psoriasis (E-PAP).
Topics: Antirheumatic Agents; Cyclosporine; Evaluation Studies as Topic; Humans; Methods; Prognosis; Psoriasis; Remission Induction; Severity of Illness Index; Time Factors | 1998 |
Risk of cancer with cyclosporine in psoriasis.
Topics: Adult; Age Factors; Clinical Trials as Topic; Cyclosporine; Data Collection; Florida; Humans; Immunosuppressive Agents; Incidence; Michigan; Middle Aged; Neoplasms; Psoriasis; Risk Assessment; Risk Factors; Time Factors | 1997 |
Neoral in Psoriasis. Proceedings from a roundtable meeting. Phoenix, Arizona, USA. January 21-22, 1997.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Psoriasis | 1997 |
Renal function after 10 years' treatment with cyclosporin for psoriasis.
Topics: Adult; Aged; Creatinine; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Immunosuppressive Agents; Kidney; Kidney Diseases; Male; Middle Aged; Psoriasis | 1998 |
Maintenance treatment with cyclosporin in psoriasis.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Psoriasis | 1998 |
Renal biopsy findings in long-term cyclosporin treatment of psoriasis.
Topics: Biopsy; Cyclosporine; Humans; Immunosuppressive Agents; Kidney; Kidney Diseases; Psoriasis | 1998 |
Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine efficacy in psoriasis.
Topics: Adult; Aged; Cells, Cultured; Cyclosporine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Psoriasis; Severity of Illness Index | 1998 |
Breast and lung cancers in two cyclosporin-A-treated psoriatic women.
Topics: Adult; Breast Neoplasms; Cyclosporine; Female; Humans; Immunosuppressive Agents; Lung Neoplasms; Middle Aged; Psoriasis | 1998 |
[Renal biopsy in connection with long-term treatment of psoriasis with cyclosporine].
Topics: Adult; Aged; Biopsy; Cyclosporine; Female; Fibrosis; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Psoriasis; Time Factors | 1998 |
Effect of obesity on cyclosporine trough concentrations in psoriasis patients.
Topics: Adult; Aged; Cyclosporine; Female; Fluorescence Polarization Immunoassay; Humans; Immunosuppressive Agents; Male; Middle Aged; Obesity; Psoriasis; Regression Analysis | 1998 |
Altered expression of the alpha2 laminin chain in psoriatic skin: the effect of treatment with cyclosporin.
Topics: Adult; Collagen; Cyclosporine; Dermatologic Agents; Epidermis; Female; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Laminin; Male; Middle Aged; Prospective Studies; Psoriasis; Skin | 1998 |
Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports).
Topics: Aged; Cyclosporine; Dermatologic Agents; Etretinate; Humans; Male; Middle Aged; Psoriasis; Skin; Treatment Outcome | 1998 |
Eruptive angiomas after treatment with cyclosporine in a patient with psoriasis.
Topics: Adult; Cyclosporine; Dermatologic Agents; Hemangioma; Humans; Male; Psoriasis; Skin Neoplasms | 1998 |
Verruca vulgaris developing during cyclosporin therapy for psoriasis vulgaris.
Topics: Cyclosporine; Drug Administration Schedule; Facial Dermatoses; Humans; Immunosuppressive Agents; Leg Dermatoses; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Sjogren's Syndrome; Skin Diseases; Warts | 1998 |
The use of cyclosporin in a child with generalized pustular psoriasis.
Topics: Child; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Male; Psoriasis | 1998 |
Generalized pustular psoriasis following a short course of cyclosporin (Neoral)
Topics: Adult; Cyclosporine; Dermatologic Agents; Drug Eruptions; Female; Humans; Psoriasis | 1998 |
[Findings in children with psoriasis].
Topics: Adolescent; Adrenal Cortex Hormones; Anthralin; Anti-Inflammatory Agents; Aspirin; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Female; Genetic Predisposition to Disease; Humans; Male; Phototherapy; Psoriasis; Retrospective Studies; Tars; Treatment Outcome; Tretinoin | 1999 |
Low dose cyclosporin A and methotrexate in the treatment of psoriasis.
Topics: Adult; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Male; Methotrexate; Psoriasis; Treatment Outcome | 1999 |
Treatments of generalized pustular psoriasis: a multicenter study in Japan.
Topics: Adult; Cyclosporine; Data Collection; Etretinate; Female; Glucocorticoids; Humans; Japan; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Tonsillectomy | 1999 |
Combination low-dose cyclosporin (Neoral) and hydroxyurea for severe recalcitrant psoriasis.
Topics: Aged; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Psoriasis | 1999 |
B-cell lymphoma developing in a patient on cyclosporin for recalcitrant psoriasis.
Topics: Cyclosporine; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Lymphoma, B-Cell; Male; Middle Aged; Psoriasis | 1999 |
Generalized pustular psoriasis following withdrawal of oral cyclosporin treatment for palmo-plantar pustulosis.
Topics: Adult; Cyclosporine; Dermatologic Agents; Drug Eruptions; Female; Humans; Middle Aged; Psoriasis; Substance Withdrawal Syndrome | 1999 |
Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis.
Topics: Acitretin; Anti-Bacterial Agents; Cefazolin; Cephalosporins; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Middle Aged; Psoriasis; Sepsis; Staphylococcal Infections; Streptococcal Infections; Vancomycin | 1999 |
Cyclosporine-associated lymphoma.
Topics: Cyclosporine; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Psoriasis | 1999 |
Risk of malignancy associated with cyclosporin use in psoriasis.
Topics: Cyclosporine; Dermatologic Agents; Humans; Neoplasms; Psoriasis; Risk Factors | 1999 |
Interaction between lovastatin and cyclosporine A after heart and kidney transplantation.
Topics: Anticholesteremic Agents; Azathioprine; Cyclosporine; Drug Interactions; Heart Transplantation; Humans; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Middle Aged; Postoperative Complications; Prednisolone; Psoriasis | 1999 |
Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis.
Topics: Adult; Chronic Disease; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies | 1999 |
Effects of cyclosporin A on immune activation markers in patients with active psoriasis.
Topics: Adult; Aged; Antigens, CD; Biomarkers; Cyclosporine; Cytokines; Dermatologic Agents; Female; HLA-DR Antigens; Humans; Immunophenotyping; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interleukins; Lymphocytes; Male; Middle Aged; Neopterin; Psoriasis; Th1 Cells | 1999 |
Short-term cyclosporin monotherapy for chronic severe plaque-type psoriasis.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Cyclosporine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis | 1999 |
1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice.
Topics: Animals; Calcitriol; CD4-CD8 Ratio; Cyclosporine; Flow Cytometry; Humans; Immunosuppressive Agents; Interleukin-10; Mice; Mice, SCID; Psoriasis; Receptors, Interleukin-2; Skin Transplantation; T-Lymphocyte Subsets; Transplantation, Heterologous | 1999 |
[Renal function during long-term cyclosporin treatment of psoriasis].
Topics: Adult; Creatinine; Cyclosporine; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kidney Function Tests; Long-Term Care; Male; Middle Aged; Psoriasis | 2000 |
Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A.
Topics: Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Psoriasis | 2000 |
Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapy.
Topics: Adolescent; Cyclosporine; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Psoriasis; Time Factors | 2000 |
Gingival hyperplasia in psoriasis patients treated with cyclosporin.
Topics: Aged; Cyclosporine; Dermatologic Agents; Female; Gingival Hyperplasia; Humans; Male; Middle Aged; Psoriasis | 2000 |
Palmoplantar pustulosis with pustulotic arthroosteitis involving temporal osteomyelitis and meningitis.
Topics: Acquired Hyperostosis Syndrome; Chest Pain; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; Headache; Humans; Magnetic Resonance Imaging; Male; Meningitis; Middle Aged; Osteomyelitis; Psoriasis; Pterygoid Muscles; Radionuclide Imaging; Sternoclavicular Joint; Temporal Bone; Temporal Muscle; Tomography, X-Ray Computed; Tonsillectomy | 2000 |
Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody.
Topics: Antibodies, Monoclonal; Basiliximab; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Middle Aged; Psoriasis; Receptors, Interleukin-2; Recombinant Fusion Proteins; Treatment Outcome | 2000 |
Serum adenosine deaminase levels in patients with psoriasis: a prospective case-control study.
Topics: Adenosine Deaminase; Adult; Biomarkers; Case-Control Studies; Cyclosporine; Female; Humans; Immunosuppressive Agents; Lymphocyte Activation; Male; Prospective Studies; Psoriasis; PUVA Therapy; Severity of Illness Index; T-Lymphocytes | 2000 |
Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis.
Topics: Aged; Cyclosporine; Female; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Middle Aged; Mycophenolic Acid; Psoriasis; Severity of Illness Index; Treatment Outcome | 2000 |
[Immunosuppressive macrolides and their use in dermatology].
Topics: Administration, Topical; Clinical Trials as Topic; Cyclosporine; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Psoriasis; Sirolimus; Tacrolimus | 2000 |
Cyclosporine in the treatment of psoriasis.
Topics: Clinical Trials as Topic; Creatinine; Cyclosporine; Dermatologic Agents; Drug Interactions; Follow-Up Studies; Humans; Kidney; Patient Selection; Psoriasis; Risk Factors; Skin Neoplasms; Time Factors | 2000 |
Cryptococcal meningitis during cyclosporin treatment in a patient with psoriasis.
Topics: Adult; Cyclosporine; Dermatologic Agents; Fever; Headache; Humans; Male; Meningitis, Cryptococcal; Opportunistic Infections; Psoriasis | 2000 |
Relationship between lymphocyte cyclosporin sensitivity and clinical progress of psoriasis.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Blood Urea Nitrogen; Creatinine; Cyclosporine; Drug Resistance; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Psoriasis | 2001 |
Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenograstim; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nuclear Family; Psoriasis; Recombinant Proteins; T-Lymphocyte Subsets; Transplantation Chimera; Vidarabine | 2001 |
Treatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study.
Topics: Administration, Topical; Analysis of Variance; Anthralin; Anti-Inflammatory Agents; Calcitriol; Complementary Therapies; Cyclosporine; Dermatologic Agents; Europe; Female; Health Care Surveys; Humans; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Steroids; Surveys and Questionnaires | 2001 |
Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with Cyclosporin A and clobetasol propionate.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Clobetasol; Cyclosporine; Dermatologic Agents; Glucocorticoids; Humans; Lymphocyte Function-Associated Antigen-1; Mice; Mice, SCID; Psoriasis; Reference Values; Skin; Skin Transplantation; Transplantation, Heterologous | 2001 |
Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study.
Topics: Carcinoma, Squamous Cell; Cross-Over Studies; Cyclosporine; Female; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Prospective Studies; Psoriasis; PUVA Therapy; Risk Factors; Skin Neoplasms | 2001 |
Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis.
Topics: Administration, Oral; Adolescent; Adult; Chronic Disease; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Mycophenolic Acid; Psoriasis; Treatment Outcome | 2001 |
Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment.
Topics: Adult; Biopsy; Cell Transformation, Neoplastic; Cyclosporine; Dermatitis, Atopic; Humans; Immunohistochemistry; Immunosuppressive Agents; Lymphoma, Large-Cell, Anaplastic; Male; Mycosis Fungoides; Polymerase Chain Reaction; Psoriasis; Skin Neoplasms; Staphylococcal Skin Infections | 2001 |
Cyclosporine in childhood psoriasis.
Topics: Child; Cyclosporine; Dermatologic Agents; Female; Humans; Infant; Male; Psoriasis | 2001 |
Oral cyclosporin does not arrest progression of androgenetic alopecia.
Topics: Administration, Oral; Adult; Alopecia; Cyclosporine; Dermatologic Agents; Disease Progression; Drug Eruptions; Humans; Hypertrichosis; Male; Psoriasis | 2001 |
Psoriasis and side-effects of mesotherapy.
Topics: Aged; Aminophylline; Anesthetics, Local; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Injections, Intradermal; Lidocaine; Psoriasis; Sciatica; Vasodilator Agents; Xanthinol Niacinate | 2001 |
Bilateral femoral avascular necrosis in a man with psoriasis: responsibility of topical corticosteroids and role of cyclosporine.
Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Cyclosporine; Drug Interactions; Femur Head Necrosis; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis | 2001 |
Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate.
Topics: Cost-Benefit Analysis; Cyclosporine; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Humans; Male; Methotrexate; Models, Economic; Psoriasis; Severity of Illness Index; Treatment Outcome; United States | 2002 |
[Quantitative changes in CD4+ and CD8+ T-lymphocytes in the skin of patients with psoriasis treated with cyclosporin A].
Topics: Adult; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Psoriasis; Skin; T-Lymphocyte Subsets | 2001 |
[Generalized pustular psoriasis during pregnancy: an effective treatment with cyclosporin].
Topics: Cyclosporine; Dermatologic Agents; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Psoriasis; Treatment Outcome | 1999 |
Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling.
Topics: Adult; Cyclosporine; Female; Gene Expression Profiling; Humans; Immunosuppressive Agents; Interleukin-11; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Psoriasis; Recombinant Proteins; RNA, Messenger | 2001 |
Adverse effects with long-term cyclosporin for severe psoriasis.
Topics: Acute Kidney Injury; Adult; Aged; Cost of Illness; Cyclosporine; Dermatologic Agents; Female; Humans; Hypertension; Long-Term Care; Male; Middle Aged; Psoriasis; Quality of Life; Retrospective Studies | 2002 |
Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A.
Topics: Biological Transport; Calcineurin; Calcineurin Inhibitors; Carcinogens; Cell Differentiation; Cell Membrane; Cell Nucleus; Cells, Cultured; Cyclophilin A; Cyclosporine; DNA-Binding Proteins; Enzyme Inhibitors; Fibroblasts; Humans; Immunosuppressive Agents; Ionomycin; Ionophores; Keratinocytes; NFATC Transcription Factors; Nuclear Proteins; Psoriasis; Signal Transduction; Skin; Tacrolimus; Tacrolimus Binding Protein 1A; Tetradecanoylphorbol Acetate; Transcription Factors | 2002 |
Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine.
Topics: Cyclosporine; Diagnosis, Differential; Fatal Outcome; Female; Humans; Immunohistochemistry; Middle Aged; Mycosis Fungoides; Psoriasis; Risk Assessment; Severity of Illness Index; Skin Neoplasms | 2002 |
Psoriasis: current concepts and new approaches to therapy.
Topics: Cyclosporine; Dietary Fats; Eicosanoids; Eicosapentaenoic Acid; Fatty Acids, Essential; Humans; Inflammation; Lymphokines; Malondialdehyde; Models, Biological; Psoriasis; Superoxides | 1992 |
Use of cyclosporin for psoriasis in HIV-positive patient.
Topics: Contraindications; Cyclosporine; HIV Infections; Humans; Male; Middle Aged; Psoriasis | 1992 |
Cyclosporin ointment for psoriasis and atopic dermatitis.
Topics: Adolescent; Adult; Aged; Cyclosporine; Dermatitis, Atopic; Humans; Middle Aged; Ointments; Psoriasis | 1992 |
CD4 antibody therapy and cyclosporin A differentially affect HLA-DR and ICAM-1 expression in psoriatic skin.
Topics: Antibodies; CD4 Antigens; Cell Adhesion Molecules; Cyclosporine; HLA-DR Antigens; Humans; Immunotherapy; Intercellular Adhesion Molecule-1; Psoriasis; Skin | 1992 |
T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal, epidermis.
Topics: CD4-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Cyclosporine; Epidermal Cells; Epidermis; Fibronectins; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Interleukins; Keratinocytes; Leukocytes, Mononuclear; Lymphocyte Activation; Psoriasis; Receptors, Antigen, T-Cell; T-Lymphocytes; Up-Regulation | 1992 |
Effects of cyclosporin A on resident and passenger immune cells of normal human skin and UV-induced erythema reactions.
Topics: Adult; Antigens, CD; Cell Adhesion Molecules; Cyclosporine; Erythema; Humans; Immunohistochemistry; Intercellular Adhesion Molecule-1; Keratinocytes; Langerhans Cells; Leukocytes; Macrophages; Male; Middle Aged; Psoriasis; PUVA Therapy; Skin; Ultraviolet Rays | 1992 |
Possible role of histamine in pathogenesis of autoimmune diseases: implications for immunotherapy with histamine-2 receptor antagonists.
Topics: Autoimmune Diseases; Autoimmunity; Cyclosporine; Histamine; Histamine H2 Antagonists; Humans; Immunity, Cellular; Immunotherapy; Major Histocompatibility Complex; Methotrexate; Models, Biological; Psoriasis; T-Lymphocytes | 1992 |
Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation.
Topics: Cyclosporine; HLA-DR Antigens; Humans; Interleukin-6; Keratins; Lymphocyte Activation; Psoriasis; Receptors, Interleukin-2; Regeneration; Skin; T-Lymphocytes; Transforming Growth Factor alpha | 1992 |
Anti-CD4 monoclonal antibody therapy in severe psoriasis.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antigens, CD1; CD3 Complex; CD4 Antigens; Cell Adhesion Molecules; Cyclosporine; Female; HLA-DR Antigens; Humans; Immunoglobulin G; Immunoglobulin M; Immunohistochemistry; Intercellular Adhesion Molecule-1; Maternal-Fetal Exchange; Middle Aged; Pregnancy; Psoriasis; PUVA Therapy; T-Lymphocyte Subsets; Time Factors | 1992 |
Hypertriglyceridemia in patients with psoriasis treated with cyclosporine.
Topics: Cyclosporine; Dose-Response Relationship, Drug; Humans; Hypertriglyceridemia; Psoriasis | 1992 |
Cyclosporine therapy for psoriasis: a cell cycle-derived dosing schedule.
Topics: Adult; Aged; Blood Pressure; Body Surface Area; Cell Cycle; Clinical Protocols; Creatinine; Cyclosporine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Paresthesia; Psoriasis; Remission Induction | 1992 |
[Cyclosporine in the treatment of psoriasis].
Topics: Cyclosporine; Humans; Psoriasis | 1992 |
Etretinate or cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis.
Topics: Adolescent; Adult; Aged; Cyclosporine; Etretinate; Female; Humans; Male; Middle Aged; Neutrophils; Psoriasis; Respiratory Burst | 1992 |
How to improve the risk-benefit ratio of cyclosporin therapy for psoriasis.
Topics: Cyclosporine; Drug Therapy, Combination; Humans; Kidney Diseases; Methotrexate; Psoriasis; PUVA Therapy; Retinoids | 1992 |
Bullous pemphigoid and severe erythrodermic psoriasis: combined low-dose treatment with cyclosporine and systemic steroids.
Topics: Anti-Inflammatory Agents; Cyclosporine; Drug Therapy, Combination; Humans; Male; Middle Aged; Pemphigoid, Bullous; Pregnenediones; Psoriasis | 1992 |
Cytokine-stimulated human dermal microvascular endothelial cells produce interleukin 6--inhibition by hydrocortisone, dexamethasone, and calcitriol.
Topics: Acitretin; Calcitriol; Cyclosporine; Cytokines; Dexamethasone; Drug Therapy, Combination; Endothelium, Vascular; Humans; Hydrocortisone; Infant; Infant, Newborn; Interleukin-1; Interleukin-6; Male; Microcirculation; Psoriasis; Skin; Tumor Necrosis Factor-alpha | 1992 |
Decreased peripheral blood eosinophil counts in severe psoriatic patients treated with low-dose cyclosporine A.
Topics: Adult; Cyclosporine; Eosinophils; Female; Humans; Leukocyte Count; Male; Psoriasis | 1992 |
Failure of reticular erythematous mucinosis to respond to cyclosporine.
Topics: Cyclosporine; Female; Humans; Middle Aged; Mucinoses; Photosensitivity Disorders; Psoriasis; Rosacea | 1992 |
Topical cyclosporine is ineffective in the treatment of psoriasis.
Topics: Administration, Cutaneous; Adult; Cyclosporine; Female; Humans; Male; Middle Aged; Psoriasis; Treatment Failure | 1992 |
Psoriasis symposium. Cyclosporine.
Topics: Cyclosporine; Humans; Kidney; Psoriasis | 1992 |
Psoriasis: immunopathology and long-term treatment with cyclosporin.
Topics: Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Psoriasis | 1992 |
Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.
Topics: Aryl Hydrocarbon Hydroxylases; Breath Tests; Carbon Dioxide; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Hydrocortisone; Liver; Oxidoreductases, N-Demethylating; Psoriasis; Regression Analysis; Rifampin; Troleandomycin | 1992 |
Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day.
Topics: Adult; Aged; Creatinine; Cyclosporine; Drug Administration Schedule; Female; Humans; Kidney Diseases; Male; Middle Aged; Psoriasis | 1992 |
Lymphocytic infiltrates of the skin in association with cyclosporine therapy.
Topics: Cell Movement; Cyclosporine; Erythema; Humans; Lymphocytes; Male; Middle Aged; Psoriasis | 1992 |
Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens.
Topics: Adult; Biopsy; Creatinine; Cyclosporine; Female; Fibrosis; Humans; Kidney; Male; Middle Aged; Psoriasis | 1992 |
Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.
Topics: Adolescent; Adult; Age Factors; Autoimmune Diseases; Blood Pressure; Creatinine; Cyclosporine; Diabetes Mellitus, Type 1; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Multivariate Analysis; Psoriasis; Retrospective Studies; Risk Factors; Sjogren's Syndrome; Uveitis | 1992 |
Cyclosporine therapy for autoimmune disease.
Topics: Arthritis, Rheumatoid; Autoimmune Diseases; Behcet Syndrome; Cyclosporine; Diabetes Mellitus, Type 1; Humans; Kidney Diseases; Psoriasis | 1992 |
The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine.
Topics: Administration, Oral; Aged; Cyclosporine; Humans; Lymphoma, B-Cell; Male; Maxillary Neoplasms; Neoplasms, Multiple Primary; Orbital Neoplasms; Palatal Neoplasms; Psoriasis | 1992 |
Serum creatinine or glomerular filtration rate for monitoring cyclosporin therapy.
Topics: Creatinine; Cyclosporine; Glomerular Filtration Rate; Humans; Monitoring, Physiologic; Psoriasis | 1991 |
Exanthematic type of pustular psoriasis consisting of two types of pustular lesion.
Topics: Administration, Oral; Adult; Cyclosporine; Dose-Response Relationship, Drug; Exanthema; Female; Foot Dermatoses; Hand Dermatoses; Humans; Psoriasis; Skin | 1991 |
Multiple eruptive benign keratoses associated with cyclosporine therapy for psoriasis.
Topics: Cyclosporine; Female; Humans; Keratosis; Middle Aged; Psoriasis; Skin | 1992 |
Effects of chloroquine on antigen-presenting functions of epidermal cells from normal and psoriatic skin.
Topics: Antigen-Presenting Cells; Chloroquine; Cyclosporine; Humans; Lymphotoxin-alpha; Psoriasis; Skin | 1992 |
Hypertriglyceridemia in patients with psoriasis treated with cyclosporine.
Topics: Adult; Cholesterol; Cyclosporine; Etretinate; Fasting; Humans; Hypertriglyceridemia; Male; Middle Aged; Psoriasis; Time Factors; Triglycerides | 1991 |
Role of T cell activation in the pathogenesis of psoriasis.
Topics: Cyclosporine; Humans; Lymphocyte Activation; Psoriasis; T-Lymphocytes | 1991 |
Facial and eyelid psoriasis after cyclosporin withdrawal.
Topics: Cyclosporine; Eyelid Diseases; Facial Dermatoses; Humans; Male; Middle Aged; Psoriasis; Substance Withdrawal Syndrome | 1991 |
Efficacy of ciclosporin in two cases of erthrodermic psoriasis.
Topics: Adult; Cyclosporine; Dermatitis, Exfoliative; Female; Humans; Male; Psoriasis | 1991 |